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Summary 
The present work evaluates the role of metabolism in development and progression of 
hepatocellular carcinoma (HCC). This study focuses on changes of central metabolic pathways, 
including glycolysis, gluconeogenesis, tricarboxylic acid (TCA) cycle and other processes involved in 
cellular metabolism and known to be dysregulated during cancer formation. Comprehensive 
multiomics analyses, such as proteomics, metabolomics and targeted genome sequencing, were 
applied in order to better understand HCC developmental mechanisms in vivo. Two main systems 
were studied: the ASV-B mouse model and clinical samples from human patients. The human 
cohort was composed of biopsy and surgery material from 95 patients: 47 HCC and 48 non-HCC. 
Proteomic data from both mice and humans show a clear downregulation of the main 
energy-producing pathways in HCC. Glycogen metabolism, de novo glucose synthesis, glutamine 
uptake to the TCA cycle, approximately 60% of enzymes of TCA cycle, and transport of pyruvate to 
mitochondria are downregulated in HCC. An isoform switch at various levels of central carbon 
metabolism was demonstrated in this work. Both mice and humans with HCC reveal isoform 
switches at the level of phosphoglycerate mutases and pyruvate kinases. The key features are 
found in both mouse and human, showing a universal metabolic HCC fingerprint. This study also 
demonstrates that proteomic analysis of the bioptate material is a strong and sufficient molecular 
diagnostic tool for research in cancer: the proteomic analysis of liver material allows the 
distinction of tumor samples from non-tumor samples and also to track the level of disease 
progression. 
Targeted genome sequencing revealed that no clear distinction between cancer and 
precancerous conditions could be made exclusively from the mutation analysis. Human 
metabolomic data remains inconclusive, possibly due to the different sources of tissue samples. 
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Zusammenfassung 
Die vorliegende Arbeit untersucht die Rolle des Metabolismus in der Entstehung und 
Progression des Hepatozellulären Karzinoms (HZK). Der Schwerpunkt der Studie liegt auf 
Veränderungen zentraler Stoffwechselwege, unter anderem der Glykolyse, der Gluconeogenese, 
des Citratzyklus und anderer Prozesse des Zellstoffwechsels. Umfassende Multiomikanalysen, wie 
etwa Proteomik, Metabolomik und gezielte Genomsequenzierung wurden angewandt, um in vivo 
die Mechanismen der HZK Entstehung zu verstehen. Es wurden zwei Systeme untersucht: das ASV-
B Mausmodell und klinische Patientenproben. Die Kohorte bestehend aus Biopsien und 
Resektaten von 95 Patienten umfasste 47 Fälle von HZK und 48 Fälle ohne HZK. 
Das Proteom des Mausmodells und der Patientenkohorte zeigen eine deutliche 
Herabregulierung wesentlicher Energie bereitstellender Kreisläufe im HZK: Glykogenstoffwechsel, 
de novo Synthese von Glukose, Glutaminaufnahme in den Citratzyklus, des weiteren sind 60% der 
Enzyme des Citratzyklus, und des Transports von Pyruvat in Mitochondrien im HZK herabreguliert. 
In dieser Arbeit wurde ein Isoformenwechsel auf mehreren Ebenen des zentralen 
Kohlenstoffmetabolismus gezeigt. Sowohl das Mausmodell, als auch die Gewebeproben von HZK-
Patienten weisen Isoformenwechsel der Phosphoglyzeratmutasen und der Pyruvatkinasen auf. Die 
Hauptmerkmale finden sich sowohl in Modellmäusen, als auch in Patienten, und stellen so einen 
universalen metabolomischen Fingerabdruck des HZK dar. Darüber hinaus demonstriert diese 
Studie, dass die Proteomanalyse von bioptischen Material ein aussagekräftiges und ausreichendes 
molekular-diagnostisches Instrument für die Krebsforschung ist: die Proteomanalyse von 
Lebermaterial erlaubt die Unterscheidung von Tumorgewebe und tumorfreien Proben und die 
Dokumentation des Krankheitsverlaufs. 
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Outline 
Hepatocellular carcinoma (HCC) is a malignant tumor which originates from hepatocytes and 
causes death in 95% of cases within five years from the established diagnosis. The deficit of 
fundamental knowledge about processes taking place in HCC development leads to a lack of 
diagnostic and treatment options, and therefore to the poor prognosis of the disease. In this work 
I aim to elucidate the role of metabolism in HCC development and progression. I am particularly 
interested in central metabolic pathways, e.g. glycolysis, gluconeogenesis, tricarboxylic acid (TCA) 
cycle and other processes involved in cellular metabolism known to be dysregulated during cancer 
formation. In this regard it is important not only to study metabolism and to investigate the 
features which can help differentiate HCC from non-HCC, but also to explore metabolic and 
genetic heterogeneity among the HCC samples. In this study I performed comprehensive 
multiomics analyses, which included proteome, metabolome and genetic background analyses, to 
better understand HCC developmental mechanisms in two main systems: the ASV-B mouse model 
and clinical samples from human patients. Defining the HCC signature changes in metabolism 
could shed light on universal HCC biomarker discovery. 
The ASV-B mouse model is a transgenic model which shows dysplastic nodule formation at 
the age of 8 weeks. By the 12th week, adenomas in the liver can be observed, and differentiated 
HCC develops by the 16th week in these mice, the age at which they were used in this study. 
C57BL/6J mice were used as a control (Dubois, et al., 1991). The human cohort was composed of 
biopsy and surgery material from 95 patients: 47 HCC and 48 non-HCC (which comprised various 
other conditions affecting the liver such as fatty liver, hepatitis B or C, fibrosis and others). Several 
issues had to be considered during the cohort formation to reduce the great heterogeneity among 
patients. We excluded patients, according to their anamnesis, with exposure to certain 
hepatotoxins, as well as patients with long-term usage of certain medication, patients with known 
exposure to certain hepatotoxins, patients receiving lifelong medication, and those with 
hereditary conditions or immune-mediated diseases. Current hepatitis viral load on the day of 
material acquisition was considered, and separate groups of patients with hepatitis virus B or C 
were formed. Patients with other detected viruses (e.g. HIV1) were excluded from the cohort. To 
the best of our knowledge patients did not get any treatment prior to surgery or biopsy 
procedures. 
                                                          
1
 HIV – human immunodeficiency virus 
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To obtain data about proteins and metabolites in liver samples I used mass spectrometry 
(MS). For protein analysis, a shotgun proteomics approach was used, which combines nano Ultra-
High Performance Liquid Chromatography (nanoUHPLC) with MS. For the analysis of metabolites, 
we used gas chromatography time-of-flight (GC-TOF) MS. This method allows a specific separation 
and quantification of central-carbon metabolism-related metabolites. The main cancer-related 
somatic mutations in human material were analyzed in a targeted way with Ion Personal Genome 
Machine (PGM) Torrent and an Ion AmpliSeq Cancer HotSpot Panel v2. 
Proteomic data from the ASV-B mouse model showed a specific picture of metabolic 
reprogramming in the damaged liver. In cancerous liver tissue glycogen metabolism was impaired 
via the inhibition of glycogen synthase 2 (Gys2). Several enzymes of glycolysis showed isoform 
switches e.g. phosphoglycerate mutases (Pgm), pyruvate kinases (Pk)), which represents one of 
the most striking features of metabolic changes in cancer. Gluconeogenesis was downregulated at 
the level of phosphoenolpyruvate carboxykinase 1 (Pck1) and glucose-6-phosphatase catalytic-
subunit (G6pc). Transport of pyruvate to mitochondria was inhibited at the level of mitochondrial 
pyruvate carriers 1 and 2 (Mpc 1, 2). 60% of TCA cycle enzymes were downregulated, for example 
citrate synthase (Cs) and succinate dehydrogenases A, B and C (Sdha, b, c). Enzymes, which are 
responsible for the glutamine uptake into the TCA cycle had decreased expression in the HCC 
samples: glutamate pyruvate transaminase (Gpt), glutamate pyruvate transaminase 2 (Gpt2), and 
glutaminase 2 (Gls2) were downregulated at the proteomic level. At the metabolic level the higher 
amounts of glucose-6-phosphate, fructose-6-phosphate and lactic acid were detected. Levels of 
TCA cycle metabolites were higher in HCC as well: fumaric and malic acids were higher in HCC 
compared to control. 
In the proteomic profile of the human samples a similar signature of tumor-specific 
metabolic reprogramming was found. At the proteomic level, glycogen metabolism was 
downregulated via dysregulation of glycogen phosphorylase L (PYGL) and glycogen synthase 2 
(GYS2). Glucose de novo synthesis, which is essential for an organism during the fasting time, was 
downregulated at the level of fructose-1,6-bisphosphatase 1 (FBP1): FBP1 expression was 
approximately 7 times less in HCC compared to control group. This observation suggests that liver 
cannot maintain one of its’ main metabolic functions - gluconeogenesis. Glycolysis was 
characterized by an upregulation of some enzymes, such as hexokinases (HK), and by an isoform 
switch at the levels of phosphoglycerate mutases (PGM), aldolases (ALDO), enolases (ENO), 
pyruvate kinases (PK), and lactate dehydrogenases (LDH). 65% of the enzymes of the TCA cycle 
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were downregulated, and isocitrate dehydrogenase (IDH) showed a switch between subunits. 
Glutaminolysis was downregulated at the level of glutamate pyruvate transaminase (GPT) and 
glutaminase 2 (GLS2).  Due to the tremendous heterogeneity of the phenotypes of human 
patients, metabolic data was mostly inconclusive, thus could not be used as a reliable source of 
data. This diversity may come from different environmental conditions, diets, and associated 
diseases of patients in cohort. 
Targeted genome sequencing was used in order to track well characterized cancer-related 
somatic mutations. The same mutations were detected in samples with fatty liver, hepatitis B and 
C, fibrotic liver, cirrhosis, and HCC. No clear distinction between cancer and precancerous 
conditions could be made exclusively from the mutation analysis. However, several CTNNB1
1
 
mutations were specific for tumor samples and were detected in 15% of HCC. This observation can 
indicate that CTNNB1 mutation is not a necessary but sufficient factor for the CCM changes, and, 
when present, affects metabolism in a drastic way which has an impact on major liver functions. 
Thus, the above mentioned CTNNB1 mutations should further be validated on larger cohorts for 
potential use as a prognostic biomarker of survival or metastatic status. 
Taken together, proteomic data from both mice and humans showed a clear dysregulation 
of the main energy-producing pathways in HCC. Glycogen metabolism (via PYGL and GYS2), de 
novo glucose synthesis (on various levels), glutamine uptake to the TCA cycle (via GPT, GLS2), and 
approximately 60% of enzymes of TCA cycle (SDHs, SUCLs, ACO etc.), and transport of pyruvate to 
mitochondria (MPCs) were downregulated in HCC. The proteomic data demonstrated one of the 
most common features of cancer cells: metabolic reprogramming. An isoform switch, which is one 
of the fundamental mechanisms in reprogramming, was demonstrated in this work. Both mice and 
humans with HCC revealed isoform switches at the level of phosphoglycerate mutases and 
pyruvate kinases. Despite the diversity of genetic background of human samples the proteomic 
HCC signature is very robust in both bioptate and surgery material. The key features were found in 
both mouse and human, showing a universal metabolic HCC fingerprint. This study also 
demonstrates that proteomic analysis of the bioptate material is a strong and sufficient molecular 
diagnostic tool for research in cancer: the proteomic analysis of liver material allows the 
distinction of tumor samples from non-tumor samples and also to track the level of disease 
progression. 
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Introduction 
In the introduction I present general information about hepatocellular carcinoma (HCC), the 
details about prognosis, epidemiology, risk factors, and classification. Further, I discuss the clinical 
picture, diagnostic HCC markers and treatment possibilities. In the Introduction, molecular 
mechanisms of central carbon metabolism are described, including its liver-specific features and 
regulation. Here I also introduce the HCC-specific changes of CCM and systems biology and 
translational medicine approaches to this problem. The Introduction finishes with the aims of the 
present work. 
Hepatocellular carcinoma 
Et Tumor, Brute?  
-Bethesda Softworks, Fallout 4, 2015 
 
HCC is a malignant liver tumor with hepatocellular differentiation (Fritz, et al., 2000). 
Diverse histological subtypes of HCC are described (Bosman, Carneiro, Hruban, & Theise, 2010; 
Deepali, 2015; Fritz, et al., 2000), however, all of them express common trends. Most common 
patterns are trabecular with 4 or more cells surrounded by a layer of flattened endothelial cells. 
Sinusoidal vessels surrounding tumor cells are an important feature of HCC, as well as scanty 
stroma, and vascular invasion (a detailed histological picture can be found in l Appendix 1) 
(Deepali, 2015).  
Prognosis 
The prognosis for patients with HCC is generally very poor. Statistical studies report median 
of less than 5-years survival of HCC patients after the diagnosis (Altekruse, McGlynn, & Reichman, 
2009; Bosman, et al., 2010; Fritz, et al., 2000; Greten, et al., 2005; Lee, et al., 2006). This value may 
vary depending on the etiology or treatment, for example median survival for HBV
1
-related HCC in 
less than 16 months (Nguyen, Law, & Dore, 2009). 
Epidemiology 
HCC is the most common type of liver cancer, accounting for 90% of all liver cancers (Jelic & 
Sotiropoulos, 2010). It is a major public health problem, accounting for approximately 745 000 
deaths worldwide in 2012 according to the data from the International Agency for Research on 
                                                          
1
 HBV - hepatitis B virus 
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Cancer (IARC, 2012). The number of diagnosed cases is similar to the number of deaths attributed 
to HCC worldwide, which highlights that diagnostic tools and treatment methods are currently 
limited, since proper diagnosis is often made in a disease state where treatment options focus on 
palliative care. 
Risk factors 
Several risk factors are described by researchers and doctors. In most cases, HCC is 
associated with chronic liver injury of different etiology (HBV, HCV
1
 and alcoholic cirrhosis). 
Chronic infection with HBV in the setting of cirrhosis increases the risk of HCC from 5- to 100-fold 
(El-Serag, 2012). Statistically speaking, 5–30% of individuals with HCV infection develop chronic 
liver disease, 30% of them progress to cirrhosis. 1–2% of these patients per year without proper 
treatment and elimination of damaging factors will develop HCC. Median age at diagnosis is 
between 50 and 60 years (Jelic & Sotiropoulos, 2010). Overall, patients with cirrhosis are at 
highest risk of developing HCC (Forner, Llovet, & Bruix, 2012). HCC is four to eight times more 
common in men (Jelic & Sotiropoulos, 2010). Chiesa et al. in 2000 discovered that 87% of the cases 
of HCC occurring in Brescia, northern Italy, developed in a cirrhotic liver, including most of those 
attributable to alcohol intake (Chiesa, et al., 2000). Ukawa et al. discovered that 26% of 1245 HCC 
patients from BioBank Japan suffered from alcoholism (Ukawa, et al., 2017). 
Additionally, other toxins can increase the risk of developing HCC, for example aflatoxin. 
Aflatoxin, a contaminant produced by the fungi Aspergillus flavus and Aspergillus parasiticus in 
maize and nuts, is a known human liver carcinogen (Liu & Wu, 2010). This factor is a good example 
for territory-dependent HCC risk factors. Most cases are detected in sub-Saharan Africa, Southeast 
Asia and China, where populations suffer from both high HBV and food aflatoxin exposure (Liu & 
Wu, 2010). 
The above mentioned risk factors have been proven to strongly correlate to the HCC 
incidence. Human liver is a primary organ of detoxification. Liver enzymes catalyze the oxidation, 
hydrolysis and reduction (phase I) of chemical molecules and drugs, and their conjugation (phase 
II) (Grant, 1991). However, several chemicals could be converted to more toxic substances and 
metabolites, causing toxic effects on liver and whole organism. The liver is extremely sensitive to 
chemical- and viral-induced carcinogenesis. 
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Steatosis and non-alcoholic steatohepatitis (NASH) - early stages of non-alcoholic fatty liver 
disease (NAFLD) - are associated with abdominal obesity and type 2 diabetes (Margini & Dufour, 
2016). For example, 95-100% of patients with BMI
1
 over 30 kg/m2 are diagnosed with steatosis, 
and 20-47% with NASH (Ludwig, Viggiano, McGill, & Oh, 1980; Powell, et al., 1990). Patients with 
type 2 diabetes or with defective glucose tolerance are diagnosed with steatosis in 60% of cases, 
and with NASH in 15% of cases. Patients with lipid metabolism defects are diagnosed with 
steatosis and NASH in 20-80% of cases (Roytberg & Strutynskiy, 2013). The epidemic of obesity has 
been correlated to an increased risk of various types of cancer (Vucenik & Stains, 2012). According 
to the study by Ukawa et al. on the BioBank Japan project 22% of 1245 HCC patients were obese 
(BMI ≥30 kg/m
2
) (Ukawa, et al., 2017). 
Gene polymorphisms and gene-environment interactions may also be risk factors for HCC, 
particularly genes that code for metabolic enzymes (glutathione-S-transferase, epoxide hydrolase, 
cytochrome p4502E1) or DNA repair enzymes (XRCC1, UDP-glucuronosyltransferase 1A7) 
(Borentain, et al., 2007; Degli Esposti, et al., 2012).  
Due to the variety of etiology described above, many HCC-associated molecular alterations 
have been detected and no universal molecular signature is definitively associated with all hepatic 
tumors, neither in humans nor in experimental animals (Degli Esposti, et al., 2012; Pei, Zhang, 
Renault, & Zhang, 2009).  
It is rather difficult to distinguish the risk factors of HCC from its cause and from the 
associated diseases. Additionally, multiple risk factors (or causes) can be present in one HCC case. 
Therefore, the classification based on the cause of HCC cannot be considered reliable due to its 
inability to provide unambiguous grouping.  
Classification 
Mutation-based classification, suggested by Boyault et al. (Boyault, et al., 2007), does not 
rely exclusively on risk factors/causes. It is mostly based on involved biological pathways, gene 
mutations and methylation, while clinical information does not play a major role or sometimes is 
not considered at all. Six major groups of different types of HCC and its genetic and clinical (when 
available) alterations are described (Figure 1).  
The first (G1) group of tumors is characterized by a low copy number of HBV and by an 
overexpression of the following genes: sex determining region Y boxes-9 (SOX9), insulin-like 
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growth factor 2 (IGF2), alpha-fetoprotein (AFP) and other genes which are expressed in fetal liver. 
G2 includes HCCs with a high copy number of HBV and mutations in phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) and tumor protein tp53 (TP53). In G1 and 
G2 groups AKT/PKB signaling pathway activation was detected. G3 contains tumors with mutated 
genes TP53 and an overexpression of genes responsible for the cell cycle control. In particular, the 
DNA replication licensing factors MCM2, 3 and 6 are overexpressed. G4 is described as a 
heterogeneous tumor group including hepatocyte nuclear factor 1 (TCF1)-mutated hepatocellular 
adenomas and carcinomas. G5’s distinguishing feature is the presence of catenin mutations that 
lead to Wnt pathway activation. The beta-catenin target genes in the liver are overexpressed. The 
picture for the G6 group is similar to G5 but additionally includes tumors with satellite nodules, 
higher activation of the Wnt pathway, overexpression of beta-catenin target genes and E-cadherin 
underexpression. Boyault et al. came to the conclusion that approximately 50% of the tumors 
were related to the activation of either AKT or WNT pathways.  
 
 
Figure 1. G1-G6 HCC groups. Schematic of the different HCC subgroups defined by transcriptome 
analysis with their related clinical and genetic pathways. G1 to G6 are the subgroups of HCCs 
defined by transcriptome analysis. Vertical lines indicate significantly associated features. Red and 
green primarily indicate over- and underexpressed genes, respectively, in that particular functional 
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category. LOH, loss of heterozygosity; Hemochrom., hemochromatosis; AFP, alpha-fetoprotein; 
HBV, hepatitis B virus;
*
rare feature (Boyault, et al., 2007). 
 
This classification covers most of the known genetic alterations, present in HCC and includes 
a few clinical features detected in patients. It is interesting that G3-G6 groups do not show any 
specific clinical component. In the present work, I used the above mentioned classification as a 
starting point for the genetic analysis. Currently, genomic alterations are mostly used for research 
purposes, but are not widely applied in clinics for diagnosis or treatment of HCC. 
Diagnosis 
Clinical picture 
The strategy of HCC diagnostics follows an established protocol. However, it can vary in 
different cases. Usually patients with chronic liver damage have several symptoms, such as 
jaundice, tiredness (fatigue), itch, discomfort over the liver, and red or pink blotchiness of the 
hands. Considering these symptoms doctors suggest several diagnostics tools: ultrasound, 
measurement of liver enzymes (the most common specific elevated liver enzymes are alanine 
transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyltransferase (GGT), and 
they are currently considered to be non-specific for HCC), computerized tomography (CT) and, to 
confirm the suggested diagnosis, histological examination of a biopsy sample. As a general rule, 
patients with either hepatitis B or C or cirrhosis are recommended for regular ultrasound checkups 
(Roytberg & Strutynskiy, 2013).  
 
HCC markers 
Testing for specific HCC markers is considered a rather questionable method at the moment 
due to its lack of specificity. For a long time alpha-fetoprotein (AFP) was used as a common marker 
for HCC. Discovered about half a century ago AFP is the major serum fetal protein in mammals 
(Abelev, Perova, Khramkova, Postnikova, & Irlin, 1963; Bergstrand & Czar, 1956). It is mostly 
produced during the lifetime of the fetus by liver hepatocytes. If the hepatocyte undergoes 
cancerous changes it starts to produce more AFP. However, AFP has been proven by several 
authors to be non-specific as an HCC marker. According to research by Paul et al. AFP shows no 
significant elevation in patients with cirrhosis compared to patients with cirrhosis and HCC (Paul, 
et al., 2007). Gupta and his colleagues came to the same conclusion for patients with hepatitis C 
(Gupta, Bent, & Kohlwes, 2003). Tomomi Masuda and Eiji Miyoshi noted, that levels of AFP, GP73, 
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HSP70, and glypican 3 can also correspond to chronic inflammation and stress (Masuda & Miyoshi, 
2011). 
Several authors have claimed that fucosylated AFP (AFP-L3) has better diagnostic value (Luk 
& Liu, 2011; Masuda & Miyoshi, 2011; Zinkin, et al., 2008).  
The level of Protein Induced by Vitamin K Absence/antagonist-II (PIVKA-II) (also known as 
des-gamma carboxyprothrombin (DCP)) can change in the presence of HCC (Bertino, et al., 2013; 
Masuda & Miyoshi, 2011; Zinkin, et al., 2008).  
Heat Shock Protein 70 (HSP70) and HSP27 are of special relevance in human cancer because 
they inhibit apoptosis. HSP70 could be a sensitive marker for the differential diagnosis of early HCC 
from precancerous lesions or non-cancerous liver, a difficult distinction for pathologists due to the 
very well-differentiated histology with little atypia in early HCC (Masuda & Miyoshi, 2011).  
Those and many other potential markers can be found in literature, but none of the 
suggested markers is used nowadays as a ‘Gold Standard’ for the differential HCC diagnosis. Thus, 
current biomarker-based diagnostics of HCC requires a lot of improvement. One of the aims of this 
thesis is to obtain more specific knowledge about possible novel HCC markers.  
 
Treatment 
Main treatment options, according to (Roytberg & Strutynskiy, 2013), include: 
• Liver transplantation (Chang, et al., 2017); 
• Partial surgical resection to remove a tumor and surrounding liver tissue, retaining 
normal liver tissue (J. Y. Shen, et al., 2016); 
• Interventional radiology (various embolizations (Andreana, et al., 2012; Lobo, et al., 
2016), radiofrequency ablation (damages tumor with local heating) (Clasen, et al., 
2014; Ueno, et al., 2015), selective internal radiation therapy (Hilgard, et al., 2009; 
Lambert & Van De Wiele, 2009), percutaneous ethanol injection (Huang, et al., 
2015; Yang, et al., 2015) etc.); 
• Sorafenib (receptor tyrosine kinase inhibitor) is occasionally used in patients with 
advanced HCC (Keating, 2017; Llovet, et al., 2008; A. Shen, et al., 2013). Sorafenib 
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inhibits tumor-cell proliferation and tumor angiogenesis, and increases the rate of 
apoptosis in other tumor models. 
Despite obvious diversity of causes, background conditions, genetic alterations, clinical 
pictures, and histological types of HCC, current treatment options are non-selective in the majority 
of cases. Possibly, this non-specific approach leads to an overall poor prognosis of HCC. Deep 
analysis of various metabolic phenotypes of different HCC cases could potentially shed the light on 
discrepant classification and treatment options of this severe disease. 
 
Molecular mechanisms 
Healthy liver tissue plays a major role in carbohydrate metabolism: it synthesizes and stores 
glycogen, releases glucose into the blood by glycogenolysis, performs glucose de novo synthesis. 
Some of these processes are part of central carbon metabolism (CCM). CCM is a biochemical 
network of enzymes and metabolites of cells, representing the most basic aspect of life (Kanehisa, 
Furumichi, Tanabe, Sato, & Morishima, 2017; Kanehisa & Goto, 2000; Kanehisa, Sato, Kawashima, 
Furumichi, & Tanabe, 2016; Sudarsan, Dethlefsen, Blank, Siemann-Herzberg, & Schmid, 2014). The 
classic textbook knowledge of CCM includes the Embden-Meyerhof-Parnas pathway (glycolysis), 
the TCA cycle, and the pentose phosphate pathway (Nelson, Nelson, Lehninger, & Cox, 2008). 
Additional pathways connected to CCM, such as do novo synthesis of glucose and glycogen, and 
glutaminolysis, are analyzed in this work as they participate in crucial liver functions. The scheme 
of these processes is presented on Figure 2 (full names of enzymes and metabolites for both 
human and mouse species see in Appendix 2). It includes major enzymes participating in CCM and 
its isoforms. These different forms of proteins may be produced from different genes, or from the 
same gene by alternative splicing (MeSH, 1999), and have similar functions. Structurally related 
forms of an enzyme are called isoenzymes. Each isoenzyme has the same mechanism and 
classification, but differs in its chemical, physical, or immunological characteristics (MeSH, 1999). 
In normal conditions one isoform or isoenzyme is quantitatively prevalent over another, and their 
ratio can be changed in various biological processes, such as cancer development. These processes 
is called an isoform switch (due to historical reasons). Understanding the interactions between 
CCM members in various tissues under healthy and pathological conditions is of primary interest 
in systems biology. 
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Figure 2. Scheme of central carbon metabolism (CCM). Visualization of major CCM enzymes and 
its isoforms and subunits, and metabolites. Enzymes are visualized with squares, metabolites with 
circles, mitochondrion membrane is indicated with the grey line. For the full names of enzymes 
and metabolites for both human and mouse species see in Appendix 2. 
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Regulation of CCM  
As some of central carbon metabolism (CCM) processes run in opposite directions, they 
have to be strictly regulated. If glycolysis and gluconeogenesis were active both at the same time, 
glucose would be converted to pyruvate, and then back to glucose, which would lead to futile ATP
1
 
consumption (Boiteux & Hess, 1981). While this cycle exists in nature to produce heat in the 
brown adipose tissue, in terms of liver metabolism this would be a drastic waste of energy. 
Therefore, in liver tight regulation is required to facilitate liver adjustment to constantly changing 
circumstances. 
Glycolysis in liver is mainly regulated by four major enzymes: GCK, HK, PFK, and PK. GCK has 
a special role in liver: releasing glucose to the blood when blood glucose is low, and taking up and 
metabolizing glucose when the blood glucose level is high. PFK is formed by different 
combinations of three types of subunits: platelet (P), muscle (M), and liver and red blood cells (LR). 
PFK is allosterically inhibited by ATP and citrate, and activated by fructose-2,6-bisphosphate. PK is 
inhibited by ATP and acetyl-CoA2, and PKLR is inhibited by c-AMP3. On the other hand fructose-1,6-
bisphosphate activates PKM. Gluconeogenesis is regulated at the level of PCK1, which is activated 
by acetyl-CoA, and by FBP1, which is inhibited by fructose-2,6-bisphosphate and AMP. Glucagon 
raises cAMP level in the cell, and inhibits fructose-2,6-bisphosphate. This leads to the inhibition of 
glycolysis and stimulation of gluconeogenesis. Insulin on its turn increases the level of fructose-
2,6-bisphosphate, which leads to an opposite effect: stimulation of glycolysis and inhibition of 
gluconeogenesis (Elliott & Elliott, 2005; Nelson, et al., 2008). 
 
 
The TCA cycle is controlled by the conversion ratio of pyruvate to acetyl-CoA, and by the flux 
through CS, OGDH
4
, and IDH. These fluxes are regulated by the concentrations of substrates and 
products: NADH
5
 and ATP are inhibitors, and NAD+
6
 and ADP
7
 are activators. The key enzyme PDH 
                                                          
1
 ATP - Adenosine triphosphate 
2
 CoA – Coenzyme A 
3
 AMP - Adenosine monophosphate 
4
 OGDH – Oxoglutarate dehydrogenase 
5
 NADH - Nicotinamide adenine dinucleotide phosphate 
6
 NAD+ - Nicotinamide adenine dinucleotide 
7
 ADP - Adenosine diphosphate 
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complex is allosterically inhibited by several metabolites including acetyl-CoA, NADH, ATP and 
fatty acids, while the PDH complex is activated by AMP, NAD+ and CoA (Elliott & Elliott, 2005; 
Nelson, et al., 2008). 
Changes of CCM in cancer 
The above described liver metabolism and its regulation is valid for the healthy liver. 
However, the impairment of metabolism during liver cancer has not yet been investigated in a 
global way. The vast majority of publications are devoted to metabolism of other cancer types. 
Under normal conditions most healthy cells have a low rate of glycolysis which is followed by 
further oxidation of pyruvate in the mitochondria.  According to Otto Warburg’s findings in 1956 
(Warburg, 1956), a hallmark of cancer cells is anaerobic glycolysis even under aerobic conditions. 
This behavior, involving increased glucose consumption with consequent excessive production of 
lactate, is called the Warburg effect. Further studies of the Warburg effect in various cancer types 
have addressed the efficiency of cancer cell metabolism. Even though mitochondrion metabolism 
does not work at full capacity, the metabolites produced from nutrients in CCM can be taken up 
and incorporated into the nucleotides, amino acids, and lipids (Vander Heiden, Cantley, & 
Thompson, 2009). However, liver metabolism is different from the metabolism of other tissues 
and organs, it has various metabolic functions, and regulation of these functions is liver-specific. 
One of the main aims of this work is to find out whether the samples analyzed in the present work 
show a Warburg effect-like behavior, and evaluate the role of major regulator enzymes of CCM 
and others enzymes participating in liver metabolism.  
The diversity of metabolic phenotypes and metabolic reprogramming of HCC has not yet 
been studied with a systematic approach. Several authors, however, addressed this subject in a 
focused way. For example, Yu and colleagues in 2015 suggest kidney-type glutaminase (GLS1) as a 
biomarker for pathologic diagnosis and prognosis of HCC (Yu, et al., 2015). The authors studied an 
altered glutaminolysis in HCC, but did not perform a full CCM analysis. A conceptually similar 
approach was applied by Hirata et al. in their work devoted to fructose-1,6-bisphosphatase level 
changes during tumor progression of HCC (Hirata, et al., 2016). A more global and ambitious 
attempt at analysis of the tissue metabolome of HCC was published by Beyoğlu and colleagues in 
2013. These authors studied tumor energy metabolism and the role of the above mentioned 
transcriptomic classification (Beyoglu, et al., 2013). While the authors indeed found some 
differences in various types of HCC (based on G1-G6 classification), their cohort and human tissue 
material choices had limitations, which will be properly discussed in this thesis later. While 
recognizing the scientific significance of those very thorough and detailed works, it is important to 
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point out a lack of global systematic studies of the whole CCM as a process in the field of HCC 
research. The deficit of fundamental knowledge of processes taking place during HCC 
development may lead to a lack of diagnostic and treatment options, and therefore to a poor 
disease prognosis. Elucidation of HCC-specific key features of metabolism will lead to a better 
understanding of this disease, and potentially point to additional diagnostic and treatment 
options. 
 
 
Systems biology approach 
Systems biology...is about putting together rather than taking 
apart, integration rather than reduction…  
-Denis Noble, The music of life: Biology beyond the genome, 2006 
To evaluate the metabolic phenotype of HCC a systematic approach is required (R. Z. Shang, 
Qu, & Wang, 2016), and systems biology is ideally suited to work on this task (Tian, Price, & Hood, 
2012; Willekens, et al., 2009). Systems biology studies the interactions between various 
components of biological systems and how these interactions affect the behavior of that system 
(Snoep & Westerhoff, 2005). For example, proteome and metabolome studies uncovers the in situ 
phenotypes of various tissues (Yizhak, Benyamini, Liebermeister, Ruppin, & Shlomi, 2010). Prior to 
mass spectrometry, proteomics approaches mostly included western blotting (Burnette, 1981; 
Paoletti & Chang, 2000) and enzymatic essays (Reisch & Elpeleg, 2007; Tietze, 1969). While these 
methods are reliable and specific, they are rather time-consuming, which reduces the possibility of 
comparatively fast thorough analysis of large amount of proteins. Two dimensional polyacrylamide 
gel electrophoresis (2D-PAGE) allows the analysis of hundreds to thousands of proteins, but its 
pipeline does not include automated high throughput analysis (Berth, Moser, Kolbe, & Bernhardt, 
2007; Klose, 1975; O'Farrell, 1975). By contrast, modern shotgun mass spectrometry proteome 
analysis grants the possibility to reliably detect and identify thousands of proteins in tissue sample 
as small as 1 mg (Guo, et al., 2015; Jacobs, et al., 2005).  
Metabolomic methods allow users to analyze various metabolites in living systems. 
Metabolomics studies are performed mostly with several methods, such as nuclear magnetic 
resonance (NMR) (Cohen, Shulman, & McLaughlin, 1979; Lin, Wu, Tjeerdema, & Viant, 2007; 
Martínez-Granados, et al., 2006), various assays (Gough, Armour, & Baker, 1997; Tolosa, Malak, 
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Raob, & Lakowicz, 1997), and analytical instruments (such as Seahorse XF technology by Agilent 
(Pandya, et al., 2016)), and MS. NMR is reproducible, however the sensitivity is an issue. Seahorse 
XF technology allows to measure only few products of the intracellular reactions. The spectrum of 
metabolites analyzed by these methods and assays is very limited compared to the possibilities of 
MS. In-house MS associated bioinformatics pipelines developed in the Kempa group allow us not 
only to detect and identify, but also to potentially quantify more than a hundred metabolites in a 
single sample (Kuich, Hoffmann, & Kempa, 2014).  
Genome analysis can be performed in using both non-targeted (whole genome sequencing 
(Fujimoto, et al., 2012; Ng & Kirkness, 2010)) and targeted methods. The latter is achieved by 
panel sequencing (Easton, et al., 2015; Kammermeier, et al., 2014), where the researched focuses 
on analysis of known mutations. It allows the detection of mutations (for example, main somatic 
cancer-associated mutations) in the genome and avoids massive data sets, in contrary to whole 
genome sequencing. In the present work, I used panel sequencing to identify the main cancer-
related somatic mutations in human liver tissue. Combined with proteomics and metabolomics, 
analysis of mutations could allow the evaluation of links between mutations and metabolic 
phenotypes. 
Thus, I focused on proteomic and metabolomic analyses as well as genotyping for a better 
understanding of the mechanisms which cause changes in the liver during progression from a 
normal state to HCC. 
Aims 
Current work aims to answer the following questions: 
• What is the role of metabolism in HCC development? 
• Are the metabolic changes in HCC-affected liver tissue mirrored in serum samples? 
• Which differences can be detected in the metabolomic, proteomic, and genomic profiles 
of liver tissues with developed HCC compared to non-cancerous liver tissue? 
• How heterogeneous are the CCM profiles of various HCC samples across multiple 
patients? 
• How are the proteomic and metabolomic profiles and perturbations in HCC 
interconnected and how does this relate to the genetic mutations status of HCC tissue? 
• Is there a way to predict the patient’s prognosis? 
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Mouse model 
The description of the model we used in our research was published by Nathalie Dubois and 
her colleagues in 1991 (Dubois, et al., 1991). The authors developed a transgenic ASV-B mouse 
HCC model with the presence of lung metastasis in 10% of the cases. The ASV-B mouse model was 
established in the B6D2F1 mouse, which is a cross between a C57BL/6J female and a DBA/2J male. 
A precise targeting of the SV40 T early region expression in the liver of transgenic mice was 
obtained using 700 bp of the antithrombin III regulatory sequence to control oncogene expression. 
In the strain expressing the highest level of SV40 large T antigen (Tag), the incidence of 
hepatocarcinoma was 100% (Dubois, et al., 1991). The progress of HCC was reproducible and 
characterized by the development of cytolysis by the 4th week, when no morphological and 
histological modifications were visible. Hepatic cytolysis can be indicated by measuring the 
ornnithine transcarbamylase (OTC) activity in the serum of mice (Dubois, et al., 1991). The OTC 
level increases drastically in plasma after hepatic cell lysis (Feigelson, Pecau, Cathelineau, & 
Navarro, 1975). A pre-neoplastic state was marked by a progression from hyperplasia to 
proliferative nodules composed of highly differentiated cells exhibiting a high Tag expression, 
which could elicit tumor formation in nude mice and could proliferate in vitro. In 10% of the cases, 
hepatocellular carcinoma was associated with lung metastasis (Dubois, et al., 1991).  
The ASV-B mouse model used shows dysplastic nodule formation at the age of 8 weeks. By 
the 12th week, adenomas in the liver can be observed and differentiated HCC develops in these 
mice by the 16th week. The cohort for the current study was formed from 7 mice at 16 weeks old 
with fully developed HCC and 7 C57BL/6J mice of the same age as healthy controls. The C57BL/6J 
mice had to be used as healthy control, because all ASV-B mice (both males and females) are 
genetically modified thus cannot be considered healthy.  
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Materials and methods 
Mice 
Mouse model 
The ASV-B model described by (Dubois, et al., 1991) was used in this study. The cohort 
included 7 ASV-B mice at 16 weeks old and 7 healthy C57BL/6J at 16 weeks old as a healthy 
control. Both male and female mice from ASV-B model have modified genetic background, thus 
the healthy control had to be obtained from a different mouse strain. 
All mice were maintained under standard conditions at the animal facilities in Berlin 
(Charité) and Aachen (Institut für Versuchstierkunde, University Hospital Aachen). Animal 
procedures were performed in accordance to approved protocols (Landesamt für Gesundheit und 
Soziales, Berlin (0024/12) and Landesamt für Natur, Umwelt und Verbraucherschutz, Düsseldorf 
(84-02.04.2015.A344, AZ84-02.04.2016.A018 and 84-02.04.2015.A216)) and followed 
recommendations for proper care and use of laboratory animals. 
Material overview 
The liver tissue obtained from the mice was used for proteomic and metabolomic analysis. A 
full description of the method development is described in Results section. The amount of 
material used for proteomics was: 4.4-9.1 mg, for metabolomics: 3.9-8.9 mg; and for test 
extraction of DNA: 4.9-8.2 mg. DNA was extracted and quantified in order to estimate the amount 
of material which could be obtained by this method. However, in this study we have not 
performed the genomics analysis of the mouse model, because all mice have the same known 
genetic background. 
Proteomics 
The samples were lysed in urea buffer using a Tissue Lyser (Precellys 24 lysis and 
homogenization, Bertin Technologies, France) and zirconium beads (5000 rpm, 20 second cycle 
time, 2 cycles). 
In-solution digestion 
Proteins were reduced in 2mM dithiothreitol (DTT) for 30 minutes at 25 °C and free 
cysteines were alkylated (to prevent the formation of disulfide bridges) in 11 mM iodoacetamide 
(IAA) for 20 minutes at room temperature in darkness. LysC digestion was performed by adding 
LysC (Wako) in a ratio 1:40 (w/w) to the sample and incubating it for 18 hours under gentle 
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shaking at 30°C. After LysC digestion, the samples were diluted 4-fold with 50 mM ammonium 
bicarbonate solution, 7 µL of immobilized trypsin (Applied Biosystems) was added and samples 
were incubated for 4 hours on a rotator at 30 °C (Rotator SB3, Stuart, UK).  Digestion was stopped 
by acidification with 10 µL of trifluoroacetic acid (TFA) and trypsin beads were removed after the 
centrifugation. 15 µg of protein were desalted on C18 STAGE Tips, dried in rotational vacuum 
concentrator and dissolved in 25 µl of 0.5 % acetic acid in water (Rappsilber, Ishihama, & Mann, 
2003). 
LC-MS analysis 
5 µL of peptides in 0.5% acetic acid were injected in duplicate on a nano LC-MS/MS system 
(NanoLC-Ultra, Eksigent, Singapore) coupled to LTQ-Orbitrap Velos mass spectrometer (Thermo 
Fischer Scientific, USA), using a 240 minutes gradient ranging from 5% to 40% of solvent B (80% 
acetonitrile, 0.1 % formic acid; solvent A=5 % acetonitrile, 0.1 % formic acid). For the 
chromatographic separation a 20 cm long capillary (75 µm inner diameter) was packed with 3 µm 
C18 beads (Reprosil-AQ, Dr. Maisch). On one end of the capillary a nanospray tip was generated 
using a laser puller (P-2000 Laser Based Micropipette Puller, Sutter Instruments), allowing fretless 
packing. 
The nanospray source was operated with a spray voltage of 1.9 kV and ion transfer tube 
temperature of 260 °C. Data were acquired in data dependent mode, with one survey MS scan in 
the Orbitrap mass analyzer (resolution 60000 at m/z 400) followed by up to 20 MS/MS (LTQ-
Orbitrap Velos) in the ion trap on the most intense ions (intensity threshold=750 counts). Once 
selected for fragmentation, ions were excluded from further selection for 30 seconds, in order to 
increase new sequencing events. 
Data processing and analysis 
Raw data were analyzed using the MaxQuant proteomics pipeline (v1.5.2.8) and the built-in 
Andromeda search engine (Cox, et al., 2011) with the updated Uniprot database including 
isoforms (UniProtconsortium, 2017). Carbamidomethylation of cysteines was chosen as a fixed 
modification, oxidation of methionine and acetylation of N-terminus were chosen as variable 
modifications. The search engine peptide assignments were filtered at 1% FDR
1
 and the feature 
match between runs was not enabled; other parameters were left at default settings.  
                                                          
1
 FDR – false discovery rate 
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After detection and identification, the contaminants (according to the list of contaminants 
provided by the software), proteins only identified by the modified site, and reversed were 
removed from the further analysis. The quality control of the proteome data was performed via in-
house developed software PTXQC (Bielow, Mastrobuoni, & Kempa, 2016). 
Metabolomics 
The metabolite extraction procedure consisted of a biphasic solvent extraction consisting of 
a mixture of methanol-chloroform-water (MCW) (5:2:1 v:v:v) (Methanol LC-MS-grade, Chloroform 
Reagent Plus ® 99,8% Sigma-Aldrich) with cinnamic acid (2 µg/mL, Sigma-Aldrich) as an internal 
standard. Samples were lysed in MCW (1 mL per 30 mg of sample) using the tissue lyser (Precellys 
24 lysis and homogenization, Bertin Technologies, France) and zirconium beads, samples were 
cooled on ice between the shaking cycles. Samples were shaken for 60 min at 1000 rpm at 4°C. 
After addition of ice cold water (at half the MCW volume originally used) samples were shaken for 
10 min at 1000 rpm at 4°C. Samples were centrifuged for 10 min at 20000 rcf to separate the polar 
(top), lipid (bottom) and interphase (tissue debris) layers. The polar phase containing polar 
metabolites was dried under vacuum for 12 h (in the Rotational vacuum concentrator (RVC) 2-33 
CD plus, Christ, Germany). 
The derivatization procedure consisted of the dried extracts being dissolved in 10 μL of 
methoxyamine hydrochloride solution (Sigma, 40 mg/mL in pyridine (Roth)) and incubated for 
90 min at 30°C with shaking at 1000 rpm followed by the addition of 40 μl of N-methyl-N-
[trimethylsilyl] trifluoroacetamide (MSTFA; Machery-Nagel, Dueren, Germany) and incubation at 
37°C for 45 min with shaking at 1000 rpm. The extracts were centrifuged for 10 min at 20000 rcf, 
and aliquots of 30 μL were transferred into glass vials (Chromacol, UK) for gas chromatography-
mass spectrometry (GC-MS) analysis. 
The analysis of metabolites was performed with a Pegasus IV mass-spectrometer (LECO, St. 
Joseph, USA) (details are described in (Pietzke, Zasada, Mudrich, & Kempa, 2014)).  
Data analysis: the GC-MS chromatograms were pre-processed with the ChromaTOF software 
(LECO). Calculation of retention index, mass spectra identification and metabolite quantification 
were performed using the in house Maui-VIA Software tool (Kuich, et al., 2014). Cinnamic acid was 
added as an internal control to estimate the extraction quality, and further normalization of the 
signal intensities. The 75% of cinnamic acid intensity of all samples was used a cut-off line. 
Samples, which had an intensity of cinnamic acid lower than 75% of the median were excluded 
from the analysis (one sample in the case of the mouse model).  
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Visualization of both proteomic and metabolomic data was performed with Vanted software 
v2.2.1. 
Genomics 
DNA extraction was performed from biopsy or surgery frozen material with DNeasy Blood 
and Tissue Kit (catalog number: 69504, Qiagen Inc, USA) according to manufacturer specifications: 
Purification of Total DNA from Animal Tissues (Spin-Column Protocol) (QIAGEN, 2006). The 
amount of DNA was measured by NanoDrop (NanoDrop ND-1000, Peqlab, Thermo Fischer 
Scientific, USA). 
Human cohort 
All procedures with human samples were performed in accordance to approved ethics 
protocol EK 206/09. 
Material overview 
In this study two types of human liver samples were analyzed: bioptate and surgical 
material. 95 patients were involved in this study. The cohort description and the rationale behind 
its development is given in the Results section. Amount of material for proteomics (obtained from 
both bioptate and surgery): 4.0-41.1 mg, for genomics: 6.9-66.0 mg, for metabolomics (the 
material amount was not sufficient for all the samples due to the small size of biopsy): 7.6-88.0 
mg. 
The cohort of human serum samples included 5 HCC patients, from whom serum was taken 
prior to and from 3 to 7 days after liver resection surgery. 5 patients with either hemangioma or 
cyst formed the control group. 
 
Proteomics 
Protein extraction from human samples was performed in the same way as the mice 
samples as described above. 
For all the samples in the time course experiment, 5 µL were injected on a LC-MS/MS system 
(samples 1-24 [batch 1]: NanoLC 1D Plus (Eksigent, Singapore) coupled to an LTQ-Orbitrap Velos 
(Thermo Fischer Scientific, USA); samples 25-95 [batch 2], serum samples: QExactive Plus (Thermo 
Fischer Scientific, USA)), using a 240 minutes gradient ranging from 5% to 45% of solvent B (80% 
acetonitrile, 0.1% formic acid; solvent A=5% acetonitrile, 0.1% formic acid). For the 
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chromatographic separation a 20 cm long capillary (75 um inner diameter) was packed with C18 
beads (Reprosil-AQ, Dr. Maisch). On one end of the capillary a nanospray tip was generated using 
a laser puller (P-2000 Laser Based Micropipette Puller, Sutter Instruments). 
The nanospray source was operated with a spay voltage of 2.1 kV and an ion transfer tube 
temperature of 260 degrees. Data were acquired in data dependent mode, with a top 20 method 
on the LTQ-Orbitrap Velos (batch 1: samples 1-24 of liver biopsies) (one survey MS scan in the 
Orbitrap mass analyzer, 60000 resolution at 400 m/z, followed by up to 20 MS/MS scans in the ion 
trap on the most intense ions, intensity threshold=750 counts) or a top 10 method on the 
QExactive Plus (batch 2: 25-95 of liver biopsies, and serum samples) (one survey MS scan with 
resolution 70,000 at m/z 200, followed by up to 10 MS/MS scans on the most intense ions, 
intensity threshold 5,000). Once selected for fragmentation, ions were excluded from further 
selection for 30 seconds, in order to increase new sequencing events. 
Both batches of raw data were analyzed together in one run using the MaxQuant 
proteomics pipeline (v1.5.3.12) and the built in the Andromeda search engine (Cox & Mann, 2008). 
MaxQuant enables high peptide identification rates, individualized parts per billion range (ppb-
range) mass accuracies and proteome-wide protein quantification (Cox & Mann, 2008) and the 
updated Uniprot database including isoforms was employed (UniProtconsortium, 2017).  
Carbamidomethylation of cysteines was chosen as fixed modification, oxidation of methionine and 
acetylation of N-terminus were chosen as variable modifications. The search engine peptide 
assignments were filtered at 1% FDR and the feature match between runs was enabled; other 
parameters were left at their default settings. 
After detection and identification, the contaminants (according to the list of contaminants 
provided by the software), proteins only identified by a modified site, and reversed were removed 
from the further analysis. The quality control of the proteome data was performed via in-house 
developed software PTXQC (Bielow, et al., 2016). The 17
th
 sample was excluded from the further 
data analysis because it did not pass the quality control, by not reaching the cut-off line of 1000 
protein identification counts.  
The proteomic analysis of human serum samples was performed in the same way. 
Metabolomics 
The extraction procedure of the metabolites from human samples were performed in the 
same way as with the mice samples described above. The analysis of metabolites, data analysis 
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and visualization were performed as described above for the mouse model. The availability of the 
samples is presented in Appendix 3. 
Genomics 
The following work was performed in the collaboration with Prof. Dr. Christine Sers and 
members of her lab: Dr. Soulafa Mamlouk and Andrea Menne. DNA extraction was performed 
from the biopsy or surgery frozen material with DNeasy Blood and Tissue Kit (catalog number: 
69504, Qiagen Inc, USA) according to the following protocol: Purification of Total DNA from Animal 
Tissues (Spin-Column Protocol) (QIAGEN, 2006). Due to the lack of DNA mutation data on the 
samples 32, 47, 74, 33, 16 is not available. 
Qualification and quantification of the extracted DNA was performed by TaqMan RNase P 
detection Reagents Kit (catalog number: 4316831, ThermoFisher scientific, USA). The amount of 
DNA varies from 0.7 to 50.1 ng/μL. The amplification of genomic DNA and the library preparation 
was performed using an Ion AmpliSeq Cancer HotSpot Panel v2 (CHP primer pool) was used 
(catalog number: 4475346, ThermoFisher scientific, USA). 
Library Preparation was performed in the following way. 10ng DNA was used for PCR 
amplification. Ion AmpliSeq Library Kit 2.0 (catalog number: 4475346, ThermoFisher scientific, 
USA) was used: PCR amplification with CHP primer pool; adapter ligation (IonXpress Barcode 
Adapters 1-16 (catalog number: 4471250, ThermoFisher scientific, USA) and IonXpress Barcode 
Adapters 17-23 (catalog number: 4474009, ThermoFisher scientific, USA)); purification using 
Agencourt AMPure beads (catalog number: A63881, Beckman coulter, Germany). 
Sequencing of each 32 samples (were pooled in each run) was performed in a single run on 
an IonTorrent PGM using a 318v2 Chip. 
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Results 
The phenomenon of metabolic reprogramming is one of the hallmarks of cancer. In the 
current work I aim to evaluate the role of metabolic changes in the hepatocellular carcinoma 
(HCC) development. The ASV-B mouse model suits this purpose very well: all the mice have the 
same genetic background, the same known cause of liver cancer and predictable time frames of 
HCC development. They are also easy to maintain in identical conditions. The mouse model also 
allows the inclusion of a suitable control group. Metabolomic and proteomic profiles of mice 
usually show rather stable trends due to the controlled experimental setup. By contrast, humans 
have heterogeneous genetic backgrounds and live in varying environmental conditions, resulting 
in many diverse causes (etiologies) of HCC. Numerous associated medical conditions are possible, 
and several factors, such as dietary habits or alcohol or drug abuse often remain unknown. Thus, 
analyses of the human proteome and metabolome often reveal less consistent profiles, then in 
laboratory mice. Researches have to assemble large cohorts to level the great heterogeneity in the 
human population in order to identify robust changes between HCC and non-HCC conditions in 
humans. Further comparison of knowledge obtained from both mice and humans would allow 
identification of universal key features of metabolic changes in HCC. 
 
1. Mice 
Mouse model 
In the present study I used 7 mice at 16 weeks old with fully developed HCC and 7 C57BL/6J 
mice of the same age as a healthy control. 
Method development 
In order to test whether the amount of material taken from each patient would be enough 
for the planned study, we took HCC material from mice using a biopsy needle. After the collection, 
the material was immediately frozen in liquid nitrogen and stored at -80 
◦
C. Prior to the analysis 
each sample was manually cut with a scalpel into 3 pieces in a pre-cooled mortar (scalpel, mortar, 
and forceps were cooled with liquid nitrogen). Biopsy sections were used for the proteomic, 
metabolomic and genomic analyses (Figure 3). The smaller piece of biopsy was used for proteomic 
analysis, medium-size part was used for genomic analysis, and the larger part was used for 
metabolomic analysis. The amount of material used was as follows: for proteomics: 4.4-9.1 mg, for 
38 
 
metabolomics: 3.9-8.9 mg; test extraction of DNA: 4.9-8.2 mg. Further multiomics analysis showed 
that the amount of material obtained by this procedure is enough for the designed experiments. 
 
 
Figure 3. Biopsy sample. Each biopsy was split on 3 parts: for the proteome, metabolome, and 
genome analyses respectively. 
 
Proteome analysis was performed on the respective part of biopsy. After detection and 
identification, the contaminants were removed, and thus the output matrix of MaxQuant 
(maxquant.org) consisted of 4335 proteins. For metabolomics, a GS-MS untargeted analysis of the 
metabolites extracted from the respective part of biopsy was performed. The investigation was 
focused on the panel of metabolites, which were detected and identified using the in-house 
developed software Maui-VIA (Kuich, et al., 2014). Using this developed pipeline and software we 
detected, identified and quantified 54 metabolites. 11 metabolites which participate in CCM, were 
used for further analysis. The amount of DNA extracted from the respective part of biopsy was 
sufficient for the further analysis of equivalent amount of human liver tissue. 
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Proteomics 
Proteome overview 
4335 proteins from 7 tumor and 7 control samples are reported in this study. Gene Ontology 
(GO) (Ashburner, et al., 2000; GOconsortium, 2015) framework in Perseus (v. 1.5.1.6) to estimate 
the molecular function of detected proteins was used. According to the GO 53.7% of all proteins 
detected participate in cellular metabolism. 53.8% of all proteins detected and identified in this 
experiment were significantly changed according to t-test, and 59% of the significantly changed 
ones belonged to cellular metabolism (Figure 4A). The t-test with adjustment for multiple testing 
was performed using the built-in algorithms in Perseus (v. 1.5.1.6). A p-value of below 0.05 was 
considered significant. 
Figure 4B shows the data obtained by different statistical approach, applied in Perseus (v. 
1.5.1.6). In order to work with the normally distributed data, it was log2 transformed. Filtering was 
applied to each group (control and HCC) to ensure neither group had more than 30% missing 
values before a two sample t-test was performed with an adjustment for multiple testing. 
Statistical significance was deemed to be 95% i.e. a p-value of less than 0.05. The output matrix 
contained 2581 proteins. 59% of fished-out proteins according to GO belonged to the group of 
cellular metabolism proteins. 72% of proteome was significantly changed in HCC group compared 
to non-HCC. 60% of significantly changed proteins belonged to cellular metabolism proteins 
according to GO (t-test, p<0.05). 
Both applied statistical methods revealed more than 50% of significantly changed proteins.  
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Figure 4. The mice proteome overview. Proteomic data was analyzed using Gene Ontology (GO) 
(Ashburner, et al., 2000; GOconsortium, 2015) framework in Perseus (v. 1.5.1.6) to estimate the 
molecular function of detected proteins. A. A Student’s t-test with adjustment to multiple testing 
was applied for the MaxQuant output matrix of 4335 proteins. According to the GO, 53.7% of all 
proteins detected participate in cellular metabolism. 53.8% of all proteins were significantly 
changed according to Student’s t-test, and 59% of the significantly changed proteins were 
identified by GO as belonging to cellular metabolism (t-test, p<0.05). B shows the data obtained by 
different statistical approach, applied in Perseus (v. 1.5.1.6). Log2 transformed data was used in 
order to work with the normally distributed data. The filtering on HCC and non-HCC groups were 
applied for each group to have no more than 30% of missing values, the data imputation (replaced 
missing values with normal distribution) was applied, and the two sample t-test was applied with 
the adjustment for multiple testing. The output matrix contained 2581 proteins. 59% of proteins 
according to GO belonged to the group of cellular metabolism proteins. 72% of proteome was 
significantly changed in the HCC group compared to control. 60% of significantly changed proteins 
belonged to cellular metabolism proteins according to GO (t-test, p<0.05). Rest – proteins which 
have not been shown to be significantly changed in the HCC group. 
 
Focused proteome analysis 
Further analysis concentrated on the enzymes of CCM and its isoforms. I selected 91 protein 
which participate in glucose metabolism, TCA cycle, FA synthesis and degradation, glycogen 
metabolism, pentose phosphate pathway (PPP) (Figure 2). Full names and short names are 
presented in Appendix 2. This list of 91 proteins remains the same for both mouse and human 
species. However, not all of the listed proteins were detected in the actual proteomic data. Some 
of proteins were detected only in human (for example, hexokinases). Thus, in the case of the 
mouse model, this list was shortened to 67 proteins.  
Hierarchical clustering in Perseus (v. 1.5.1.6) (parameters: distance - Pearson correlation, 
linkage – average) was performed on the protein label-free quantification (LFQ) intensities and 
revealed perfect separation of samples of two distinct groups: tumor and healthy control (Figure 
5). 
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Figure 5. Mice samples clustering based on chosen and detected proteins of CCM. Dendrogram 
clustering (parameters: distance - Pearson correlation, linkage – average, preprocessed without k-
means) performed on LFQ intensities of 67 proteins detected from a starting list of 91 chosen 
proteins revealed perfect separation of samples of two distinct groups: tumor and healthy control. 
Metabolomics 
In order to evaluate the changes in CCM at the metabolomic level between tumor and non-
tumor conditions, we extracted metabolites from mouse liver material (5 tumor samples and 7 
controls). We performed the GC-MS-based untargeted analysis of the metabolites. Further 
investigation focused on the panel of metabolites, which were detected and identified using the 
in-house developed software MAUI-VIA (Kuich, et al., 2014; Pietzke, et al., 2014). Using the 
developed methods and software, we were able to detect and identify 54 metabolites. In the mice 
samples 11 metabolites, which participate in CCM (Figure 2) were used for the further analysis: 
glucose, glucoses-6-phosphate, fructose-6-phosphate, phosphoenolpyruvate, lactate, citrate, 
succinate, fumarate, malate, aspartate, and glutamine. 
Multiomics picture 
The major aim of this project was to identify differences between HCC and non-HCC 
metabolism of liver tissue. Vanted software (v. 2.2.1) was used to visualize the relative changes in 
the main metabolic enzymes at an isoform level, and metabolites. Here and further I compared 
the changes of mean values of proteins and metabolites intensities. 
Proteome and metabolome analyses revealed several striking differences between HCC and 
normal liver metabolism (Figure 6, 7, 8, 9). Figure 6 represents the overview of CCM changes in 
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HCC. In liver tissue damaged by HCC the glycogen metabolism was impaired: glycogen synthase 
(Gys2) level was 3.6 fold lower in HCC compared to control (t-test, p=3.26*10
-8
).  
Gluconeogenesis was downregulated at the level of phosphoenolpyruvate carboxykinase 1 
(Pck1), which was expressed 16 times less in HCC samples (t-test, p=2.96*10
-14
), G6pc was not 
detected in HCC samples.  
Transport of pyruvate to mitochondria was impaired at the level of mitochondrial pyruvate 
carrier 1 (Mpc1): 4.2 times lower in HCC (t-test, p=1.08*10
-5
), and Mpc2: 1.3 times lower
1
 in HCC 
(t-test, p=2.54*10
-3
) (Figure 7). 
60% of TCA cycle enzymes were downregulated, for example citrate synthase (Cs) 
expression was 2.6 times lower in HCC (t-test, p=2.18*10
-14
), and succinate dehydrogenases A and 
B (Sdha and Sdhb) were expressed 2 and 3 times less respectively in HCC (t-test, p=1.14*10
-10
 and 
p=2.96*10
-14
 p=3.58*10
-16
 respectively) (Figure 8). 
Enzymes, which are responsible for the glutamine uptake to the TCA cycle showed lower 
expression in the HCC samples. Glutamate pyruvate transaminase (Gpt), glutamate pyruvate 
transaminase 2 (Gpt2), and glutaminase 2 (Gls2) were 1.8, 1.5, and 11 times lower in HCC, 
respectively (t-test, p=5.51*10
-8
, p=3.71*10
-5
, p=6.83*10
-14
) (Figure 8).  
Phosphoglycerate mutases (Pgm) and pyruvate kinases (Pk) showed isoform switches, which 
represents one of most striking features of metabolic changes in cancer.  
At the metabolomic level the upregulation of glycolysis could be observed: glucose-6-
phosphate level in the tumor was 3.2 times higher (t-test, p=0.0006), fructose-6-phosphate 3.2 
times higher in tumor, (t-test, p=0.0007). Lactic acid level was 1.4 times higher (t-test, p=0.007), 
fumaric acid 1.4 times higher in HCC samples (t-test, p=0.03), and malic was 1.9 times higher in 
HCC (t-test, p=5.16*10
-7
) (Figure 9) compared to control. 
                                                          
1
 Here and further it is important to note, that while statistically speaking this difference is significant, its 
biological impact is questionable. However, even a small fold change in a hormone or in a key regulatory 
enzyme may have large consequences. Thus, I chose to present the data even though the fold change is less 
than 2, because the trends of changes are relevant in this work. 
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Figure 6. Changes in CCM in mouse HCC tissue compared to a control group. The figure visualizes 
with a colour code the changes of metabolism in liver tissue damaged by HCC compared to a 
group of control samples at the proteomic and metabolomic levels. The glycogen metabolism at 
the proteomic level was perturbed at the level of Gys2 enzyme (here and further proteins are 
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visualized with squares): it was 3.6 fold lower in HCC compared to a control group (t-test, 
p=3.26*10
-8
). Gluconeogenetic enzyme Pck1 was expressed 16 times less in HCC samples 
compared to a control group (t-test, p=2.96*10
-14
), while G6pc enzyme was not detected in HCC 
samples (and detected in control samples). Mpc1 (responsible for the transport of pyruvate to 
mitochondria) was expressed 4.2 times lower in HCC compared to a control group (t-test, 
p=1.08*10
-5
), and Mpc2 (participates in the transport of pyruvate to mitochondria as well) was 
expressed 1.3 times lower in HCC (t-test, p=2.54*10
-3
). Approximately 60% of TCA cycle enzymes 
were downregulated. Cs enzyme was expressed 2.6 times lower in HCC (t-test, p=2.18*10
-14
), and 
Sdha and Sdhb were expressed 2 and 3 times lower in HCC (t-test, p=1.14*10
-10
 and p=3.58*10
-16
 
respectively). Sdhc was not detected in HCC samples, while it was detected in the samples of a 
control group. Other TCA cycle enzymes, such as Gpt, Gpt2, Gls2 were 1.8, 1.5, and 11 times lower 
in HCC, respectively (t-test, p=5.51*10
-8
, p=3.71*10
-5
, p=6.83*10
-14
). Isoform switch in HCC 
samples was detected at the level of two glycolytic enzymes: PGMs, PKs. Changes in metabolites 
(visualized with circles) were detected in glycolysis. Glucose-6-phosphate level was 3.2 times 
higher in HCC samples compared to a control group (t-test, p=0.0006), fructose-6-phosphate is 3.2 
times higher in HCC samples compared to a control group, (t-test, p=0.0007). Several metabolites 
of TCA cycle undergo changes. The detected lactic acid level was 1.4 times higher (t-test, p=0.007) 
in HCC samples compared to a control group, fumaric acid was 1.4 times higher in HCC samples (t-
test, p=0.03) compared to a control group, and malic acid was 1.9 times higher in HCC group of 
samples (t-test, p=5.16*10
-7
) compared to a control group. The metabolites are visualized with 
circles, the proteins are visualized with squares, bold frame indicates the changes with p<0.05 (t-
test), grey colour of the metabolite (circle) or protein (square) at the scheme indicates that data 
regarding certain enzyme or metabolite was not available. Red colour indicates decrease of 
intensity in HCC samples, blue colour indicates increase of intensity in HCC samples. 
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Figure 7. Box plots with the relative intensities of glycolytic and gluconeogenetic enzymes, and 
mitochondrion pyruvate transporters in mouse HCC samples compared to a control group. An 
intensity of Gys2 enzyme was 3.6 lower in HCC samples compared to a control group (t-test, 
p=3.26*10
-8
), G6pc was not detected in HCC samples while detected in the samples of control 
group, Pck1 intensity was 16 times lower in HCC samples compared to a control group (t-test, 
p=2.96*10
-14
). Mpc1 intensity was  4.2 times lower in HCC group of samples compared to a control 
group (t-test, p=1.08*10-5), and Mpc2 intensity was 1.3 times lower in HCC samples compared to 
control samples (t-test, p=2.54*10
-3
). N.d. – not detected. 
N.d. 
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Figure 8. Box plots with the relative intensities of TCA cycle and glutaminolysis enzymes in 
mouse HCC samples compared to a control group. Relative intensity of Cs enzyme was 2.6 times 
lower (t-test, p=2.18*10-14) in HCC samples compared to a control group, an intensity of Sdha was 
2 times lower in HCC samples compared to a control group (t-test, p=1.14*10
-10
), an intensity of 
Sdhb was 3 times lower (t-test, p=3.58*10-16) in HCC samples compared to a control group. 
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Relative intensities of Gpt, Gpt2, Gls2 were 1.8, 1.5, and 11 times lower in HCC compared to a 
control group, respectively (t-test, p=5.51*10
-8
, p=3.71*10
-5
, p=6.83*10
-14
). 
 
Figure 9. Box plots with the relative intensities of detected metabolites of CCM in mouse HCC 
compared to a control group. Relative intensity of glucose-6-phosphate was 3.2 times higher in 
HCC samples compared to a control group (t-test, p=0.0006), fructose-6-phosphate intensity was 
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3.2 times higher in HCC samples compared to a control group, (t-test, p=0.0007). Relative 
intensities of TCA cycle enzymes were the following: lactic acid intensity was 1.4 times higher in 
HCC samples compared to a control group (t-test, p=0.007), an intensity of fumaric acid was 1.4 
times higher in HCC samples in HCC samples compared to a control group (t-test, p=0.03), and 
malic acid intensity was 1.9 times higher in HCC compared to a control group (t-test, p=5.16*10
-7
). 
 
2. Human cohort 
Formation of the patient cohort  
This study focuses on the comparison of the main metabolic changes between liver samples 
with HCC and samples with pre-cancerous conditions and comparatively mild liver conditions, such 
as fatty liver. Several possible confounding factors had to be considered during the cohort 
formation to account for the great heterogeneity among patients. Nutritional factors/diet and 
alcohol abuse are usually difficult to track, due to the incomplete anamnesis collection and 
patients not willing to admit to any illegal actions. We excluded patients (according to their 
anamnesis) with known exposure to certain hepatotoxins (e.g. aflatoxin, industrial toxins), as well 
as patients with long-term usage of certain medication (6 month of use or longer) (for example, 
insulin or aspirin) (to avoid including various drug-induced liver diseases in the cohort). Patients 
with hereditary conditions, metabolic disorders or autoimmune diseases were excluded from the 
second part of cohort (samples 36-95). Thus the patients with hemochromatosis, Gilbert's 
syndrome, Dubin–Johnson syndrome, Crigler–Najjar syndrome, Wilson's disease, alpha 1-
antitrypsin deficiency, mucoviscidosis, galactosemia, dyslepidemia, and others were not included 
in the cohort. However, a few samples from patients with diabetes, obesity, and alcohol addiction 
happen to be in the cohort1 (for example, the information about BMI came to the lab later than 
the actual sample).  
Current hepatitis viral load was considered, and a separate groups of patients with hepatitis 
virus B or C were formed. Unfortunately, we were not able to track whether the patients had a 
history of previous hepatitis exposure. Patients with other detected viruses (e.g. HIV) were 
excluded from the cohort. We also excluded patients who required regular blood transfusions, 
because the iron overload of the liver could affect the metabolic picture. Liver cancer types were 
histologically diagnosed in the clinic. All HCC samples were diagnosed with primary tumors. To the 
                                                          
1
 Diabetes type 1: 21; diabetes type 2:19, 23, 24, 28; patients 18, 20, 24, 46, 49, 56, 65 suffered from obesity 
(BMI ≥30 kg/m
2
, recidive HCC: 74, 84; alcohol addiction: 16, 17, 18, 23, 26, 30, 64, 80, and 93. 
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best of our knowledge patients did not get any treatment (radionuclide treatment, percutaneous 
ethanol injections, chemotherapy etc.) prior to the surgery or the biopsy procedures. Blood tests 
(aspartate transaminase (AST), alanine transaminase (ALT), AFP, blood count, biochemistry) are 
the subject of further investigation. Figure 10 shows the heterogeneity of the diseases and 
conditions of the patients used in this study. Full diagnosis and additional information including 
the availability of material for full multiomics analysis is to be found in Appendix 3. 
 
 
Figure 10. Human cohort overview. The cohort consisted of 95 patients with various conditions, 
such as fatty liver, fibrosis, cirrhosis, hepatitis B and C, and HCC.  
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Human liver material overview 
In this study two types of human liver samples were analyzed: bioptate and surgery 
material. The human biopsy material was taken under the control of CT from the patients prior to 
the treatment. Since we were interested in the investigation of the in situ picture, this study was 
focused only on patients prior to any medical intervention (radionuclide treatment, percutaneous 
ethanol injections, chemotherapy etc.). The surgical material was obtained during the resection of 
liver damaged by HCC. 
A total of 6213 proteins were detected in the 94 samples (excluding the 17
th
) and included in 
the study. Using the developed pipeline and the software we were able to detect and identify 89 
metabolites, 8 of these which participate in CCM, were used for further analysis. Our cohort 
included 95 patients, however the amount of material for targeted genomic analysis was only 
available from 90 patients due to the lack of material. Mutations in 10 different genes were 
detected in the cohort. 
Proteomics 
Proteome overview 
The proteome analysis was performed in Perseus (v. 1.5.1.6). As shown in Figure 11A, 56% of 
proteins according to GO belonged to the group of cellular metabolism proteins. A Kruskal-Wallis-
Test (KW-test) (the choice of method was performed according to the article published by du Prel 
(du Prel, Röhrig, Hommel, & Blettner, 2010)) with adjustment for multiple testing revealed that 
44% of proteins were significantly changed in tumor samples compared to control, 61% of which 
belonged to metabolic proteins (KW-test, p<0.05). 
Figure 11B shows the data obtained by a different statistical approach, applied in Perseus (v. 
1.5.1.6). In order to work with normally distributed data, it was log2 transformed. The filtering for 
HCC and non-HCC groups was applied such that each group has no more than 30% missing values, 
the two sample t-test was applied with the permutation-based FDR and adjustment for multiple 
testing was performed (with the Perseus build-in algorithms). The output matrix contained 2556 
proteins. 67% of proteins according to GO belonged to the group of cellular metabolism proteins. 
65% of proteome was significantly changed in HCC group compared to non-HCC. 64% of 
significantly changed proteins belonged to cellular metabolism proteins according to GO (t-test, 
p<0.05). 
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Both applied statistical methods (KW and t-test) revealed approximately 50% of significantly 
changed data. Reasons for such high number of significantly changed proteins are reviewed in the 
Discussion section. 
A. 
  
B. 
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Figure 11. Human proteome overview. A. A total of 6213 proteins were annotated with Gene 
Ontology (GO). According to GO, 56% of proteins belonged to the group of cellular metabolism 
proteins. A Kruskal-Wallis test with correction for multiple testing revealed expression of 44% of 
proteins as significantly changing in tumor samples compared to control, 61% of which belonged 
to the class of metabolic proteins (KW-test, p<0.05). B. In order to work with normally distributed 
data, data was log2 transformed. Filtering was applied to both HCC and non-HCC groups such that 
neither group has more than 30% missing values. Following this, a two sample t-test was applied 
to the data with a permutation-based FDR and adjustment for multiple testing. The output matrix 
contained 2556 proteins. 67% of these proteins (according to GO) belonged to the group of 
cellular metabolism proteins. 65% of the proteome was significantly changed in the HCC group 
compared to non-HCC. 64% of the significantly changed proteins belonged to the group of cellular 
metabolism proteins according to GO (t-test, p<0.05). Rest refers to the proteins where no 
statistically significant change was observed. 
 
Focused proteome analysis 
The subsequent analysis was focused on CCM enzymes and enzymes and their isoforms 
which are responsible for the main liver metabolic functions. The same 91 proteins were used 
which were chosen for the mouse model analysis (Figure 2, Appendix 2). However, in the case of 
human samples, not all of the listed proteins were detected in the obtained proteomics data. 
Thus, this list was shortened to 87 proteins.  
Additionally, in Perseus (v. 1.5.1.6), I performed a hierarchical clustering analysis based on 
proteomic data (parameters: distance - Pearson correlation, linkage – average), displayed in Figure 
12. This figure displays the clustering according to the label-free quantification (LFQ) values of the 
91 proteins mentioned above in patients 01-95. Pearson correlation was selected as a similarity 
measure since it ensures internal normalization in contrast to Euclidian distance. I also performed 
the clustering using Spearman correlation, which showed similar trends (Appendix 4). Since the 
calculation of the Spearman correlation requires an additional ranking step and reduces the 
information of the data, we decided to work further with the Pearson correlation. However both 
Euclidian and Spearman clustering show similar trends for the separation of different groups. 
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Figure 12. Human samples clustering based on chosen and detected 87 protein of CCM. 
Clustering according to the LFQ intensities of 91 proteins of patients 01-95 (the 17
th
 sample was 
excluded, because it did not pass the quality control (the explanation in the text)). Parameters: 
distance - Pearson correlation, linkage – average. 
 
Metabolomics 
In order to evaluate the changes of CCM at the metabolomic level for tumor and non-tumor 
conditions, I extracted metabolites from human liver material from clinical cases (see the 
availability of the material in Appendix 3). I performed GC-MS untargeted analysis of metabolites. 
The further investigation was focused on the panel of metabolites which were detected and 
identified using the in-house developed software Maui-VIA (Kuich, et al., 2014). Using the 
developed pipeline and the software we could detect and identify 89 metabolites. In the 
experiment with human samples, 8 metabolites which participate in CCM (Figure 2) were used for 
the further analysis: lactate, pyruvic acid, citrate, glutamic acid, succinic acid, fumaric acid, malic 
acid, and aspartate. 
It is crucial to underline that in general an overall increase in metabolite signal in the 
samples from the surgery was detected compared to the signal obtained from the biopsy material. 
Figure 13 shows the intensities of pyruvic, succinic, and citric acids in two groups of samples. The 
upper panel contains groups of samples with both surgical and biopsy material, the lower panel 
shows only the group without surgically delivered samples (only biopsies). All metabolites shown 
in the upper panel showed higher average intensities in the HCC group compared to tumor-free 
samples. Out of all detected and identified metabolites only 5% were higher in the tumor-free 
group of samples. The lower panel shows the intensities of metabolites extracted only from biopsy 
material. Out of all metabolites identified from biopsy material, 56% were at higher intensities in 
the tumor-free group. This unequal distribution of intensities of metabolites could be explained by 
the surgical conditions. The conditions under which the material from the patient is obtained takes 
several hours due to the necessary actions, such as fasting of the patient prior to the surgery, 
anesthesia, medication, clipping of the arteries and veins of the liver prior to the procedure etc. 
This leads to the adjusted metabolome profile, possibly determined by the hypoxic environment. 
We propose that the metabolome data obtained from the surgical material does not represent the 
original picture in situ of the intact liver. Thus, for the further metabolome analysis we decided to 
use only the data obtained from the bioptate material. 
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Figure 13. Box plots of recorded relative intensities of selected metabolites from surgical and 
biopsy material in HCC samples and tumor-free samples. Relative intensities of pyruvic, succinic, 
and citric acids are shown as two groups of samples. In the upper panel: values for pyruvic acid, 
succinic acid and citric acid obtained from the samples collected from both surgery and biopsy 
material. The average intensities of the measured metabolites in the HCC group were higher than 
in the tumor-free group. Lower panel: values for pyruvic acid, succinic acid and citric acid obtained 
from the biopsy samples exclusively showed different distribution of metabolites intensities, as 
compared to the values, obtained from surgery material. 
Genomics 
Our cohort included 95 patients, however, due to restrictions in amount of available 
material, only 90 patients were sequenced (excluding #16, 32, 33, 47, and 74 due to lack of 
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material). Sequence reads were aligned to the GRCh37 sequence using the Torrent Mapping and 
Alignment Program (TMAP) (ThermoFisher Scientific, USA). Variants were called on the processed 
reads using the Torrent Variant Caller (TVC) (ThermoFisher Scientific, USA) under the “strict” 
setting as specified by the IonTorrent Suite. The resulting data was analyzed with an in-house 
pipeline (developed by our collaborators in the lab of Prof. Dr. rer. nat. Christine Sers). We used a 
cut-off of 4% allele frequency (Table 2). Further analysis included removing known SNPs (The 
Genomes Project, 2015) and low quality reads (a threshold of quality Q=50 was used). 
Questionable mutations were verified by Sanger sequencing (CTNNB1 mutation in sample 95 was 
confirmed, SMAR mutation in sample 82 was found to be an error). Table 2 includes the verified 
mutations list: the mutated gene, exact mutation, patient code and diagnosis.  
The most commonly mutated gene in the cohort was TP53 gene (approximately 40% of all 
mutations detected): TP53 mutations were detected 13 times in the cohort (15% of all sequenced 
patients). 60% of TP53 mutations were detected in HCC samples, 40% in non-HCC samples. The 
second most commonly mutated gene is CTNNB1: 8% of sequenced patients had mutation in this 
gene (21% of all mutations in the cohort, detected only in HCC samples). Other genes (APC, ATM, 
CDKN2A, NOTCH1, PIK3CA, PTEN, RB1, STK11) were found to be mutated less frequently, in both 
HCC and non-HCC samples. No clear distinction between HCC and non-HCC samples was possible 
to perform exclusively from targeted mutation analysis. 
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Table 2. Detected, identified and verified somatic tumorigenic mutations in human cohort. Additional 
information about patients can be found in Appendix 3. HAV, Hepatitis A virus; HBV, Hepatitis B virus; 
HCV, Hepatitis C virus; Fibrosis+, Advanced Fibrosis/Cirrhosis; Diab2, Diabetes Type 2;, del, deletion; 
ins, insertion; fs, frame shift. 
Gene Mutation Amino acid Diagnosis Patient ID Allele frequency 
TP53 c216delC p.V73fs OGDH 2 0.32 
RB1 c.C1966T p.R656W HBV 2 0.44 
STK11 c.C1062G p.F354L Fatty Liver 9 0.48 
CTNNB1 c.A121G p.T41A HCC, HCV, Diab2, Obesity 24 0.19 
TP53 c544_550del p.182_394del HCC, HCV, Diab2, Obesity 24 0.22 
PTEN c.T882G p.S294R HCC, HAV, HBV 27 0.08 
TP53 c.C452A p.P151H HCC 29 0.81 
PIK3CA c.A3140G p.H1047R HCC 35 0.09 
CTNNB1 c.T133C p.S45P HCC 35 0.22 
CDKN2A c.A248G p.H83R HCC 35 0.21 
TP53 c216delC p.V73fs HCV, Fatty Liver 38 0.82 
TP53 c216delC p.V73fs HCV, Fatty Liver 40 0.80 
APC c3916_3917insA p.I1307fs HCV, Fatty Liver 42 0.08 
APC c3916_3917insA p.I1307fs Fatty Liver 53 0.09 
TP53 c216delC p.V73fs HCV, Fibrosis+ 58 0.80 
NOTCH1 c4732_4734del p.1578_1579del HCV, Fibrosis+, Alcohol 64 0.04 
TP53 c.A704G p.N235S HCV, Fibrosis+, Obesity 65 0.51 
CTNNB1 c.C110T p.S37F HCC 67 0.23 
ATM c.T2572C p.F858L HCC 70 1.00 
TP53 c216delC p.V73fs HCC 71 0.79 
CTNNB1 c.C134T p.S45F HCC 76 0.42 
TP53 c216delC p.V73fs HCC 76 0.72 
TP53 c902delC p.P301fs HCC, Alcohol 80 0.62 
TP53 c.T581G p.L194R HCC, HBV 81 0.05 
ATM c.A8626G p.I2876V HCC 83 0.54 
CTNNB1 c.C134T p.S45F HCC 83 0.56 
PTEN c.G754T p.D252Y HCC 86 0.64 
TP53 c.C298T p.Q100X HCC, HAV, HBV 90 0.07 
STK11 c.C1040G p.A347G HCC 91 0.51 
CTNNB1 c.C134T p.S45F HCC 91 0.07 
PTEN c.A203G p.Y68C HCC, HBV, Alcohol 93 0.58 
TP53 c902delC p.P301fs HCC, HBV, Alcohol 93 0.62 
CTNNB1 c.C98T p.S33F HCC 95 0.39 
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Multiomics picture 
Classification 
Classification based on mutations 
Several possibilities of classification of HCC are currently discussed in the scientific 
community. We decided to start our work from the one suggested by Boyault et al. in 2007 
(Boyault, et al., 2007) and adapted by Beyoğlu et al. in 2013 (Beyoglu, et al., 2013). We tested 
whether this classification is applicable for the cohort we work with. Figure 14 displays the 
clustering according to the LFQ intensities of the 87 above mentioned proteins of samples 01-95 
(except 17). Mutations found are indicated with the name of the mutated gene in the lower part 
of the figure. Different colours represent different groups of HCC, according to the classification of 
Boyault (Boyault, et al., 2007). The primary decision on the grouping was based on the mutation 
status of the HCC samples. Since both G5 and G6 groups include CTNNB1 mutations, further 
distinction was based on e-cadherin expression. Samples which are not labeled with any colour do 
not fit in the any of the suggested groups. Samples labeled with two colours fit in both groups of 
HCC. Less than 1/3 of all HCC samples could be allocated to a group according to the features used 
by this classification system. Groups G1 and G4 did not include any human sample from the cohort 
I worked with. It is important to note that mutations were not detected in all of the samples. 
Various mutations existed in both HCC groups, and non-cancerous conditions, the lesion group 
also included patients where no mutations were found. 
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Figure 14. G1-G6 groups of HCC and its application to the cohort clustering according to the LFQ 
intensities of 87 above mentioned proteins of samples 01-95 (except 17). Mutations found are 
indicated with the name of the mutated gene in the lower part of the figure (detailed information 
can be found in Table 2). Different colours represent different groups of HCC, according to the 
classification of Boyault (Boyault, et al., 2007). Samples which are not labeled with any colour did 
not fit into any of the suggested groups. Samples labeled with two colours fitted into both groups 
of HCC. Groups G1 and G4 are not labeled with colours because none of samples from the cohort 
fitted into G1 or G4. 
 
Classification based on proteome 
In the current study I suggest an alternative grouping according to CCM proteins’ expression 
which is presented in Figure 15. It shows the separation of different liver disorders based on the 
proteome data with the focus on 87 CCM enzymes listed above. Group A is labeled with a violet 
colour, Group B is labeled with a red colour. The mutation status of each patient is indicated with 
the name of mutated gene (detailed information can be found in Table 2). Thus, Group A includes 
proteome data from 16 patients: 32, 70, 69, 71, 31, 27, 28, 30, 88, 82, 19, 20, 77, 85, 25, 86; and 
Group B from 31 patients: 24, 91, 68, 84, 94, 89, 90, 26, 33, 73, 23, 78, 93, 66, 74, 75, 22, 92, 21, 
29, 34, 95, 67, 87, 83, 79, 80, 35, 76, 81, 72.  
Further detailed proteome and metabolome analysis of CCM required a careful choice of 
control group. Healthy liver biopsies samples were not available due to ethical reasons. The next 
section (Control group) will describe the approach I used to define the control group of this study. 
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Figure 15. Groups A and B of HCC samples. The separation of different patients based on the 
proteomic data (LFQ intensities) with the focus on CCM enzymes and suggested grouping 
according to the proteome clustering. Group A is labeled with a violet, Group B is labeled with a 
red. The mutation status of each patient is indicated with the name of mutated gene.  
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Control group 
The aim to evaluate specific proteomic and metabolomic changes in CCM of HCC required a 
relevant control group. Healthy biopsy controls are difficult to obtain due to several ethical issues. 
Initially our experimental design included fatty liver (FL) samples as a control group, which, in our 
opinion, was the least severe condition in cohort. The group of FL samples is rather heterogeneous 
by gender and age of patients, presence of SNPs, and associated diseases. Therefore we 
performed an additional data analysis to evaluate the appropriate samples for the control group 
and confirm that FL group is indeed a valid control. 
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Table 3. Possible control groups from the human cohort comprised of fatty liver samples. 
Table shows possible control groups for the cohort: the group of fatty liver samples with no 
mutations and SNPs found consisted of 3 samples (dark green), which is not a sufficient amount 
for a valid control group. The other FL samples either did not have enough DNA for sequencing 
(#47), or contained SNPs and hotspots. The samples with confirmed potentially carcinogenic 
mutations (#9, 53) were excluded from the control group, as well as the sample #47 with no data 
available. Two different groups of possible controls were compared: [11, 12, 51] ‘small’ group 
(dark green), in which no mutations were found in the samples and [7, 8, 10, 11, 12, 46, 48, 49, 50, 
51, 52, 54, 55] ‘large’ group (pale green), which also contains the ‘small’ group in addition to 
samples with SNPs in order to validate that the ‘large’ can be used as a control group. 
  
Sample 
Code 
Diagnosis  Mutations and SNPs 
Mutations 
confirmed 
Age Gender 
7 Fatty Liver TP53 PIK3CA KDR   47 f 
8 Fatty Liver TP53 MET   49 m 
9 Fatty Liver STK11 KDR STK11 59 f 
10 Fatty Liver PIK3CA KDR   49 f 
11 Fatty Liver     43 m 
12 Fatty Liver     40 m 
46 Fatty Liver, Fibrosis TP53   46 m 
47 Fatty Liver, Fibrosis na   30 m 
48 Fatty Liver, Fibrosis SMARCB KDR   48 m 
49 Fatty Liver TP53   51 m 
50 Fatty Liver TP53 PIK3CA KDR   31 m 
51 Fatty Liver     64 f 
52 Fatty Liver, Fibrosis TP53 KDR   58 f 
53 Fatty Liver TP53 APC APC 55 m 
54 Fatty Liver, Fibrosis KDR MET   46 m 
55 Fatty Liver TP53 KDR   36 m 
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Figure 16 shows the correlation of the values taken from multiple CCM enzymes (60 proteins 
out of 91; proteins which were not detected in one of the groups were excluded from this 
analysis), the x axes contains the FL small group/HCC values, the y axes contains the FL large 
group/HCC values; y=0.92x+0.03, R2=0.96 of the trend line, confirming the high homogeneity of 
both groups. 
Based on the performed analysis the control group for further CCM proteome analysis 
contains samples: [7, 8, 10, 11, 12, 46, 48, 49, 50, 51, 52, 54, 55]; this allowed the use of a more 
heterogeneous and large cohort of control samples and considered the fibrotic and FL background 
as well as the possible influence of SNPs. 
 
Figure 16. The correlation of CCM proteins (LFQ intensities) between two possible control groups. The 
correlation of the values taken from multiple CCM enzymes (60 proteins out of 91, excluding proteins 
which were not detected in one of the groups), the x axes contains the FL small group/HCC values, the y 
axes contains the FL large group/HCC values; y=0.92x+0.03, R2=0.96 of the trend line. 
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FL small group – a group of Fatty Liver samples where no mutations or SNPs were found. The group 
includes samples 11, 12, 51. 
FL large group – a group of Fatty Liver samples with detected SNPs or with no mutations detected. The 
group includes samples 7, 8, 10, 11, 12, 46, 48, 49, 50, 51, 52, 54, 55.  
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Common changes in Central Carbon Metabolism of all HCC samples  
In order to visualize the proteome and metabolome changes I used Vanted (v. 2.2.1). I used 
the previously described CCM pathway with the 91 selected key enzymes. Figure 17 represents the 
colour-coded relative proteomic and metabolomic changes of CCM of the group including all HCC 
samples compared to the defined control group. At the proteomic level several key features of 
altered HCC liver metabolism could be underlined.  
Glycogen metabolism was downregulated: glycogen synthase, liver form (GYS2) was 2.5 
times lower in HCC (t-test, p=0.008), glycogen phosphorylase, liver form (PYGL) was 2.8 times 
lower in HCC (t-test, p=4.6*10
-7
) (Figure 18).  
Glucose de novo synthesis was downregulated: fructose-1,6-bisphosphatase 1 (FBP1) was 
2.9 times lower in HCC (t-test, p=1.13*10
-7
) (Figure 18).  
Transketolase (TKT) enzyme, involved in pentose phosphate pathway was 4.5 higher in HCC 
samples (t-test, p=1.09*10
-3
) (Figure 18). Several enzymes of glycolysis are upregulated, for 
example hexokinase 1 (HK1) was not detected in any of control samples, but was present in HCC 
samples (Figure 18). Glycolysis also showed an isoform switch at the level of phosphoglycerate 
mutases, aldolases, enolases, lactate dehydrogenases, and pyruvate kinases. For example, Figure 
19 shows that aldolase A (ALDOA) was expressed 7.4 times higher in HCC (t-test, p=5.12*10
-4
), and 
aldolase B (ALDOB) 3 times lower in HCC (t-test, p=4.49*10
-8
); enolase 3 (ENO3) was 6.4 times 
higher in control samples (t-test, p=2.83*10
-8
), D-lactate dehydrogenase (LDHD)  was 2.8 fold 
higher in HCC (t-test, p=1.71*10
-6
).  
Figure 20 shows the downregulation of the TCA cycle and glutaminolysis enzymes 
expression. Cytoplasmic aconitate hydratase (ACO1) was expressed 1.8 times lower in HCC 
samples (t-test, p=4.73*10
-4
), Succinate dehydrogenase flavoprotein subunit, mitochondrial 
(SDHA) was 2 times lower in HCC samples (t-test, p=1.42*10
-7
), succinate dehydrogenase iron-
sulfur subunit, mitochondrial (SDHB) was 1.5 times lower in HCC (t-test, p=2.81*10
-2
), GPT was 4 
times lower in HCC (t-test, p=1.12*10
-9
). An isoform switch was revealed at the level of isocitrate 
dehydrogenases: isocitrate dehydrogenase, cytoplasmic (IDH1) was expressed at higher intensity 
in the control 1.4 (t-test, p=1.21*10
-2
), isocitrate dehydrogenase, mitochondrial (IDH2) was not 
changed significantly, and isocitrate dehydrogenase subunit alpha, mitochondrial (IDH3A) 4.9 
times higher in the HCC (t-test, p=1.68*10
-3
), while subunit beta IDH3B and subunit gamma IDH3G 
were only detected in the HCC samples (Figure 21). 
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Changes in metabolic picture of CCM in all HCC samples compared to control group are 
represented in boxplots in Figure 22. The intensities of several metabolites are presented: lactic 
acid level was 4.5 fold lower in HCC
1
 (t-test, p=0.001), citric acid was 3.8 fold higher in HCC (t-test, 
p=0.01) and succinic acid 1.6 was fold lower in HCC (t-test, p=0.03). 
                                                          
1
 The observation of lactic acid level decreased in HCC contradicts the Warburg effect. The possible reason 
for this phenomenon is reviewed in the Discussion section. 
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Figure 17. Metabolic changes in all human HCC samples compared to a control group. The 
colour-coded proteome and metabolome changes in CCM of HCC group compared to a defined 
control group (FL samples). At the level of proteins glycogen metabolism was downregulated via 
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GYS2 and PYGL enzymes. GYS2 was 2.5 times lower in HCC group of samples compared to a 
control group (t-test, p=0.008), PYGL was 2.8 times lower in HCC samples compared to a control 
group (t-test, p=4.6*10-7). An LFQ intensity of FBP1, an enzyme responsible for glucose de novo 
synthesis, was 2.9 times lower in HCC compared to a control group (t-test, p=1.13*10-7). Changes 
in pentose-phosphate pathway were characterized by a higher intensity of TKT: it was 4.5 higher in 
HCC samples compared to a control group (t-test, p=1.09*10-3). A striking feature of glycolytic 
process was that HK1 was not detected in any of control samples, but was present in HCC samples. 
Other glycolytic enzymes expressed an isoform switches: phosphoglycerate mutases, aldolases, 
enolases, lactate dehydrogenases, and pyruvate kinases – these enzymes showed an isoform 
switch in HCC compared to a control group of samples. Aldolase A was prevalent over aldolase B in 
HCC samples: ALDOA was expressed 7.4 times higher in HCC compared to a control group of 
samples (t-test, p=5.12*10-4), and ALDOB was 3 times lower in HCC compared to a control group 
of samples (t-test, p=4.49*10-8). Enolase 3 was prevalent over enolase 2 in HCC samples: ENO3 
was 6.4 times higher in control samples (t-test, p=2.83*10-8). LDHD was prevalent over other 
lactate dehydrogenase in HCC samples: it’s intensity was 2.8 fold higher in HCC compared to a 
control group (t-test, p=1.71*10-6). TCA cycle enzymes mostly showed the trend of 
downregulation in HCC samples: an intensity of ACO1 was 1.8 times lower in HCC samples (t-test, 
p=4.73*10-4), an intensity of SDHA 2 was times lower in HCC samples (t-test, p=1.42*10-7), an 
intensity of SDHB was 1.5 times lower in HCC compared to a control group of samples (t-test, 
p=2.81*10-2). Glutamine uptake changes were characterized by GPT enzyme intensity being 4 
times lower in HCC compared to control (t-test, p=1.12*10-9). An isoform switch was revealed at 
the level of isocitrate dehydrogenase subunits: IDH1 intensity was lower in HCC in 1.4 times 
compared to control (t-test, p=1.21*10-2), and IDH3A intensity was 4.9 times higher in the HCC (t-
test, p=1.68*10-3), while IDH3B and IDH3G were only detected in the HCC and not in the control 
samples. Changes in metabolome were characterized by lactic acid intensity being 4.5 fold lower in 
HCC compared to control (t-test, p=0.001), citric acid intensity was 3.8 fold higher in HCC 
compared to control (t-test, p=0.01), succinic acid intensity was 1.6 fold lower in HCC compared to 
control (t-test, p=0.03). The metabolites are visualized with circles, the proteins are visualized with 
squares, bold frame indicates the changes with p<0.05 (t-test), grey colour of the metabolite 
(circle) or protein (square) at the scheme indicates that data regarding certain enzyme or 
metabolite is not available. Red colour indicates decrease of intensity in HCC samples, blue colour 
indicates increase of intensity in HCC samples. 
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Figure 18. Box plots with the relative intensities of enzymes of glycolysis, gluconeogenesis, 
glycogen metabolism, and pentose phosphate pathway in all human HCC samples compared to a 
control group. Glycogen metabolism was downregulated: GYS2 is expressed 2.5 times lower in 
N.d. 
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HCC (t-test, p=0.008), PYGL was 2.8 times lower in HCC (t-test, p=4.6*10
-7
). Glucose de novo 
synthesis was downregulated: FBP1 was expressed 2.9 times lower in HCC (t-test, p=1.13*10
-7
). 
TKT enzyme was expressed 4.5 higher in HCC samples (t-test, p=1.09*10
-3
). The enzymes of 
glycolysis were upregulated, for example HK1 was not detected at any of control samples, but was 
present at HCC samples. N.d. – not detected. 
 
Figure 19. Box plots with the relative intensities of glycolytic enzymes with the detected isoform 
switch in all human HCC samples compared to a control group. ALDOA was expressed 7.4 times 
more in HCC (t-test, p=5.12*10
-4
), and ALDOB was 3 times lower in HCC (t-test, p=4.49*10
-8
); ENO3 
was 6.4 times higher in control samples (t-test, p=2.83*10
-8
), LDHD was 2.8 fold lower in HCC (t-
test, p=1.71*10
-6
). N.d. – not detected. 
 
N.d. 
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Figure 20. Box plots with the relative intensities of TCA cycle enzymes and enzymes of 
glutaminolysis in all human HCC samples compared to a control group. ACO1 was expressed 1.8 
times lower in HCC samples (t-test, p=4.7*10
-4
), SDHA was 2 times lower in HCC samples (t-test, 
p=1.42*10
-7
), SDHB was 1.5 times lower in HCC (t-test, p=2.81*10
-2
), GPT was 4 times lower in HCC 
(t-test, p=1.12*10
-9
). 
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Figure 21. Box plots with the relative intensities of TCA cycle enzymes with revealed isoform 
switch in all human HCC samples compared to a control group. IDH1 was expressed at higher 
N.d. 
N.d. 
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intensity in the control 1.4 (t-test, p=1.21*10
-2
), IDH2 was not changed significantly. IDH3A was 
expressed 4.9 times higher in the HCC (t-test, p=1.68*10
-3
), while IDH3B and IDH3G were only 
detected in the HCC samples. N.d. – not detected.  
 
Figure 22. Box plots with the relative intensities of CCM metabolites in all human HCC samples 
compared to a control group. Lactic acid level was 4.5 fold lower in HCC (t-test, p=0.001), citric 
acid was 3.8 fold higher in HCC (t-test, p=0.01), succinic acid 1.6 was fold lower in HCC (t-test, 
p=0.03). 
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Changes in Central Carbon Metabolism of different HCC groups 
The above mentioned focused proteome analysis of samples reveals different subgroups of 
HCC (Figure 15). I hypothesize that different groups of HCC will show different transformations of 
CCM. Further I visualize that transformations of CCM (Figure 23 and 29). Group A includes 
proteome data from 16 patients: 32, 70, 69, 71, 31, 27, 28, 30, 88, 82, 19, 20, 77, 85, 25, 86; and 
Group B from 31 patients: 24, 91, 68, 84, 94, 89, 90, 26, 33, 73, 23, 78, 93, 66, 74, 75, 22, 92, 21, 
29, 34, 95, 67, 87, 83, 79, 80, 35, 76, 81, 72. Only metabolome data obtained from the biopsies 
was used in the profiles visualization, due to the above mentioned reasons (Figure 13).  
HCC Group A 
Figure 23 shows the characteristic changes of CCM in human HCC Group A compared to 
control. At protein expression level glycogen metabolism was downregulated, for example, PYGL 
was expressed 1.4 times lower in HCC (t-test, p=0.025), while both muscle and liver forms of 
glycogen synthase (GYS1 and GYS2) were not changed significantly (Figure 24).  
Glucose de novo synthesis was downregulated: FBP1 was expressed at levels 1.4 times lower 
in HCC (t-test, p=0.023) (Figure 24).  
TKT enzyme was expressed 2.9 fold more in HCC samples (t-test, p=0.012).  
The enzymes of glycolysis were upregulated or underwent an isoform switch at the level of 
phosphoglycerate mutases, aldolases, and lactate dehydrogenases. ALDOA was expressed 3.8 
times higher in HCC (t-test, p=0.0001), ALDOB was 1.5 times lower in HCC (t-test, p<0.05) (Figure 
24), ENO3 was 2.3 times higher in control samples (t-test, p=0.014), pyruvate kinase M (PKM) was 
3.8 times higher in HCC samples (t-test, p=0.002) (Figure 25). Lactate dehydrogenases underwent 
isoform switch: LDHB was expressed 2.5 times more in HCC samples (t-test, p=0.004) and LDHD 
was 1.5 fold more in the control (t-test, p=0.011) (Figure 25). 
Most of the enzymes of the TCA cycle did not show any drastic change in expression: both 
cytoplasmic and mitochondrial aconitate hydratases (ACO1 and ACO2) (Figure 25) were not 
changed significantly, as well as malate dehydrogenases, and the majority of isocitrate 
dehydrogenase subunits (Figure 26).  
Glutaminolysis was downregulated at the proteomic level: GPT was expressed 1.8 times less 
in HCC, and GLS2 was 2.2 times less (t-test, p=0.0014 and p=0.031 respectively) (Figure 27). At the 
metabolomic level various changes were detected: lactic acid level was 4.2 fold decreased in HCC 
(t-test, p=0.013), citric acid level was 5 times higher in HCC (t-test, p=0.002), fumaric acid level was 
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1.6 times higher in HCC (t-test, p=0.024), and glutamic acid level was 2.6 times higher in HCC (t-
test, p=0.004) (Figure 28). 
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Figure 23. CCM changes in human HCC Group A compared to a control group. The colour-coded 
relative proteome and metabolome changes in CCM of HCC group A compared to defined control 
group of FL samples. At the proteomic level glycogen metabolism was downregulated, for 
example, PYGL was expressed 1.4 times lower in HCC (t-test, p=0.025), while both GYS1 and GYS2 
were not changed significantly. Glucose de novo synthesis is downregulated: FBP1 was expressed 
1.4 times less in HCC (t-test, p=0.023). TKT enzyme was expressed 2.9 fold more in HCC samples (t-
test, p=0.012). The enzymes of glycolysis were upregulated or underwent an isoform switch at the 
level of phosphoglycerate mutases, aldolases, and lactate dehydrogenases. ALDOA was expressed 
3.8 times more in HCC (t-test, p=0.0001), and ALDOB 1.5 times less in HCC (t-test, p<0.05), ENO3 
2.3 times higher in control samples (t-test, p 0.014), PKM 3.8 times higher in HCC samples (t-test, 
p=0.002). Lactate dehydrogenases underwent an isoform switch: LDHB was expressed 2.5 higher 
in HCC samples (t-test, p=0.004) and LDHD 1.5 fold higher in control (t-test, p=0.011). Most of the 
enzymes of the TCA cycle did not show any drastic change in the expression: both ACO1 and ACO2 
were not changed significantly, neither was malate dehydrogenases, or the majority of isocitrate 
dehydrogenase subunits. Glutaminolysis was downregulated at the proteomic level: GPT was 
expressed 1.8 times lower in HCC, and GLS2 2.2 times lower (t-test, p=0.0014 and p=0.031 
respectively). At the metabolomic level, various changes were detected: the lactic acid level was 
4.2 lower in HCC (t-test, p=0.013), the citric acid level was 5 times higher in HCC (t-test, p=0.002), 
the fumaric acid level was 1.6 times higher in HCC (t-test, p=0.024), and the glutamic acid level was 
2.6 times higher in HCC (t-test, p=0.004). The metabolites are visualized with circles, the proteins 
are visualized with squares, bold frame indicates the changes with p<0.05 (t-test), grey colour of 
the metabolite (circle) or protein (square) at the scheme indicates that data regarding certain 
enzyme or metabolite is not available. Red colour indicates decrease of intensity in HCC samples, 
blue colour indicates increase of intensity in HCC samples. 
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Figure 24. Box plots with the relative intensities of glycolytic and gluconeogenetic enzymes, and 
enzymes participating in glycogen metabolism in human HCC Group A compared to a control 
group. PYGL was expressed 1.4 times lower in HCC (t-test, p=0.025), GYS2 was not changed 
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significantly, FBP1 was expressed 1.4 times less in HCC (t-test, p=0.023), ALDOA was 3.8 times 
more in HCC (t-test, p=0.0001), and ALDOB was 1.5 times lower in HCC (t-test, p<0.05). 
 
Figure 25. Box plots with the relative intensities of glycolytic and TCA cycle enzymes in human 
HCC Group A compared to a control group of samples. ENO3 was 2.3 times higher in control 
samples (t-test, p=0.014), PKM was 3.8 times higher in HCC samples (t-test, p=0.002). Lactate 
81 
 
dehydrogenases undergo isoform switch: LDHB was expressed 2.5 higher in HCC samples (t-test, 
p=0.004) and LDHD 1.5 fold higher in control (t-test, p=0.011). ACO2 was not changed significantly. 
 
Figure 26. Box plots with the relative intensities of TCA cycle enzymes in human HCC Group A 
compared to a control group. IDH1 and IDH2 expression was not changed significantly in HCC 
samples, and IDH3A was expressed significantly higher in HCC (t-test, p=0.0003). MDH1 was 
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expressed 1.3 fold higher in HCC (t-test, p=0.004) and MDH2 was not significantly changed in the 
HCC samples.  
 
 
Figure 27. Box plots with the relative intensities of enzymes of glutaminolysis in human HCC 
Group A compared to a control group. GPT was expressed 1.8 times lower in HCC (t-test, p=0.001) 
and GLS2 was 2.2 times lower in HCC (t-test, p=0.031). 
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Figure 28. Box plots with the relative intensities of CCM metabolites in in human HCC Group A 
compared to a control group. The lactic acid level was 4.2 lower in HCC (t-test, p=0.013), citric acid 
level was 5 times higher in HCC (t-test, p=0.002), fumaric acid level was 1.6 times higher in HCC (t-
test, p=0.024), and glutamic acid level is 2.6 times higher in HCC (t-test, p=0.004).  
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HCC Group B 
Figure 29 represents the changes of CCM in the HCC Group B compared to control. At the 
proteomic level glycogen metabolism was downregulated, for examples, PYGL was expressed 5.4 
times lower in HCC (t-test, p=1.16*10
-15
), GYS2 8.7 times lower in HCC (t-test, p=4.78*10
-9
) (Figure 
30).  
Glucose de novo synthesis was downregulated: FBP1 was expressed 6.9 times lower in HCC 
(t-test, p=4.46*10
-19
) (Figure 30).  
TKT was expressed 5.2 times higher in HCC (t-test, p=3.12*10
-4
), and glucose-6-phosphate 1-
dehydrogenase (G6PD), which is also involved in pentose phosphate pathway, was not detected in 
the control samples (Figure 30).  
Glycolysis in HCC was characterized by an isoform switch at the levels of phosphoglycerate 
mutases, aldolases, enolases, pyruvate kinases, and lactate dehydrogenases. ALDOA was 
expressed 9.2 times higher in HCC (t-test, p=1.24*10
-4
), ALDOB 6.3 times lower in HCC (t-test, 
p=5.31*10
-14
), ALDOC was not changed (Figure 31). ENO1 was expressed 1.3 fold higher in HCC (t-
test, p=4.84*10
-2
), ENO3 was 122 times lower in HCC (t-test, p=5.43*10
-18
) (Figure 31). PKM was 
expressed 13 times higher in HCC samples (t-test, p=2.95*10
-3
), and PKLR 3 times lower in HCC (t-
test, p=7.14*10
-4
) (Figure 32). LDHB was expressed 6.6 times higher in HCC samples (t-test, 
p=3.81*10
-2
), LDHD was 4.7 fold higher in control (t-test, p=3.79*10
-9
), LDHA was not changed 
significantly (Figure 32).  
65% of the enzymes of the TCA cycle were downregulated: ACO1 was expressed 2.7 and 
ACO2 1.3 times lower (t-test, p=6.43*10
-9
 and p=4.31*10
-2
 respectively) (Figure 33). IDH showed a 
switch within subunits: IDH1 was expressed 1.7 times lower in HCC (t-test, p=4.63*10
-4
), IDH3A 
was 5.6 times higher in HCC (t t-test, p=1.65*10
-3
), IDH3B was only detected in HCC (Figure 33).  
Glutaminolysis was downregulated at the proteomic level: GPT was expressed 10.5 times 
lower in HCC (t-test, p=1.11*10
-17)
, and GLS2 was not detected in HCC samples (with the exception 
of 1 sample) (Figure 34).  
At the metabolomic level various changes were detected: the lactic acid level was 4.9 lower 
in HCC (t-test, p=0.018), the malic acid level was 2.7 times lower in HCC (t-test, p=0.004), and the 
succinic acid level was 2.1 times lower in HCC (t-test, p=0.04) (Figure 35). 
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 Figure 29. CCM changes in human HCC Group B compared to a control group. At the proteomic 
level glycogen metabolism was downregulated, for examples, PYGL was expressed 5.4 times lower 
in HCC (t-test, p=1.16*10
-15
), GYS2 is 8.7 times less in HCC (t-test, p=4.78*10
-9
). Glucose de novo 
synthesis was downregulated: FBP1 is expressed 6.9 times lower in HCC (t-test, p=4.46*10
-19
). TKT 
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was expressed 5.2 times higher in HCC (t-test, p=3.12*10
-4
), and G6PD, which is also involved in 
pentose phosphate pathway, was not detected in control samples. Glycolysis was characterized by 
an isoform switch at the levels of phosphoglycerate mutases, aldolases, enolases, pyruvate 
kinases, and lactate dehydrogenases. ALDOA was expressed 9.2 times higher in HCC (t-test, 
p=1.24*10
-4
), ALDOB was 6.3 times less in HCC (t-test, p=5.31*10
-14
), ALDOC was not changed. 
ENO1 was expressed 1.3 fold higher in HCC (t-test, p=4.84*10
-2
), ENO3 was 122 times lower in HCC 
(t-test, p=5.43*10
-18
). PKM was expressed 13 times higher in HCC samples (t-test, p=2.95*10
-3
), 
and PKLR was 3 times lower in HCC (t-test, p=7.14*10
-4
). LDHB was expressed 6.6 times higher in 
HCC samples (t-test, p=3.81*10
-2
), LDHD was 4.7 fold higher in control (t-test, p=3.79*10
-9
), LDHA 
was not changed significantly. 65% of the enzymes of the TCA cycle are downregulated: ACO1 was 
expressed 2.7 and ACO2 was 1.3 times lower (t-test, p=6.43*10
-9
 and p=4.31*10
-2
 respectively). 
IDH showed a switch between subunits: IDH1 was expressed 1.7 times lower in HCC (t-test, 
p=4.63*10-4), IDH3A 5.6 times higher in HCC (t t-test, p=1.65*10-3), IDH3B was only detected in 
HCC. Glutaminolysis was downregulated at the proteomic level: GPT was expressed 10.5 times 
lower in HCC (t-test, p=1.11*10-17), and GLS2 was not detected in HCC samples (with the exception 
of 1 sample). At the metabolomic level various changes were detected: the lactic acid level was 4.9 
lower in HCC (t-test, p=0.018), the malic acid level was 2.7 times lower in HCC (t-test, p=0.004), 
and the succinic acid level was 2.1 times lower in HCC (t-test, p=0.04). The metabolites are 
visualized with circles, the proteins are visualized with squares, bold frame indicates the changes 
with p<0.05 (t-test), grey colour of the metabolite (circle) or protein (square) at the scheme 
indicates that data regarding certain enzyme or metabolite is not available. Red colour indicates 
decrease of intensity in HCC samples, blue colour indicates increase of intensity in HCC samples. 
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Figure 30. 
Box plots with the relative intensities of enzymes of gluconeogenesis, glycogen metabolism, and 
pentose phosphate pathway in human HCC Group B compared to a control group. PYGL was 
expressed 5.4 times less in HCC (t-test, p=1.16*10
-15
), GYS2 was 8.7 times more in HCC (t-test, 
p=4.78*10
-9
). FBP1 was expressed 6.9 times less in HCC (t-test, p=4.46*10
-19
). TKT was expressed 
N.d. 
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5.2 times higher in HCC (t-test, p=3.12*10
-4
), and G6PD was not detected in control samples. N.d. – 
not detected. 
 
Figure 31. Box plots with the relative intensities of glycolytic enzymes in human HCC Group B 
compared to a control group (aldolases, enolases). ALDOA was expressed 9.2 times more in HCC 
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(t-test, p=1.24*10
-4
), ALDOB was 6.3 times less in HCC (t-test, p=5.31*10
-14
), ALDOC was not 
changed. ENO1 was expressed 1.3 fold more in HCC (t-test, p=4.84*10
-2
), ENO3 was 122 times less 
in HCC (t-test, p=5.43*10
-18
). 
 
Figure 32. Box plots with the relative intensities of glycolytic enzymes in human HCC Group B 
compared to a control group (pyruvate kinases, lactate dehydrogenases). PKM was expressed 13 
times more in HCC samples (t-test, p=2.95*10
-3
), and PKLR was 3 times less in HCC (t-test, 
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p=7.14*10
-4
). LDHB was expressed 6.6 times more in HCC samples (t-test, p=3.81*10
-2
), and LDHD 
4.7 fold more in control (t-test, p=3.79*10
-9
), LDHA was not changed significantly. 
 
Figure 33. Box plots with the relative intensities of TCA cycle enzymes in human HCC Group B 
compared to a control group.  ACO1 was expressed 2.7 less and ACO2 1.3 times less in HCC (t-test, 
p=6.43*10
-9
 and p=4.31*10
-2
, respectively). IDH1 was expressed 1.7 times less in HCC (t-test, 
N.d. 
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p=4.63*10
-4
), IDH3A was 5.6 times more in HCC (t t-test, p=1.65*10
-3
), IDH3B was only detected in 
HCC. N.d. – not detected. 
 
Figure 34. Box plots with the relative intensities of enzymes of TCA cycle and glutaminolysis in 
human HCC Group B compared to a control group. SHDA was expressed 2.6 times less in HCC (t-
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test, p=1.85*10
-10
), and SDHB was 2.1 times less in HCC (t-test, p=5.06*10
-5
). GPT was expressed 
10.5 times less in HCC (t-test, p=1.11*10
-17
), and GLS2 was not detected in HCC samples (with the 
exception of 1 sample). FASN was expressed 3.4 fold more in control samples (t-test, p=4.46*10
-
19
). 
 
 
Figure 35. Box plots with the relative intensities of CCM metabolites in human HCC Group B 
compared to a control group. Lactic acid level was 4.9 lower in HCC (t-test, p=0.018), malic acid 
level was 2.7 times lower in HCC (t-test, p=0.004), and succinic acid level was 2.1 times lower in 
HCC (t-test, p=0.04). 
Thus, the separation of HCC in group A and B based on hierarchical clustering evaluated 
with proteomic and metabolomic data revealed different transformations of CMM in Group A and 
B. 
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Comparison of CCM changes in human HCC Group A and B 
In this section I compare the changes at the proteomic level between Group A and Group B. 
An isoform switch was more pronounced in HCC Group B. The average intensity of ALDOA 
was 3.7 more in Group A and 9.2 times more in Group B compared to control, and ALDOB was 1.5 
times less in Group A and 6.3 times less in Group B compared to control. ENO1 was not changed in 
Group A and it was 1.3 times more in Group B compared to control, ENO3 was 2.3 times less in 
Group A and was 122 times less in Group B compared to control. PKM was 3.8 higher in Group A, 
while PKLR was not changed. Group B was characterized by 3 times lower expression of PKLR and 
13 times higher expression of PKM compared to control. LDHB was 2.5 times higher in Group A 
and 6.6 times higher in Group B, LDHD was 1.5 times lower in Group A and 4.7 times lower in 
Group B compared to control. Pentose phosphate pathway-involved enzyme TKT was 2.9 fold 
higher in Group A and 5.2 times higher in Group B compared to control. FBP1, which participates 
in glucose de novo synthesis, was 1.4 times lower in Group A and 6.9 times lower in Group B 
compared to control. Glycogen metabolism: GYS2 was not changed in Group A, and 8.7 times 
lower in Group B compared to control, PYGL was 1.4 times lower in Group A and 5.4 times lower in 
Group B. TCA cycle analysis revealed more drastic changes in Group B compared to Group A. ACO1 
level was not changed in Group A, and it was 2.7 times lower in Group B compared to control. 
ACO2 was 1.3 times higher in Group A and 1.3 times lower in Group B. IDH subunits expressed the 
switch: IDH1 and IDH2 were not changed in Group A, and they were 1.7 and 1.4 times lower in 
Group B, respectively. IDH3A was 3.5 times higher in Group A and 5.6 times higher in Group B 
compared to control. GPT, which participates in glutaminolysis along with GLS2, was 1.8 times 
lower in Group A and 10.5 times lower in Group B. Compared to control GLS2 was 2.2 times lower 
in Group A, and was not expressed in the Groups B samples. 
The approach revealed that Group A of HCC samples underwent less severe dysregulation 
of CCM proteome pool sizes compared to Group B. The samples were related in a way that 
reflected the functional changes of liver CCM. Thus, more pronounced and severe changes were 
typical for HCC cases, which were classified in Group B. Less pronounced functional transitions 
were found in both, HCC and non-HCC samples. Group A, with moderate changes of CCM, was not 
fully separated from non-cancerous conditions. Group B contained samples with more drastic, 
homogeneous and pronounced dysregulation of CCM, which was very consistent among the 
patients of this group, and fully separated from non-cancerous condition. 66% of HCC samples 
94 
 
were in Group B, which means that they could be detected by focused proteomic analysis. It is 
important to note, that only Group B contains CTNNB1 mutations. 23% of all samples from Group 
B contained CTNNB1 mutation.  
The metabolomic data obtained from this study showed that overall human metabolome 
profile remained elusive. Huge diversity within the patients could be explained by the influence of 
a lot of factors, which the researcher has no influence on: diet, supportive medication, stress level, 
pre-surgery medication, and others. The optimization options have to be evaluated in further 
experimental and statistical work.  
95 
 
3. Comparison of mouse and human data 
 
The analysis of changes in CMM in both mouse model in human samples allowed the 
evaluation of the signature features of HCC in both species. Figure 36 represents the common 
features changed in both mouse and human HCC. The non-common features are presented in grey 
for the purposes of simplification. 
Proteomic data from the mouse model uncovered a very specific profile of metabolic 
reprogramming of the liver. In cancer samples glycogen metabolism was impaired via the 
inhibition of Gys2. Several enzymes of glycolysis showed isoform switches (PGMs, PKs). 
Gluconeogenesis was downregulated at the level of Pck1 and G6pc. Transport of pyruvate into 
mitochondria was inhibited at the levels of Mpc1 and Mpc2. 60% of TCA cycle enzymes were 
downregulated, for example Cs, Sdha, Sdhb and Sdhc. Enzymes responsible for the glutamine 
uptake to the TCA cycle had lower expression in the HCC samples: Gpt, Gpt2, Gls2 were 
downregulated at the proteomic level.  
It is important to underline the overall consistency of mice proteomic data. Out of 67 
protein used in the CCM analysis, mouse model data showed 52 significantly changed proteins (t-
test, 50 with p<0.005, and 2 with p<0.05). Human samples showed less consistent data. The whole 
group of human HCC samples included 37 significantly changed proteins compared to the control 
group (t-test, 19 with p<0.005, and 18 with p<0.05). Group A HCC samples included 32 significantly 
changed proteins compared to control (t-test, 10 with p<0.005, and 22 with p<0.05). Group B HCC 
samples included 44 significantly changed proteins compared to the control group (t-test, 27 with 
p<0.005, and 17 with p<0.05). The higher consistency of the mouse model data could be explained 
by the same genetic background of the mice, same environmental conditions, and a strictly 
controlled experimental setup. 
Human proteomic, and especially metabolomic, profiles showed drastically lower 
consistency compared to mouse data. Nevertheless, analysis of the HCC group compared to the 
control group revealed a signature of tumor-specific metabolic reprogramming (especially in 
Group B). At the proteomic level glycogen metabolism was downregulated via dysregulation of 
PYGL and GYS2. Glucose de novo synthesis was downregulated at the level of FBP1. TKT and G6PD, 
which are involved in pentose phosphate pathway, were upregulated in HCC samples (which if 
different from the mouse model data). Glycolysis was upregulated at the level of hexokinases. 
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Glycolysis was also characterized by isoform switches at the levels of phosphoglycerate mutases, 
aldolases, enolases, pyruvate kinases, and lactate dehydrogenases. 65% of TCA cycle enzymes 
were downregulated, and isocitrate dehydrogenase showed a change of subunit composition. 
Glutaminolysis was downregulated at the level of GPT and GLS2. 
 Overall the proteomic data obtained from both mice and humans showed a clear 
dysregulation of the main energy-producing pathways in HCC, changes in CCM and in the main 
liver functions. Glycogen metabolism (via PYGL and GYS2), de novo glucose synthesis (on various 
levels), glutamine uptake to the TCA cycle (via GPT, GLS2), and approximately 60% of enzymes of 
the TCA cycle (SDHs, SUCLs, ACO etc.), and transport of pyruvate to mitochondria (MPCs) were 
downregulated in HCC. Additionally the proteome data display one of the most common features 
of the cancer cells: metabolic reprogramming. An isoform switch, which is one of the fundamental 
mechanisms in reprogramming, was demonstrated in this work. Both mice and humans with HCC 
revealed isoform switches at the level of phosphoglycerate mutases and pyruvate kinases. Despite 
the diversity of genetic background of human samples the proteome described HCC signature was 
very robust in both bioptate and surgery material. The key features were found in both mouse and 
human, showing a universal metabolic HCC fingerprint. This allowed me to confidently conclude, 
that the ASV-B mouse model appeared to be sufficiently similar to the human clinical presentation 
that it is useful for further study of the disease. 
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Changes of CCM in HCC mouse model 
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Changes of CCM in HCC human samples (Group B) 
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Figure 36. The common features changed in both mouse and human HCC compared to a 
respective control group. The non-common features are presented in grey for the purposes of 
simplification. The metabolites are visualized with circles, the proteins are visualized with squares, 
bold frame indicates the changes with p<0.05 (t-test), grey colour of the metabolite (circle) or 
protein (square) at the scheme indicates that data regarding certain enzyme or metabolite is not 
available. 
 
4. Serum data 
I obtained the proteomic data to evaluate changes in human serum samples. The cohort 
included 5 HCC patients, from whom the serum was taken prior to and from 5 to 7 days after liver 
resection surgery. 5 patients with either hemangioma
1
 or hepatic cyst
2
 formed the control group. 
The proteins from human serum samples were extracted and analyzed on a Q Exactive HF. 
460 proteins were identified. An abundance index was calculated for each protein: the intensity of 
a protein was divided by molecular mass of the protein and further each value in the column was 
divided by the mean intensity value of the column. This normalization performed on the data set is 
described in the paper of Mastrobuoni et al. 2012 (Mastrobuoni, et al., 2012). Imputation of 
missing values for both matrices (serum and bioptate material) was performed by replacing the 
missing values with a constant value (50% of the minimum non-0 value in the matrix). Here I 
applied the imputation, because for clinical purposes it is better to have imputed values of fold 
changes. The implication of data imputation revealed 15 proteins (Table 4) significantly different in 
serum from control samples compared to HCC. 
                                                          
1 
The hepatic hemangioma (haemangioma) is a benign vascular lesion. Histologically, it is a mesenchymal 
lesion consisting of blood-filled of various sizes vascular cavities, surrounded by a layer of endothelial cells, 
supported by a fibrous connective tissue. (Klotz, et al., 2013) 
2
 A cyst is a closed cavity with a distinct membrane and division compared to the nearby tissue. Hepatic 
cysts are classically divided into parasitic and non-parasitic types, with the latter being the most prevalent 
worldwide. (Maruyama, et al., 2013) 
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Table 4. Significantly changed proteins in serum samples: HCC compared to control group. 
Protein IDs Protein names tumor/ctrl t-test Gene names 
P08697 Alpha-2-antiplasmin 0.572 0.005 SERPINF2 
P01613 Ig kappa chain V-I region Ni 2970.849 0.005   
P35858 
Insulin-like growth factor-binding protein 
complex acid labile subunit 0.348 0.005 IGFALS 
P36980 Complement factor H-related protein 2 692.345 0.010 CFHR2 
P01857 Ig gamma-1 chain C region 1.390 0.015 IGHG1 
P26927;Q2TV78 
Hepatocyte growth factor-like protein; 
Putative macrophage stimulating 1-like 
protein 81.170 0.016 MST1;MST1L 
P06681 Complement C2 1.375 0.022 C2 
Q15848 Adiponectin 547.195 0.026 ADIPOQ 
Q92820 Gamma-glutamyl hydrolase 5.406 0.033 GGH 
P61769 Beta-2-microglobulin 2551.626 0.035 B2M 
P27169 Serum paraoxonase/arylesterase 1 0.497 0.040 PON1 
P61626 Lysozyme C 193.375 0.041 LYZ 
P19652 Alpha-1-acid glycoprotein 2 1.706 0.041 ORM2 
P48740 Mannan-binding lectin serine protease 1 47.672 0.041 MASP1 
P00738 Haptoglobin 3.627 0.045 HP 
 
806 proteins were found to be significantly changed in HCC bioptate material compared to 
control. Venn diagram (Figure 37) shows the amount of common proteins among significantly 
different proteins in bioptate and serum group: B2M, PON1, HP (Table 5) (VIB/UGent, 2017). 
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Figure 37. The amount of common proteins among significantly different proteins in bioptate 
and serum. These proteins are B2M, PON1, HP. 
 
Table 5. Proteins, which are significantly differentially expressed in human serum and biopsy 
HCC material. 
Gene 
names 
Protein 
IDs 
Protein names Serum Biopsies 
tumor/ctrl t-test tumor/ctrl t-test 
B2M P61769 Beta-2-microglobulin 2551.626 0.035 2.654 0.008 
PON1 P27169 
Serum 
paraoxonase/arylesterase 1 0.497 0.040 0.560 0.0001 
HP P00738 Haptoglobin 3.627 0.045 5.955 0.001 
Significantly different B2M, PON1, and HP changes in HCC were reflected in the serum, 
which revealed new opportunities for specific, sensitive, and non-invasive diagnostic tool of HCC. 
While three of the suggested diagnostic markers need to be validated further on larger cohorts as 
a potential diagnostic tool, all of the 15 proteins mentioned above are to be investigated for the 
prognostic marker efficacy. 
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Discussion 
The following section focuses on various sides of the biological relevance and medical 
implications of my results. I also approach the challenges of present work. The cohort formation 
was one of the main issues I dealt with from the beginning of the project, as well as tissue 
acquisition and any possible bias it may cause. Further I discuss the interpretation of multiomics 
data and its application to CCM research. The last part of Discussion is devoted to the analysis of 
serum from HCC patients. 
Cohort and material 
A significant part of this work was devoted to the cohort development. Several issues had to 
be resolved during the collection period in order to account for the heterogeneity among patients. 
Since liver is one of main metabolic organs, it was essential to try to avoid patents with metabolic 
disorders, such as diabetes and obesity. The pathological mechanism of NAFLD and fibrosis or 
cirrhosis development with an obesity
1
 as a background condition is well-known. However, the 
further mechanism of progression to HCC is not studied properly for both groups of patients: 
diabetic and obese and patients without these conditions. Only 7 patients from our cohort had 
obesity, 5 patients had diabetes.  
 Most of researchers have a tendency to combine etiologies in one study, without separating 
various causes and risk factors. This could lead to the certain limitations in the discovery of specific 
markers and on cause-specific changes in CCM. For examples, Tan et al. (Tan, et al., 2014) 
published the biomarker panel (which included HPS70, TKT and other proteins) for metastatic HCC, 
combining all associated diseases in one group of HCC samples. The cohort includes HBV, HCV, and 
virus-free tissues. This approach tends to be cohort-biased and non-specific. Similar problems 
were faced by Orimo et al. (Orimo, et al., 2008) in their proteomic study of HCC, looking for a 
prognostic marker in HCC. The cohort the authors worked with included HBV, HCV, HBV and HCV, 
and virus-free patients. While the suggested marker EB1 (APC-binding protein EB1) showed the 
significant results, the fundamental mechanisms of the described changes remain elusive. 
Another problem researchers deal with is the liver tissue material source. In vast majority of 
cases surgery material is used (Beyoglu, et al., 2013; Orimo, et al., 2008; Tan, et al., 2014), which is 
valid for proteomic analysis, but, as I showed in my work (Figure 13), has certain limitations in 
revealing the in situ metabolic picture. For example, Beyoğlu et al. state, that no differences in 
                                                          
1
 ‘2 hit hypothesis’ by (Dowman, Tomlinson, & Newsome, 2010) 
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glucose, lactate, malate, concentrations were found, suggesting that the CTNNB1 activates Wnt/β-
catenin pathway by mutation in groups G5 and G6 shows no specific remodeling of metabolism 
(Beyoglu, et al., 2013). This observation could possibly be bound to the usage of exclusively 
surgically-delivered liver tissue for metabolomic analysis. The opportunity to involve biopsy 
material in the further metabolic research would eliminate the obstacles described above.  
The cohort from the present work contained both surgery and biopsy tissue. Control 
samples were acquired exclusively by biopsy, while nearly 75% of HCC samples come from surgery 
material. The difference of the source of material could explain the high number of significantly 
changed proteins in HCC group of samples compared to non-HCC (Results, Human cohort, 
Proteomics, Proteome overview, Figure 11). When all the non-HCC samples come from biopsies, 
and most of the HCC samples from surgery, the result could be acquisition method-bias. However, 
further proteome-based analysis (Results, Human cohort, Multiomics picture, Classification, Figure 
15) showed that surgery and biopsy samples did not cluster according to the source of tissue. This 
observation proved that the chosen method of separating HCC on Groups A and B according to the 
proteomic changes of CCM was not affected by the choice of tissue source. This statement is fair 
for the proteomic data, and requires further validation for other types of analyses. Nonetheless, in 
future work I would prefer to work with biopsy tissue, because it more clearly represents the in 
situ picture of CCM changes. 
CCM changes 
Mouse model overview 
Proteomic data from the ASV-B mouse model showed a specific metabolic reprogramming 
of damaged liver (Figure 36). In cancer liver tissue glycogen metabolism was impaired, enzymes of 
glycolysis revealed isoform switches at the level of phosphoglycerate mutases and pyruvate 
kinases, gluconeogenesis was downregulated, as well as the pentose phosphate pathway. 
Transport of pyruvate to mitochondria was inhibited, 60% of TCA cycle enzymes were 
downregulated, and glutaminolysis was downregulated at the proteomic level. At the metabolic 
level the upregulation of glycolysis was detected. 
Human cohort overview 
The signature of tumor-specific metabolic reprogramming also was found in the proteomic 
profile of human samples (Figure 36). At the proteomic level glycogen metabolism was 
downregulated, glucose de novo synthesis was downregulated, and pentose phosphate pathway 
was upregulated in HCC (which is different from the mouse model data). Glycolysis was 
upregulated at the level of hexokinases. Glycolysis was also characterized by an isoform switch at 
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the levels of phosphoglycerate mutases, aldolases, enolases, pyruvate kinases, and lactate 
dehydrogenases. The inhibition of pyruvate transport to mitochondria was observed at the 
proteomic level, to be more specific mitochondrial pyruvate carriers 1 and 2 both were expressed 
less in HCC compared to control. 65% of the enzymes of the TCA cycle were downregulated, and 
isocitrate dehydrogenase showed a switch between subunits. Glutaminolysis in HCC sampleswas 
downregulated.  Due to the tremendous heterogeneity of the phenotypes of human patients, 
metabolic data was not consistent over the entire cohort. However, a tendency of the metabolites 
of lower glycolysis (pyruvate, lactate), and metabolites of the TCA cycle to decrease in HCC, could 
be observed. 
The approach revealed that Group A of HCC samples underwent less severe dysregulation of 
CCM proteome pool sizes compared to Group B. The samples were related in a way that reflected 
the functional changes of liver CCM. Thus, more pronounced and severe changes were typical for 
HCC cases, which were clustered in Group B. Less pronounced functional transitions were found in 
both HCC and non-HCC samples. Group A, with moderate changes of CCM, was not fully separated 
from non-cancerous conditions. Group B contained samples with more drastic, homogeneous and 
pronounced dysregulation of CCM. Described changes were very consistent among the patients of 
this group and fully separated from non-cancerous conditions. Interestingly, the human cohort 
included 2 patients with recurrent HCC (74, 84), and both of them fit in Group B. This may indicate 
that recurrent HCC tumors reveal more drastic changes of CCM, or that tumors with more drastic 
changes of CCM are prone to recidive. However, this statement needs to be validated on larger 
cohorts of patients. Additional information about patients, such as AFP level, AST and ALT levels, 
and, most importantly, at least a 5-year follow up of outcome, would allow the evaluation the 
prognostic possibilities of this classification. Testing for alcohol consumption blood biomarkers
1
 
would complement to the cause evaluation and outcome of HCC, due to patients’ resistance to 
admit alcohol addiction (less than 10% of patients claimed alcohol abuse). 
The phenomenon of lower level of lactic acid was detected in human HCC samples (Figure 
17, 23, 29). This observation does not fit to the Warburg effect. Under normal nutritional 
conditions I would expect to detect the Warburg effect at the metabolic level. However, fasting 
                                                          
1
 However, the specificity of most currently suggested blood biomarkers of alcohol consumption is 
questionable.  (Allen & Wilson, 2003; Peterson, 2004) 
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caused the overall decrease in nearly all of detected metabolites (Figure 29), due to the high 
dependency of liver tumor on glucose. Thus, supposedly, by the time of material acquisition 
glucose was used, and levels of pyruvic acid and lactic acid dropped.  
Comparison of mouse model and human cohort 
Obtained proteome and metabolome data from both mice and humans showed the clear 
dysregulation of the main energy-producing pathways in HCC, as shown at the scheme on Figure 
37. Glycogen metabolism, de novo glucose synthesis, glutamine uptake to the Krebs cycle, and 
other processes were less active in HCC. The proteome and metabolome data taken together 
displayed one of the most common features of the cancer cells: the metabolic reprogramming. 
Isoform switch is one of the fundamental mechanisms in reprogramming, was demonstrated in 
this work. These observations revealed the universal, for both mouse and human species, 
mechanism of CCM changes in HCC. Due to the similarities of basic processes in HCC development, 
this study opened the possibilities for anti-HCC drug testing on animal model. ASV-B mouse model 
allows evaluating the exact CCM changes and medication influence on them. 
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Figure 37. The scheme visualizing the similarities of CCM changes in mouse HCC model and 
human HCC samples compared to control. The scheme represents common features in HCC 
metabolism for both mice and human. Cancer cells lost the ability to break down and synthesize 
glycogen, to perform gluconeogenesis, to transport pyruvate to mitochondria, to take amino acids 
to the TCA cycle. Approximately 60% of TCA cycle enzymes were downregulated. An isoform 
switch was observed at the level of phosphoglycerate mutases and pyruvate kinases. Red circles 
indicate the downregulated areas, yellow arrows point out areas with an isoform switches. 
 
This study demonstrates that the proteome analysis of the bioptate material is a strong and 
sufficient molecular diagnostic tool for research in cancer: the proteomic analysis of liver material 
allows a clear distinction of tumor samples from non-tumor samples, and tracks the level of the 
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disease progression. However the described molecular tools are applicable to material obtained by 
invasive techniques, such as biopsies and surgeries. Therefore we applied the developed 
proteomics technology and supervised statistical methods on serum taken from human patients, 
in order to evaluate the non-invasive diagnostic tools. 
 
Mutations 
Targeted genome sequencing was used in order to detect cancer-related somatic mutations 
in human samples. 1000 Genomes Project (The Genomes Project, 2015) database was used to 
evaluate the SNPs and non-harmful mutations. Due to the fact that we only worked with 
pathological tissue, there was no possibility to eliminate person-specific SNPs from analysis, thus 
we had to rely on 1000 Genome Project. The final data set from Project contains data for 2,504 
presumably healthy individuals from 26 populations, which allows to estimate the level of 
harmfulness of one mutation or another. However, the presence of certain mutation in 
presumably healthy individual does not necessarily mean that this mutation is not harmful, and 
that the individual will not develop a disease later. A disease could be on early developing stage, 
thus not affecting the picture of blood tests of subjective feeling of well-being. Another issue with 
presumably harmless SNPs that the Project does not consider the combination of those SNPs. 
Possibly the combination of several ‘harmless’ SNPs can cause the disease. Another limitation of 
this work was the application of panel sequencing. The panel sequencing is restricted to the 
known set of mutations, unlike the whole genome sequencing. In our cohort were patients with 
no mutations detected, which does not mean that individuals had no mutations. Nonetheless, 
various mutations were detected, identified in confirmed in the cohort. 
CTNNB1 
Several CTNNB1 mutations are specific for tumor samples and were detected in 15% of 
HCC. 23% of Group B samples contained CTNNB1 mutations: c.A121G, p.T41A; c.T133C, p.S45P; 
c.C134T, p.S45F; c.C110T, p.S37F; c.C98T, p.S33F, all of which were located in exon 3 (Gamallo, et 
al., 1999). 
CTNNB1 (c.C134T, p.S45F) mutation has been shown in patients with desmoid tumors (this 
type of tumors originates from fibroblasts) (Colombo, et al., 2013; Mullen, et al., 2013; Nishida, et 
al., 2016). Nishida et al. and Mullen at al. also found CTNNB1 (c.A121G, p.T41A) mutation in 
desmoid tumors. Doyen et al. show the CTNNB1 (c.A121G, p.T41A) and CTNNB1 (c.T133C, p.S45P) 
mutations and suggest that a certain CTNNB1 mutations are necessary to provide the tumor with 
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the growth advantage (Doyen, et al., 2016). Kolble et al. describes the CTNNB1 (c.T133C, p.S45P) 
mutation being present in colorectal cancer and suggests that this specific mutation if restricted to 
a hepatic metastasis (Kolble, et al., 2000). CTNNB1 (c.C98T, p.S33F) mutation can be involved in 
the development of colorectal cancer (Alomar, et al., 2016).  
Studies of Gamallo et al., Kobayashi et al. and Moreno-Bueno et al. report the CTNNB1 
(c.A121G, p.T41A) and CTNNB1 (c.C110T, p.S37F) mutations existence in ovarian and endometrial 
carcinomas (Gamallo, et al., 1999; Kobayashi, Sagae, Nishioka, Tokino, & Kudo, 1999; Moreno-
Bueno, et al., 2001). Kobayashi et al. suggest, that each mutation of CTNNB1 with the 
serine/threonine substitution results in the downregulation of beta-catenin through 
phosphorylation by GSK-3 beta kinase.  The work of Palacios and Gamallo also evaluated the role 
of mutation of CTNNB1 on exon 3, confirming the (c.A121G, p.T41A) and (c.C110T, p.S37F) 
mutations, implicating CTNNB1 mutations in ovarian malignant transformation (Palacios & 
Gamallo, 1998). 
None of the above mentioned mutations were previously described in HCC, however the 
suggested by several authors mechanism of malignisation of ovarian and endometric tissues could 
be applicable to the liver cancer development. Alternatively, considering the desmoid tumors 
publications (Colombo, et al., 2013; Mullen, et al., 2013; Nishida, et al., 2016), the origin of the 
tumors, diagnosed as hepatocellular, can be questionable. Here we excluded the ovarian cells 
origin because 5 out of 6 patients with CTNNB1 mutations are males (information about 1 patient 
is not available). 
However, several CTNNB1 mutations are specific for tumor samples and were detected in 
15% of HCC. This observation can indicate that CTNNB1 mutation is not a necessary but sufficient 
factor for the CCM changes, and, when present, affects metabolism in a drastic way, which has an 
impact on major liver functions. Thus, the above mentioned CTNNB1 mutations should further be 
validated on larger cohorts, for potential use as a prognostic biomarker of survival or metastatic 
status. 
Overall, CTNNB1 mutations present in current cohort correlated with more drastic changes 
in CCM, which were be detected by proteome analysis. CTNNB1 mutations should further be 
validated on larger cohorts for potential use as a prognostic biomarker of survival or metastatic 
status. Additionally, the mechanistic studies of the influence of CTNNB1 mutations on the changes 
of malignancy potential and invasiveness can be performed on liver and HCC cell lines. 
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TP53 
The TP53 (c.216delC, p.V73fs) mutation was frequently met in the full cohort. This specific 
mutation is described by Mouradov et al. in the KM12 colon cancer cell line (Mouradov, et al., 
2014). This paper also present the TP53 (c.902delC, p.P301fs), which was met in the cohort twice, 
in another colon cancer cell line – HCA-7. In addition, TP53 (c902delC, P301fs) was confirmed to be 
present in a colon cancer patient (Giannakis, et al., 2014).  
PIK3CA 
Janku et al. reported PIK3CA (c.A3140G, p.H1047R) mutation to be found in colorectal 
cancer patients (Janku, et al., 2012). Reiner et al. studied the cohort of 50 patient with HCC and 
found PIK3CA (c.A3140G, p.H1047R) mutation if 2% of them. Their results suggest that somatic 
PIK3CA mutations play role in the frequent activation of the PI3K/AKT pathway in carcinomas of 
the biliary tract and liver (Riener, Bawohl, Clavien, & Jochum, 2008). 
TP53, CTNNB1, and PIK3CA mutations are known in the literature to be associated with HCC 
in HBV and HCV contaminated patients (Tornesello, et al., 2013). However, in our cohort these 
mutations are present not exclusively in patients with HBV or HCV. 
The other mutations represented in Table 2 show no solid evidence in the literature to be 
involved in HCC development or functioning processes. The mutations were detected in the 
samples with fatty liver, hepatitis B and C, fibrotic liver, cirrhosis, and HCC. However, no specific 
mutations, apart from CTNNB1, were confirmed to be present only in HCC. No clear distinction 
between cancer and precancerous conditions could be achieved exclusively by the mutation 
analysis.  
Overall my analysis unravels that the mutations in HCC are more wide spread than 
expected. 
Serum analysis 
The developed shotgun proteomics technology was applied to serum samples taken from 
human patients, in order to evaluate the non-invasive diagnostic tools. Serum analysis revealed 
460 proteins (mostly components of complement, immunoglobulins and coagulation factors), 15 
of which were differentially expressed in tumor group compared to the group of samples without 
tumor. 806 proteins were found to be significantly changed in HCC bioptate material compared to 
control. The overlap of both serum and bioptate cohort uncovered 3 proteins: B2M, PON1, HP. 
B2M - Beta-2-microglobulin – component of the class I major histocompatibility complex 
(MHC). B2M is involved in the presentation of peptide antigens to the immune system 
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(UniProtconsortium, 2017). Ouda et al. detect approximately 5-fold elevation of B2M in plasma 
samples from patients with HCV-infected HCC compared to control (Ouda, Khairy, Sorour, & 
Mikhail, 2015). 
PON1 - Serum paraoxonase/arylesterase 1 – hydrolyzes the toxic metabolites, is capable of 
hydrolyzing a broad spectrum of organophosphate substrates and lactones. Mediates an 
enzymatic protection of low density lipoproteins against oxidative modification and atheroma 
formation (UniProtconsortium, 2017). Elevation of PON1 in plasma was detected in HCV-infected 
patients with alcohol abuse (Ferrin, et al., 2015).  
HP - Haptoglobin – captures free plasma hemoglobin to allow hepatic recycling of heme iron 
and to prevent kidney damage. Haptoglobin also acts as an antioxidant, has antibacterial activity 
and affects many aspects of the acute phase response. Hemoglobin/haptoglobin complexes are 
rapidly cleared by the macrophage scavenger receptor expressed on the surface of liver Kuepfer 
cells, using a pathway of an endocytic lysosomal degradation (UniProtconsortium, 2017). Altered 
levels of fucosylated haptoglobin in serum is used in diagnostics of HCC (Mondal, Saroha, Bose, & 
Chatterjee, 2016; S. Shang, Qin, Li, Zhang, & Liu, 2016; Tawara, et al., 2016). 
B2M, PON1, HP may have a diagnostic significance. Serum proteome profile reflected 
proteome changes in damaged liver samples obtained from selected patients. These markers 
potentially could be detected in serum, avoiding invasive and potentially harmful biopsy obtaining 
procedure. However additional studies on large cohorts have to be performed in order to evaluate 
diagnostics and/or prognostic perspectives. 
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Conclusions and outlook 
 
In the present work I have shown on mouse model and human samples that the metabolism 
of hepatocellular carcinoma is reprogrammed.  
ASV-B HCC mouse model showed a distinct reprogramming of central carbon metabolism at 
the proteomic level. Liver damaged with cancer revealed the impaired glycogen metabolism at the 
level of glycogen synthase 2 (Gys2). The gluconeogenesis was impaired at the level of 
phosphoenolpyruvate carboxykinase 1 (Pck1) and glucose-6-phosphatase catalytic-subunit (G6pc). 
Pyruvate transport to mitochondria was downregulated via the inhibition of pyruvate carriers 1 
and 2 (Mpc 1, 2). Most of the TCA cycle proteins were downregulated, as well as the glutamine 
uptake to TCA cycle at the level of glutamate pyruvate transaminase (Gpt), glutamate pyruvate 
transaminase 2 (Gpt2), and glutaminase 2 (Gls2). The isoform switch was shown at the level of 
phosphoglycerate mutases (Pgm) and pyruvate kinases (Pk)). At the metabolic level the higher 
amounts of glucose-6-phosphate, fructose-6-phosphate and lactic acid were detected. The 
metabolites of TCA cycle were characterized by higher levels in HCC. Fumaric and malic acid levels 
were higher in cancer compared to control. 
Human samples revealed a similar signature of tumor-specific reprogramming of CCM. At 
the proteomic level, glycogen metabolism was inhibited at the level of glycogen phosphorylase L 
(PYGL) and glycogen synthase 2 (GYS2). Gluconeogenesis was dysregulated at the level of fructose-
1,6-bisphosphatase 1 (FBP1). The upregulation of hexokinases (HK) characterizes an increased 
glycolysis, as well as an isoform switch at the levels of phosphoglycerate mutases (PGM), aldolases 
(ALDO), enolases (ENO), pyruvate kinases (PK), and lactate dehydrogenases (LDH). 65% of the 
proteins of the TCA cycle were downregulated, and isocitrate dehydrogenase (IDH) showed a 
switch between subunits. Glutamine uptake to TCA cycle was inhibited at the level of glutamate 
pyruvate transaminase (GPT) and glutaminase 2 (GLS2).  Metabolomic picture was mostly 
inconclusive, possibly due to the incredible diversity of genotypes and phenotypes in human 
cohort. This diversity may come from different environmental conditions, diets, and comorbidities 
of patients in cohort. 
In sum, proteomic data from both mice and humans showed a clear downregulation of the 
main energy-producing pathways in HCC. Glycogen metabolism (via PYGL and GYS2), 
gluconeogenesis (on various levels), glutaminolysis (via GPT, GLS2), and 60-65% of enzymes of TCA 
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cycle (SDHs, SUCLs, ACO etc.), and transport of pyruvate to mitochondria (MPCs) were 
downregulated in HCC. The proteomic data obtained in this work demonstrated one of the most 
common features of cancer cells: metabolic reprogramming. An isoform switch - one of the 
fundamental mechanisms in cancer reprogramming - was demonstrated in present study. Isoform 
switches at the level of phosphoglycerate mutases and pyruvate kinases were revealed in both 
mouse model and human samples. Even though the genetic backgrounds of human samples were 
extremely heterogeneous, the proteomic HCC signature was very robust and distinct in both 
bioptate and surgery material. The key features were found in both mouse and human, showing a 
universal metabolic HCC fingerprint. This observation confirmed that the chosen ASV-B mouse 
model was perfectly suitable to study HCC metabolism. 
The developed shotgun proteomics technology was used to analyze the serum from human 
patients, in order to evaluate the options of development the non-invasive diagnostic tool. Out of 
460 detected proteins, 15 were differentially expressed in tumor serum samples compared control 
group. The bioptate material analysis revealed 806 significantly changed proteins in HCC compared 
to control group. However, only 3 proteins were detected to be significantly changed in both 
serum and bioptate cohorts: B2M, PON1, HP. These proteins may have a diagnostic significance, 
however, this statement has to be confirmed on larger cohorts in further studies. Additionally, this 
finding suggests that serum does in part reflects the proteomic changes in liver, yet this 
observation has to be validated in larger cohorts as well. Serum proteome profile, allegedly, 
reflects proteome changes in damaged liver. 
This study confirmed that HCC metabolism might serve as therapy target due to its robust 
picture, which was independent on genetic background and mutations heterogeneity, and 
environmental conditions. Further molecular analyses of central carbon metabolism changes can 
improve the non-invasive diagnostics of HCC, and may shed the light on prognostic markers of 
outcome and possible treatment success. 
  
113 
 
Bibliography 
 
Abelev, G. I., Perova, S. D., Khramkova, N. I., Postnikova, Z. A., & Irlin, I. S. (1963). Production of 
embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation, 1, 174-
180. 
Allen, J. P., & Wilson, V. B. (2003). Assessing alcohol problems. A Guide for Clinicians and 
Researchers (2 ed.): National Institute on Alcohol Abuse and Alcoholism, NIH. 
Alomar, S. Y., Mansour, L., Abuderman, A., Alkhuriji, A., Arafah, M., Alwasel, S., Harrath, A. H., 
Almutairi, M., Trayhyrn, P., & Dar, J. A. (2016). beta-Catenin accumulation and S33F 
mutation of CTNNB1 gene in colorectal cancer in Saudi Arabia. Pol J Pathol, 67, 156-162. 
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009). Hepatocellular Carcinoma Incidence, 
Mortality, and Survival Trends in the United States From 1975 to 2005. Journal of Clinical 
Oncology, 27, 1485-1491. 
Andreana, L., Isgro, G., Marelli, L., Davies, N., Yu, D., Navalkissoor, S., & Burroughs, A. K. (2012). 
Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter 
compounds: trans-arterial radio-embolisation of HCC. Cancer Treat Rev, 38, 641-649. 
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., 
Dwight, S. S., Eppig, J. T., Harris, M. A., Hill, D. P., Issel-Tarver, L., Kasarskis, A., Lewis, S., 
Matese, J. C., Richardson, J. E., Ringwald, M., Rubin, G. M., & Sherlock, G. (2000). Gene 
Ontology: tool for the unification of biology. Nat Genet, 25, 25-29. 
Bergstrand, C. G., & Czar, B. (1956). Demonstration of a new protein fraction in serum from the 
human fetus. Scand J Clin Lab Invest, 8, 174. 
Berth, M., Moser, F. M., Kolbe, M., & Bernhardt, J. (2007). The state of the art in the analysis of 
two-dimensional gel electrophoresis images. Appl Microbiol Biotechnol, 76, 1223-1243. 
Bertino, G., Di Carlo, I., Ardiri, A., Calvagno, G. S., Demma, S., Malaguarnera, G., Bertino, N., 
Malaguarnera, M., Toro, A., & Malaguarnera, M. (2013). Systemic therapies in 
hepatocellular carcinoma: present and future. Future Oncol, 9, 1533-1548. 
Beyoglu, D., Imbeaud, S., Maurhofer, O., Bioulac-Sage, P., Zucman-Rossi, J., Dufour, J. F., & Idle, J. 
R. (2013). Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism 
and the role of transcriptomic classification. Hepatology, 58, 229-238. 
Bielow, C., Mastrobuoni, G., & Kempa, S. (2016). Proteomics Quality Control: Quality Control 
Software for MaxQuant Results. J Proteome Res, 15, 777-787. 
Boiteux, A., & Hess, B. (1981). Design of glycolysis. Philos Trans R Soc Lond B Biol Sci, 293, 5-22. 
Borentain, P., Gerolami, V., Ananian, P., Garcia, S., Noundou, A., Botta-Fridlund, D., Le Treut, Y. P., 
Berge-Lefranc, J. L., & Gerolami, R. (2007). DNA-repair and carcinogen-metabolising 
enzymes genetic polymorphisms as an independent risk factor for hepatocellular 
carcinoma in Caucasian liver-transplanted patients. Eur J Cancer, 43, 2479-2486. 
Bosman, F. T., Carneiro, F., Hruban, R. H., & Theise, N. D. (2010). WHO Classification of Tumours of 
the Digestive System (4 ed. Vol. 3). 
Boyault, S., Rickman, D. S., de Reynies, A., Balabaud, C., Rebouissou, S., Jeannot, E., Herault, A., 
Saric, J., Belghiti, J., Franco, D., Bioulac-Sage, P., Laurent-Puig, P., & Zucman-Rossi, J. 
(2007). Transcriptome classification of HCC is related to gene alterations and to new 
therapeutic targets. Hepatology, 45, 42-52. 
Burnette, W. N. (1981). "Western blotting": electrophoretic transfer of proteins from sodium 
dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic 
detection with antibody and radioiodinated protein A. Anal Biochem, 112, 195-203. 
Chang, C. C., Chen, Y. J., Huang, T. H., Chen, C. H., Kuo, F. Y., Eng, H. L., Yong, C. C., Liu, Y. W., Lin, T. 
L., Li, W. F., Lin, Y. H., Lin, C. C., Wang, C. C., & Chen, C. L. (2017). Living Donor Liver 
114 
 
Transplantation for Combined Hepatocellular Carcinoma and Cholangiocarcinoma: 
Experience of a Single Center. Ann Transplant, 22, 115-120. 
Chiesa, R., Donato, F., Tagger, A., Favret, M., Ribero, M. L., Nardi, G., Gelatti, U., Bucella, E., 
Tomasi, E., Portolani, N., Bonetti, M., Bettini, L., Pelizzari, G., Salmi, A., Savio, A., Garatti, 
M., & Callea, F. (2000). Etiology of hepatocellular carcinoma in Italian patients with and 
without cirrhosis. Cancer Epidemiol Biomarkers Prev, 9, 213-216. 
Clasen, S., Rempp, H., Hoffmann, R., Graf, H., Pereira, P. L., & Claussen, C. D. (2014). Image-guided 
radiofrequency ablation of hepatocellular carcinoma (HCC): is MR guidance more effective 
than CT guidance? Eur J Radiol, 83, 111-116. 
Cohen, S. M., Shulman, R. G., & McLaughlin, A. C. (1979). Effects of ethanol on alanine metabolism 
in perfused mouse liver studied by 13C NMR. Proceedings of the National Academy of 
Sciences, 76, 4808-4812. 
Colombo, C., Miceli, R., Lazar, A. J., Perrone, F., Pollock, R. E., Le Cesne, A., Hartgrink, H. H., Cleton-
Jansen, A. M., Domont, J., Bovee, J. V., Bonvalot, S., Lev, D., & Gronchi, A. (2013). CTNNB1 
45F mutation is a molecular prognosticator of increased postoperative primary desmoid 
tumor recurrence: an independent, multicenter validation study. Cancer, 119, 3696-3702. 
Cox, J., & Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized 
p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol, 
26, 1367-1372. 
Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., & Mann, M. (2011). Andromeda: 
a peptide search engine integrated into the MaxQuant environment. J Proteome Res, 10, 
1794-1805. 
Deepali, J. (2015). Liver and intrahepatic bile ducts - tumor. In  Hepatocellular carcinoma - General 
(Vol. 2017). 
Degli Esposti, D., Hamelin, J., Bosselut, N., Saffroy, R., Sebagh, M., Pommier, A., Martel, C., & 
Lemoine, A. (2012). Mitochondrial roles and cytoprotection in chronic liver injury. Biochem 
Res Int, 2012, 387626. 
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010). Pathogenesis of non-alcoholic fatty 
liver disease. QJM: An International Journal of Medicine, 103, 71-83. 
Doyen, J., Duranton-Tanneur, V., Hostein, I., Karanian-Philippe, M., Chevreau, C., Breibach, F., 
Coutts, M., Dadone, B., Saint-Paul, M. C., Gugenheim, J., Duffaud, F., & Pedeutour, F. 
(2016). Spatio-temporal genetic heterogeneity of CTNNB1 mutations in sporadic desmoid 
type fibromatosis lesions. Virchows Arch, 468, 369-374. 
du Prel, J.-B., Röhrig, B., Hommel, G., & Blettner, M. (2010). Choosing Statistical Tests: Part 12 of a 
Series on Evaluation of Scientific Publications. Deutsches Ärzteblatt International, 107, 
343-348. 
Dubois, N., Bennoun, M., Allemand, I., Molina, T., Grimber, G., Daudet-Monsac, M., Abelanet, R., & 
Briand, P. (1991). Time-course development of differentiated hepatocarcinoma and lung 
metastasis in transgenic mice. J Hepatol, 13, 227-239. 
Easton, D. F., Pharoah, P. D. P., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., 
Devilee, P., Meindl, A., Couch, F. J., Southey, M., Goldgar, D. E., Evans, D. G. R., Chenevix-
Trench, G., Rahman, N., Robson, M., Domchek, S. M., & Foulkes, W. D. (2015). Gene-Panel 
Sequencing and the Prediction of Breast-Cancer Risk. New England Journal of Medicine, 
372, 2243-2257. 
El-Serag, H. B. (2012). Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. 
Gastroenterology, 142, 1264-1273.e1261. 
Elliott, W. H., & Elliott, D. C. (2005). Biochemistry and molecular biology. Oxford: Oxford University 
Press. 
Feigelson, J., Pecau, Y., Cathelineau, L., & Navarro, J. (1975). Additional data on hepatic function 
tests in cystic fibrosis. Acta Paediatr Scand, 64, 337-344. 
115 
 
Ferrin, G., Rodriguez-Peralvarez, M., Aguilar-Melero, P., Ranchal, I., Llamoza, C., Linares, C. I., 
Gonzalez-Rubio, S., Muntane, J., Briceno, J., Lopez-Cillero, P., Montero-Alvarez, J. L., & de 
la Mata, M. (2015). Plasma protein biomarkers of hepatocellular carcinoma in HCV-
infected alcoholic patients with cirrhosis. PLoS One, 10, e0118527. 
Forner, A., Llovet, J. M., & Bruix, J. (2012). Hepatocellular carcinoma. The Lancet, 379, 1245-1255. 
Fritz, A., Percy, C., Jack, A., Shanmuragatnam, K., Sobin, L. H., Parkin, D. M., & Whelan, S. (2000). 
International Classification of Diseases for Oncology. Geneva: World Health Organization. 
Fujimoto, A., Totoki, Y., Abe, T., Boroevich, K. A., Hosoda, F., Nguyen, H. H., Aoki, M., Hosono, N., 
Kubo, M., Miya, F., Arai, Y., Takahashi, H., Shirakihara, T., Nagasaki, M., Shibuya, T., 
Nakano, K., Watanabe-Makino, K., Tanaka, H., Nakamura, H., Kusuda, J., Ojima, H., 
Shimada, K., Okusaka, T., Ueno, M., Shigekawa, Y., Kawakami, Y., Arihiro, K., Ohdan, H., 
Gotoh, K., Ishikawa, O., Ariizumi, S.-i., Yamamoto, M., Yamada, T., Chayama, K., Kosuge, T., 
Yamaue, H., Kamatani, N., Miyano, S., Nakagama, H., Nakamura, Y., Tsunoda, T., Shibata, 
T., & Nakagawa, H. (2012). Whole-genome sequencing of liver cancers identifies etiological 
influences on mutation patterns and recurrent mutations in chromatin regulators. Nat 
Genet, 44, 760. 
Gamallo, C., Palacios, J., Moreno, G., Calvo de Mora, J., Suarez, A., & Armas, A. (1999). beta-
catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-
catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol, 
155, 527-536. 
Giannakis, M., Hodis, E., Jasmine Mu, X., Yamauchi, M., Rosenbluh, J., Cibulskis, K., Saksena, G., 
Lawrence, M. S., Qian, Z. R., Nishihara, R., Van Allen, E. M., Hahn, W. C., Gabriel, S. B., 
Lander, E. S., Getz, G., Ogino, S., Fuchs, C. S., & Garraway, L. A. (2014). RNF43 is frequently 
mutated in colorectal and endometrial cancers. Nat Genet, 46, 1264-1266. 
GOconsortium, G. O. C. (2015). Gene Ontology Consortium: going forward. Nucleic Acids Res, 43, 
D1049-D1056. 
Gough, D. A., Armour, J. C., & Baker, D. A. (1997). Advances and prospects in glucose assay 
technology. Diabetologia, 40, S102-S107. 
Grant, D. M. (1991). Detoxification pathways in the liver. J Inherit Metab Dis, 14, 421-430. 
Greten, T. F., Papendorf, F., Bleck, J. S., Kirchhoff, T., Wohlberedt, T., Kubicka, S., Klempnauer, J., 
Galanski, M., & Manns, M. P. (2005). Survival rate in patients with hepatocellular 
carcinoma: a retrospective analysis of 389 patients. British Journal of Cancer, 92, 1862-
1868. 
Guo, T., Kouvonen, P., Koh, C. C., Gillet, L. C., Wolski, W. E., Rost, H. L., Rosenberger, G., Collins, B. 
C., Blum, L. C., Gillessen, S., Joerger, M., Jochum, W., & Aebersold, R. (2015). Rapid mass 
spectrometric conversion of tissue biopsy samples into permanent quantitative digital 
proteome maps. 21, 407-413. 
Gupta, S., Bent, S., & Kohlwes, J. (2003). Test characteristics of alpha-fetoprotein for detecting 
hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical 
analysis. Ann Intern Med, 139, 46-50. 
Hilgard, P., Muller, S., Hamami, M., Sauerwein, W. S., Haberkorn, U., Gerken, G., & Antoch, G. 
(2009). Selective internal radiotherapy (radioembolization) and radiation therapy for HCC-
current status and perspectives. Z Gastroenterol, 47, 37-54. 
Hirata, H., Sugimachi, K., Komatsu, H., Ueda, M., Masuda, T., Uchi, R., Sakimura, S., Nambara, S., 
Saito, T., Shinden, Y., Iguchi, T., Eguchi, H., Ito, S., Terashima, K., Sakamoto, K., Hirakawa, 
M., Honda, H., & Mimori, K. (2016). Decreased Expression of Fructose-1,6-bisphosphatase 
Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma. 
Cancer Res, 76, 3265-3276. 
Huang, H., Liang, P., Yu, X. L., Cheng, Z. G., Han, Z. Y., Yu, J., & Liu, F. Y. (2015). Safety assessment 
and therapeutic efficacy of percutaneous microwave ablation therapy combined with 
116 
 
percutaneous ethanol injection for hepatocellular carcinoma adjacent to the gallbladder. 
Int J Hyperthermia, 31, 40-47. 
IARC, I. A. f. R. o. C. (2012). GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and 
Prevalence Worldwide in 2012. In  Cancer Fact Sheets: International Agency for Research 
on Cancer. 
Jacobs, J. M., Diamond, D. L., Chan, E. Y., Gritsenko, M. A., Qian, W., Stastna, M., Baas, T., Camp, D. 
G., 2nd, Carithers, R. L., Jr., Smith, R. D., & Katze, M. G. (2005). Proteome analysis of liver 
cells expressing a full-length hepatitis C virus (HCV) replicon and biopsy specimens of 
posttransplantation liver from HCV-infected patients. J Virol, 79, 7558-7569. 
Janku, F., Wheler, J. J., Naing, A., Stepanek, V. M., Falchook, G. S., Fu, S., Garrido-Laguna, I., 
Tsimberidou, A. M., Piha-Paul, S. A., Moulder, S. L., Lee, J. J., Luthra, R., Hong, D. S., & 
Kurzrock, R. (2012). PIK3CA mutations in advanced cancers: characteristics and outcomes. 
Oncotarget, 3, 1566-1575. 
Jelic, S., & Sotiropoulos, G. C. (2010). Hepatocellular carcinoma: ESMO Clinical Practice Guidelines 
for diagnosis, treatment and follow-up. Ann Oncol, 21 Suppl 5, v59-64. 
Kammermeier, J., Drury, S., James, C. T., Dziubak, R., Ocaka, L., Elawad, M., Beales, P., Lench, N., 
Uhlig, H. H., Bacchelli, C., & Shah, N. (2014). Targeted gene panel sequencing in children 
with very early onset inflammatory bowel disease—evaluation and prospective analysis. 
Journal of Medical Genetics, 51, 748-755. 
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017). KEGG: new perspectives 
on genomes, pathways, diseases and drugs. Nucleic Acids Res, 45, D353-d361. 
Kanehisa, M., & Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids 
Res, 28, 27-30. 
Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M., & Tanabe, M. (2016). KEGG as a reference 
resource for gene and protein annotation. Nucleic Acids Res, 44, D457-462. 
Keating, G. M. (2017). Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol, 12, 243-
253. 
Klose, J. (1975). Protein mapping by combined isoelectric focusing and electrophoresis of mouse 
tissues. A novel approach to testing for induced point mutations in mammals. 
Humangenetik, 26, 231-243. 
Klotz, T., Montoriol, P. F., Da Ines, D., Petitcolin, V., Joubert-Zakeyh, J., & Garcier, J. M. (2013). 
Hepatic haemangioma: Common and uncommon imaging features. Diagnostic and 
Interventional Imaging, 94, 849-859. 
Kobayashi, K., Sagae, S., Nishioka, Y., Tokino, T., & Kudo, R. (1999). Mutations of the beta-catenin 
gene in endometrial carcinomas. Jpn J Cancer Res, 90, 55-59. 
Kolble, K., Barthel, B., Ullrich, O., Pidde, H., Dohring, C., Ruschoff, J., Schlag, P. M., & Dietel, M. 
(2000). beta-Catenine as a genomic target of high-grade microsatellite instability in 
colorectal cancer. Verh Dtsch Ges Pathol, 84, 182-186. 
Kuich, P. H., Hoffmann, N., & Kempa, S. (2014). Maui-VIA: A User-Friendly Software for Visual 
Identification, Alignment, Correction, and Quantification of Gas Chromatography-Mass 
Spectrometry Data. Front Bioeng Biotechnol, 2, 84. 
Lambert, B., & Van De Wiele, C. (2009). Selective internal radiation therapy of HCC and liver 
metastases: a locoregional or worldwide therapy? Q J Nucl Med Mol Imaging, 53, 302-304. 
Lee, J. G., Kang, C. M., Park, J. S., Kim, K. S., Yoon, D. S., Choi, J. S., Lee, W. J., & Kim, B. R. (2006). 
The Actual Five-year Survival Rate of Hepatocellular Carcinoma Patients after Curative 
Resection. Yonsei Medical Journal, 47, 105-112. 
Lin, C. Y., Wu, H., Tjeerdema, R. S., & Viant, M. R. (2007). Evaluation of metabolite extraction 
strategies from tissue samples using NMR metabolomics. Metabolomics, 3, 55-67. 
Liu, Y., & Wu, F. (2010). Global burden of aflatoxin-induced hepatocellular carcinoma: a risk 
assessment. Environ Health Perspect, 118, 818-824. 
117 
 
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, 
A., Raoul, J. L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., 
Galle, P. R., Seitz, J. F., Borbath, I., Haussinger, D., Giannaris, T., Shan, M., Moscovici, M., 
Voliotis, D., & Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J 
Med, 359, 378-390. 
Lobo, L., Yakoub, D., Picado, O., Ripat, C., Pendola, F., Sharma, R., ElTawil, R., Kwon, D., Venkat, S., 
Portelance, L., & Yechieli, R. (2016). Unresectable Hepatocellular Carcinoma: 
Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. 
Cardiovasc Intervent Radiol, 39, 1580-1588. 
Ludwig, J., Viggiano, T. R., McGill, D. B., & Oh, B. J. (1980). Nonalcoholic steatohepatitis: Mayo 
Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 55, 434-438. 
Luk, J. M., & Liu, A. M. (2011). Proteomics of hepatocellular carcinoma in Chinese patients. Omics, 
15, 261-266. 
Margini, C., & Dufour, J. F. (2016). The story of HCC in NAFLD: from epidemiology, across 
pathogenesis, to prevention and treatment. Liver Int, 36, 317-324. 
Martínez-Granados, B., Monleón, D., Martínez-Bisbal, M. C., Rodrigo, J. M., Olmo, J. d., Lluch, P., 
Ferrández, A., Martí-Bonmatí, L., & Celda, B. (2006). Metabolite identification in human 
liver needle biopsies by high-resolution magic angle spinning 1H NMR spectroscopy. NMR 
in Biomedicine, 19, 90-100. 
Maruyama, Y., Okuda, K., Ogata, T., Yasunaga, M., Ishikawa, H., Hirakawa, Y., Fukuyo, K., Horiuchi, 
H., Nakashima, O., & Kinoshita, H. (2013). Perioperative Challenges and Surgical Treatment 
of Large Simple, and Infectious Liver Cyst - A 12-Year Experience. PLoS One, 8, e76537. 
Mastrobuoni, G., Irgang, S., Pietzke, M., Assmus, H. E., Wenzel, M., Schulze, W. X., & Kempa, S. 
(2012). Proteome dynamics and early salt stress response of the photosynthetic organism 
Chlamydomonas reinhardtii. BMC Genomics, 13, 215. 
Masuda, T., & Miyoshi, E. (2011). Cancer biomarkers for hepatocellular carcinomas: from 
traditional markers to recent topics. Clin Chem Lab Med, 49, 959-966. 
MeSH, U. S. N. L. o. M. (1999). Medical Subject Headings (MeSH®). In  (01.01.1999 ed.). 8600 
Rockville Pike, Bethesda, MD 20894: U.S. National Library of Medicine. 
Mondal, G., Saroha, A., Bose, P. P., & Chatterjee, B. P. (2016). Altered glycosylation, expression of 
serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver 
cirrhosis and hepatocellular carcinoma patients. Glycoconj J, 33, 209-218. 
Moreno-Bueno, G., Gamallo, C., Perez-Gallego, L., de Mora, J. C., Suarez, A., & Palacios, J. (2001). 
beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite 
instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. 
Diagn Mol Pathol, 10, 116-122. 
Mouradov, D., Sloggett, C., Jorissen, R. N., Love, C. G., Li, S., Burgess, A. W., Arango, D., Strausberg, 
R. L., Buchanan, D., Wormald, S., O'Connor, L., Wilding, J. L., Bicknell, D., Tomlinson, I. P., 
Bodmer, W. F., Mariadason, J. M., & Sieber, O. M. (2014). Colorectal cancer cell lines are 
representative models of the main molecular subtypes of primary cancer. Cancer Res, 74, 
3238-3247. 
Mullen, J. T., DeLaney, T. F., Rosenberg, A. E., Le, L., Iafrate, A. J., Kobayashi, W., Szymonifka, J., 
Yeap, B. Y., Chen, Y. L., Harmon, D. C., Choy, E., Yoon, S. S., Raskin, K. A., Hornicek, F. J., & 
Nielsen, G. P. (2013). beta-Catenin mutation status and outcomes in sporadic desmoid 
tumors. Oncologist, 18, 1043-1049. 
Nelson, D. L., Nelson, D. L., Lehninger, A. L., & Cox, M. M. (2008). Lehninger principles of 
biochemistry. New York: W.H. Freeman. 
Ng, P. C., & Kirkness, E. F. (2010). Whole Genome Sequencing. In M. R. Barnes & G. Breen (Eds.), 
Genetic Variation: Methods and Protocols (pp. 215-226). Totowa, NJ: Humana Press. 
118 
 
Nguyen, V. T., Law, M. G., & Dore, G. J. (2009). Hepatitis B-related hepatocellular carcinoma: 
epidemiological characteristics and disease burden. J Viral Hepat, 16, 453-463. 
Nishida, Y., Tsukushi, S., Urakawa, H., Hamada, S., Kozawa, E., Ikuta, K., & Ishiguro, N. (2016). 
Simple resection of truncal desmoid tumors: A case series. Oncol Lett, 12, 1564-1568. 
O'Farrell, P. H. (1975). High resolution two-dimensional electrophoresis of proteins. J Biol Chem, 
250, 4007-4021. 
Orimo, T., Ojima, H., Hiraoka, N., Saito, S., Kosuge, T., Kakisaka, T., Yokoo, H., Nakanishi, K., 
Kamiyama, T., Todo, S., Hirohashi, S., & Kondo, T. (2008). Proteomic profiling reveals the 
prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular 
carcinoma. Hepatology, 48, 1851-1863. 
Ouda, S. M., Khairy, A. M., Sorour, A. E., & Mikhail, M. N. (2015). Serum Beta-2 Microglobulin: a 
Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related 
Liver Diseases. Asian Pac J Cancer Prev, 16, 7825-7829. 
Palacios, J., & Gamallo, C. (1998). Mutations in the beta-catenin gene (CTNNB1) in endometrioid 
ovarian carcinomas. Cancer Res, 58, 1344-1347. 
Pandya, J. D., Sullivan, P. G., Leung, L. Y., Tortella, F. C., Shear, D. A., & Deng-Bryant, Y. (2016). 
Advanced and High-Throughput Method for Mitochondrial Bioenergetics Evaluation in 
Neurotrauma. In F. H. Kobeissy, C. E. Dixon, R. L. Hayes & S. Mondello (Eds.), Injury Models 
of the Central Nervous System: Methods and Protocols (pp. 597-610). New York, NY: 
Springer New York. 
Paoletti, A., & Chang, F. (2000). Analysis of mid1p, a Protein Required for Placement of the Cell 
Division Site, Reveals a Link between the Nucleus and the Cell Surface in Fission Yeast. 
Molecular Biology of the Cell, 11, 2757-2773. 
Paul, S. B., Gulati, M. S., Sreenivas, V., Madan, K., Gupta, A. K., Mukhopadhyay, S., & Acharya, S. K. 
(2007). Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical 
symptomatology, imaging and alpha-fetoprotein. Oncology, 72 Suppl 1, 117-123. 
Pei, Y., Zhang, T., Renault, V., & Zhang, X. (2009). An overview of hepatocellular carcinoma study 
by omics-based methods. Acta Biochim Biophys Sin (Shanghai), 41, 1-15. 
Peterson, K. (2004). Biomarkers for alcohol use and abuse--a summary. Alcohol Res Health, 28, 30-
37. 
Pietzke, M., Zasada, C., Mudrich, S., & Kempa, S. (2014). Decoding the dynamics of cellular 
metabolism and the action of 3-bromopyruvate and 2-deoxyglucose using pulsed stable 
isotope-resolved metabolomics. Cancer Metab, 2, 9. 
Powell, E. E., Cooksley, W. G., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990). The 
natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for 
up to 21 years. Hepatology, 11, 74-80. 
QIAGEN. (2006). DNeasy® Blood & Tissue Handbook: QIAGEN. 
Rappsilber, J., Ishihama, Y., & Mann, M. (2003). Stop and go extraction tips for matrix-assisted 
laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in 
proteomics. Anal Chem, 75, 663-670. 
Reisch, A. S., & Elpeleg, O. (2007). Biochemical Assays for Mitochondrial Activity: Assays of TCA 
Cycle Enzymes and PDHc. In  Methods in Cell Biology (Vol. 80, pp. 199-222): Academic 
Press. 
Riener, M. O., Bawohl, M., Clavien, P. A., & Jochum, W. (2008). Rare PIK3CA hotspot mutations in 
carcinomas of the biliary tract. Genes Chromosomes Cancer, 47, 363-367. 
Roytberg, G. E., & Strutynskiy, A. V. (2013). Liver, bile ducts, pancreas. Textbook. Moscow, Russian 
Federation: МЕДпресс-информ. 
Shang, R. Z., Qu, S. B., & Wang, D. S. (2016). Reprogramming of glucose metabolism in 
hepatocellular carcinoma: Progress and prospects. World J Gastroenterol, 22, 9933-9943. 
119 
 
Shang, S., Qin, X., Li, W., Zhang, S., & Liu, Y. (2016). ELISA index of serum fucosylated haptoglobin 
for diagnosis of HCC using the normal and reverse AAL ELISA. Discov Med, 21, 15-23. 
Shen, A., Tang, C., Wang, Y., Chen, Y., Yan, X., Zhang, C., Liu, R., Wei, X., Zhu, Y., Zhang, H., & Wu, Z. 
(2013). A systematic review of sorafenib in Child-Pugh A patients with unresectable 
hepatocellular carcinoma. J Clin Gastroenterol, 47, 871-880. 
Shen, J. Y., Li, C., Wen, T. F., Yan, L. N., Li, B., Wang, W. T., Yang, J. Y., Xu, M. Q., & Nazar Highness, 
T. (2016). Liver transplantation versus surgical resection for HCC meeting the Milan 
criteria: A propensity score analysis. Medicine (Baltimore), 95, e5756. 
Snoep, J. L., & Westerhoff, H. V. (2005). From isolation to integration, a systems biology approach 
for building the Silicon Cell. In L. Alberghina & H. V. Westerhoff (Eds.), Systems Biology: 
Definitions and Perspectives (pp. 13-30). Berlin, Heidelberg: Springer Berlin Heidelberg. 
Sudarsan, S., Dethlefsen, S., Blank, L. M., Siemann-Herzberg, M., & Schmid, A. (2014). The 
Functional Structure of Central Carbon Metabolism in Pseudomonas putida KT2440. 
Applied and Environmental Microbiology, 80, 5292-5303. 
Tan, G. S., Lim, K. H., Tan, H. T., Khoo, M. L., Tan, S. H., Toh, H. C., & Ching Ming Chung, M. (2014). 
Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular 
carcinoma relapse in surgically resectable patients. J Proteome Res, 13, 4833-4846. 
Tawara, S., Tatsumi, T., Iio, S., Kobayashi, I., Shigekawa, M., Hikita, H., Sakamori, R., Hiramatsu, N., 
Miyoshi, E., & Takehara, T. (2016). Evaluation of Fucosylated Haptoglobin and Mac-2 
Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic 
Hepatitis C. PLoS One, 11, e0151828. 
The Genomes Project, C. (2015). A global reference for human genetic variation. Nature, 526, 68-
74. 
Tian, Q., Price, N. D., & Hood, L. (2012). Systems cancer medicine: towards realization of 
predictive, preventive, personalized and participatory (P4) medicine. J Intern Med, 271, 
111-121. 
Tietze, F. (1969). Enzymic method for quantitative determination of nanogram amounts of total 
and oxidized glutathione: Applications to mammalian blood and other tissues. Anal 
Biochem, 27, 502-522. 
Tolosa, L., Malak, H., Raob, G., & Lakowicz, J. R. (1997). Optical assay for glucose based on the 
luminescnence decay time of the long wavelength dye Cy5™. Sensors and Actuators B: 
Chemical, 45, 93-99. 
Tornesello, M. L., Buonaguro, L., Tatangelo, F., Botti, G., Izzo, F., & Buonaguro, F. M. (2013). 
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with 
hepatitis B and hepatitis C virus infections. Genomics, 102, 74-83. 
Ueno, M., Hayami, S., Shigekawa, Y., Kawai, M., Hirono, S., Okada, K., Tamai, H., Shingaki, N., Mori, 
Y., Ichinose, M., & Yamaue, H. (2015). Prognostic impact of surgery and radiofrequency 
ablation on single nodular HCC 5 cm: Cohort study based on serum HCC markers. J 
Hepatol, 63, 1352-1359. 
Ukawa, S., Okada, E., Nakamura, K., Hirata, M., Nagai, A., Matsuda, K., Yamagata, Z., Kamatani, Y., 
Ninomiya, T., Kiyohara, Y., Muto, K., Kubo, M., Nakamura, Y., & Tamakoshi, A. (2017). 
Characteristics of patients with liver cancer in the BioBank Japan project. J Epidemiol, 27, 
S43-s48. 
UniProtconsortium. (2017). UniProt: the universal protein knowledgebase. Nucleic Acids Res, 45, 
D158-D169. 
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: 
the metabolic requirements of cell proliferation. Science, 324, 1029-1033. 
VIB/UGent, B. E. G. (2017). Draw Venn Diagram. In: VIB/UGent Bioinformatics & Evolutionary 
Genomics. 
120 
 
Vucenik, I., & Stains, J. P. (2012). Obesity and cancer risk: evidence, mechanisms, and 
recommendations. Annals of the New York Academy of Sciences, 1271, 37-43. 
Warburg, O. (1956). On the origin of cancer cells. Science, 123, 309-314. 
Willekens, I., Hoorens, A., Geers, C., Op de Beeck, B., Vandenbroucke, F., & de Mey, J. (2009). 
Combined hepatocellular and cholangiocellular carcinoma presenting with radiological 
characteristics of focal nodular hyperplasia. World Journal of Gastroenterology : WJG, 15, 
3940-3943. 
Yang, B., Zan, R. Y., Wang, S. Y., Li, X. L., Wei, M. L., Guo, W. H., You, X., Li, J., & Liao, Z. Y. (2015). 
Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular 
carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol, 13, 96. 
Yizhak, K., Benyamini, T., Liebermeister, W., Ruppin, E., & Shlomi, T. (2010). Integrating 
quantitative proteomics and metabolomics with a genome-scale metabolic network 
model. Bioinformatics, 26, i255-i260. 
Yu, D., Shi, X., Meng, G., Chen, J., Yan, C., Jiang, Y., Wei, J., & Ding, Y. (2015). Kidney-type 
glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular 
carcinoma. Oncotarget, 6, 7619-7631. 
Zinkin, N. T., Grall, F., Bhaskar, K., Otu, H. H., Spentzos, D., Kalmowitz, B., Wells, M., Guerrero, M., 
Asara, J. M., Libermann, T. A., & Afdhal, N. H. (2008). Serum proteomics and biomarkers in 
hepatocellular carcinoma and chronic liver disease. Clin Cancer Res, 14, 470-477. 
 
  
121 
 
Contributions of collaborators 
 
The mice material for proteomic and metabolomics analyses was provided by our Prof. Dr. 
Thorsten Cramer and our colleagues from his laboratory, Charite Medical University, Berlin, 
Germany. 
Human samples were obtained in collaboration with Prof. Dr. Thorsten Cramer and his 
colleagues from University Hospital Aachen. 
The work with the NGS was performed in the lab of Prof. Dr. Christine Sers, Charite Medical 
University, Berlin, Germany. NGS runs were performed with the help of Andrea Menne, and data 
was analyzed with the help of Dr. Soulafa Mamlouk. 
  
122 
 
List of publications 
 
− Kettelhake A, Berndt N, Vvedenskaya O, Cramer T: Application of mathematical modelling 
to assess the functional importance of HIF1A for hepatoma biology. Z Gastroenterol, 2015; 
53 - A4_7; 
− Samhan-Arias AK, Ji J, Demidova O, Kagan VE, Amoscato AA.: Oxidized phospholipids as 
biomarkers of tissue and cell damage with a focus on cardiolipin. Biochem. Biophys. Acta, 
2012, Oct; 1818 (10):2413-23; 
− Demidova O, Stepanov GO and Osipov AN: How can free radicals activate apoptotic 
reaction? Bulletin of RSMU, 2010, 2:433. 
  
123 
 
Selected conferences and schools 
 
− Hallmarks of Cancer, Ghent, Belgium, 2016, “Metabolic reprogramming of hepatocellular 
carcinoma” (poster); 
− Young Scientists in Cancer Symposium, Berlin, Germany, 2015, “Metabolic reprogramming 
of hepatocellular carcinoma” (talk); 
− Hypoxia: from basic mechanisms to therapeutics, Royal Dublin Society, Dublin, Ireland, 
2015, “Application of mathematical modelling to assess the functional importance of HIF-1a 
for hepatoma biology” (poster coauthor); 
− Quantitative Proteomics and Data Analysis workshop, Chester, UK, 2014 (participant); 
− The SignGene Winter School "Biology of Differentiation and Cancer" Haifa, Israel, 2014, 
“Different characteristics of metabolism of Hepatocellular Carcinoma cell lines” (poster); 
− Society of Toxicology’s 51st Annual Meeting & ToxExpo, San Francisco, California, USA, 
2012, “Normal-phase/reverse-phase 2D-HPLC-MS analysis of oxidized lipid species: 
Application to the study of cardiolipin in apoptosis and damaged tissue” (poster coauthor). 
 
 
 
Appendix 1 
HCC macroscopic picture and histology 
Macroscopic picture 
 
Figure 1. Hepatocellular carcinoma with a greenish yellow hue (Deepali, 2015). 
 
Histological features (Deepali, 2015) 
• Patterns are trabecular (most common) with 4 and more cells surrounded by layer of 
flattened endothelial cells; also clear cell, giant cell; 
• Presence of sinusoidal vessels surrounding tumor cells; 
• Scanty (poor) stroma; 
• Cells are polygonal with distinct cell membranes, abundant granular eosinophilic cytoplasm, 
round nuclei with rough chromatin and thickened nuclear membrane; 
• Presence of portal vein thrombosis, vascular invasion; 
• Variable: abundant fat, bile (5-33%); 
• Minimal desmoplasia. 
 
 
Histological types (Deepali, 2015) 
• Well differentiated: thin plates (1-3 hepatocytes thick), cells smaller than normal, minimal 
nuclear atypia, nuclear density 2x normal liver; commonly change of liver composition; 
hepatocyte adenoma may be present; common pattern for small hepatocellular carcinoma; 
• Moderately differentiated: trabecular pattern with 4 and more cells thick; larger tumor cells 
than well-differentiated HCC with more eosinophilic cytoplasm, distinct nucleoli, bile and 
tumor giant cells; most common pattern in advanced HCC; 
• Poorly differentiated: large tumor cells with hyperchromatic nuclei in compact growth 
pattern with rare trabeculae or bile; may not seem to be hepatocellular; 
• Combined hepatocellular-cholangiocarcinoma: <1% of primary liver carcinomas; 
unequivocal hepatocellular and cholangiocarcinoma that are intimately admixed(Willekens, 
et al., 2009); increased CA19-9 and AFP; 
• Diffuse cirrhosis like HCC: diffuse and extensive liver involvement by small cirrhosis-like 
nodules that evade clinical and radiographic detection (Jakate, et al., 2010); 
• Steatohepatitic HCC: recently described variant associated with metabolic dysfunction such 
as non-alcoholic fatty liver disease (Salomao, et al., 2012; Salomao, Yu, Brown, Emond, & 
Lefkowitch, 2010); slightly firmer than classic HCC (due to fibrosis) and more yellow (due to 
steatosis); histology shows steatosis, hepatocyte ballooning, inflammation and pericellular 
fibrosis within neoplastic tissue. 
  
Examples of histological pictures 
 
Figure 2. The malignant cells of this hepatocellular carcinoma (seen mostly on the right) are well 
differentiated and interdigitate with normal, larger hepatocytes (seen mostly at the left) (Deepali, 
2015). 
 
 
Figure 3. Hepatocellular carcinoma, histological picture. Hepatocellular carcinoma is presented with 
liver cords that are wider than the normal liver plate that is two cells thick. No normal lobular 
architecture is observed on this picture, despite presence of vascular structures (Deepali, 2015). 
  
 Figure 4. Hepatocellular carcinoma, histological picture. The cohesive clusters of malignant 
hepatocytes appear as slender arborizing cords (Bosman, et al., 2010). 
 
 
Figure 5. Hepatocellular carcinoma, histological picture. The clusters of malignant hepatocytes with 
broad cords (more than five cells thick) are wrapped by endothelium. Note the granular cytoplasm, 
increased nucleus/cytoplasm ratio, granular chromatin and distinct nucleolus (Bosman, et al., 2010).  
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Appendix 2
Table. Full names and short names of chosen enzymes of central carbon metabolism.
Protein names Gene names (homo sapiens ) Protein IDs (homo sapiens ) Gene names (mus musculus ) Protein IDs (mus musculus )
ATP‐citrate synthase ACLY P53396;P53396‐2 Acly Q91V92
Cytoplasmic aconitate hydratase ACO1 P21399 Aco1 P28271
Aconitate hydratase, mitochondrial ACO2 Q99798 Aco2 Q99KI0
Long‐chain‐fatty‐acid‐‐CoA ligase 1 ACSL1 P33121;P33121‐2 Acsl1 P41216
Long‐chain‐fatty‐acid‐‐CoA ligase 3 ACSL3 O95573 Acsl3 Q9CZW4
Long‐chain‐fatty‐acid‐‐CoA ligase 4 ACSL4 O60488‐2;O60488 Acsl4 Q9QUJ7‐2;Q9QUJ7
Long‐chain‐fatty‐acid‐‐CoA ligase 5 ACSL5 Q9ULC5;Q9ULC5‐3 Acsl5 Q8JZR0
Long‐chain‐fatty‐acid‐‐CoA ligase 6 ACSL6 Q9UKU0;Q9UKU0‐(1,2,3,5,6,7,8) Acsl6 Q91WC3
Fructose‐bisphosphate aldolase A ALDOA P04075 Aldoa P05064
Fructose‐bisphosphate aldolase B ALDOB P05062 Aldob Q91Y97
Fructose‐bisphosphate aldolase C ALDOC P09972 Aldoc P05063
Citrate synthase, mitochondrial CS O75390 Cs Q9CZU6
Dihydrolipoyllysine‐residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial DLAT P10515 Dlat Q8BMF4
Dihydrolipoyl dehydrogenase, mitochondrial DLD P09622 Dld O08749
Dihydrolipoyllysine‐residue succinyltransferase component of 
2‐oxoglutarate dehydrogenase complex, mitochondrial DLST P36957 Dlst Q9D2G2;Q9D2G2‐2
Alpha‐enolase ENO1 P06733 Eno1 P17182
Gamma‐enolase ENO2 P09104 Eno2 P17183
Beta‐enolase ENO3 P13929;P13929‐2;P13929‐3 Eno3 P21550
Fatty acid synthase FASN P49327 Fasn P19096
Fructose‐1,6‐bisphosphatase 1 FBP1 P09467 Fbp1 Q9QXD6
Fructose‐1,6‐bisphosphatase isozyme 2 FBP2 O00757 Fbp2 P70695
Fumarate hydratase, mitochondrial FH P07954‐2;P07954 Fh P97807‐2;P97807
Glucose‐6‐phosphatase G6PC P35575 G6pc P35576
Glucose‐6‐phosphate 1‐dehydrogenase G6PD P11413;P11413‐2;P11413‐3 G6pdx Q00612
Glyceraldehyde‐3‐phosphate dehydrogenase GAPDH P04406;O14556 Gapdh P16858
Glucokinase GCK P35557‐2;P35557‐3 Gck P52792‐2;P52792
Glutaminase kidney isoform, mitochondrial GLS O94925 Gls D3Z7P3;D3Z7P3‐2
Glutaminase liver isoform, mitochondrial GLS2 Q9UI32 Gls2 Q571F8
Glutamate dehydrogenase 1, mitochondrial GLUD1 P00367 Glud1 P26443
Glutamate dehydrogenase 2, mitochondrial GLUD2 P49448 ‐
Glucose‐6‐phosphate isomerase GPI P06744;P06744‐2 Gpi P06745
Alanine aminotransferase 1 GPT P24298 Gpt Q8QZR5
Alanine aminotransferase 2 GPT2 Q8TD30;Q8TD30‐2 Gpt2 Q8BGT5
Glycogen [starch] synthase, muscle GYS1 P13807‐2;P13807 Gys1
Glycogen [starch] synthase, liver GYS2 P54840 Gys2 Q8VCB3
Hexokinase‐1 HK1 P19367;P19367‐4;P19367‐2;P19367‐3 Hk1 P17710
Hexokinase‐2 HK2 P52789 Hk2 O08528
Hexokinase‐3 HK3 P52790 Hk3 Q3TRM8
Isocitrate dehydrogenase [NADP] cytoplasmic IDH1 O75874 Idh1 O88844
Isocitrate dehydrogenase [NADP], mitochondrial IDH2 P48735 Idh2 P54071
Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial IDH3A P50213;P50213‐2 Idh3a Q9D6R2;Q9D6R2‐2
Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial IDH3B O43837;O43837‐2 Idh3b
Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial IDH3G P51553 Idh3g P70404
L‐lactate dehydrogenase A chain LDHA P00338;P00338‐3;P00338‐4;P00338‐5;P00338‐2Ldha P06151
L‐lactate dehydrogenase B chain LDHB P07195 Ldhb P16125
L‐lactate dehydrogenase C chain LDHC P07864 Ldhc P00342
Probable D‐lactate dehydrogenase, mitochondrial LDHD Q86WU2‐2;Q86WU2 Ldhd Q7TNG8
Malate dehydrogenase, cytoplasmic MDH1 P40925;P40925‐3;P40925‐2 Mdh1 P14152
Malate dehydrogenase, mitochondrial MDH2 P40926 Mdh2 P08249
NADP‐dependent malic enzyme ME1 P48163 Me1 P06801
NAD‐dependent malic enzyme, mitochondrial ME2 P23368;P23368‐2 Me2 Q99KE1
NADP‐dependent malic enzyme, mitochondrial ME3 Q16798 Me3 Q8BMF3
Mitochondrial pyruvate carrier 1 MPC1 Q9Y5U8 Mpc1 P63030
Mitochondrial pyruvate carrier 2 MPC2 O95563 Mpc2 Q9D023
2‐oxoglutarate dehydrogenase, mitochondrial
OGDH Q02218;Q02218‐2 Ogdh
Q60597;Q60597‐3;Q60597‐2;
Q60597‐4
2‐oxoglutarate dehydrogenase‐like, mitochondrial OGDHL Q9ULD0;Q9ULD0‐2;Q9ULD0‐3 Ogdhl B2RXT3
Pyruvate carboxylase, mitochondrial PC P11498 Pc Q05920
Phosphoenolpyruvate carboxykinase, cytosolic [GTP] PCK1 P35558 Pck1 Q9Z2V4
Phosphoenolpyruvate carboxykinase [GTP], mitochondrial PCK2 Q16822;Q16822‐2 Pck2 Q8BH04
Pyruvate dehydrogenase E1 component subunit alpha, 
somatic form, mitochondrial PDHA1 P08559;P08559‐3;P08559‐2;P08559‐4 Pdha1 P35486
Pyruvate dehydrogenase E1 component subunit alpha, 
testis‐specific form, mitochondrial PDHA2 P29803 Pdha2 P35487
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial PDHB P11177‐2;P11177;P11177‐3 Pdhb Q9D051
Pyruvate dehydrogenase protein X component, mitochondrial PDHX O00330;O00330‐2 Pdhx Q8BKZ9
6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase 1;
6‐phosphofructo‐2‐kinase;Fructose‐2,6‐bisphosphatase PFKFB1 P16118;Q16877;Q16875‐2;Q16875 Pfkfb1 P70266;P70266‐2
6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase 2;
6‐phosphofructo‐2‐kinase;Fructose‐2,6‐bisphosphatase PFKFB2 O60825;O60825‐2 Pfkfb2 P70265
ATP‐dependent 6‐phosphofructokinase, liver type PFKL P17858;P17858‐2 Pfkl P12382
ATP‐dependent 6‐phosphofructokinase, muscle type PFKM P08237;P08237‐3;P08237‐2 Pfkm P47857
ATP‐dependent 6‐phosphofructokinase, platelet type PFKP Q01813;Q01813‐2 Pfkp Q9WUA3;Q9WUA3‐2
Phosphoglycerate mutase 1 PGAM1 P18669 Pgam1 Q9DBJ1
Phosphoglycerate mutase 2 PGAM2 P15259 Pgam2 O70250
Serine/threonine‐protein phosphatase PGAM5, mitochondrial PGAM5 Q96HS1;Q96HS1‐2 Pgam5 Q8BX10‐2;Q8BX10
6‐phosphogluconate dehydrogenase, decarboxylating PGD P52209 Pgd Q9DCD0
Phosphoglycerate kinase 1 PGK1 P00558 Pgk1 P09411
Phosphoglycerate kinase 2 PGK2 P07205 Pgk2 P09041
Phosphoglucomutase‐1 PGM1 P36871;P36871‐2;P36871‐3 Pgm1 Q9D0F9
Phosphoglucomutase‐2 PGM2 Q96G03 Pgm2 Q7TSV4
Pyruvate kinase PKLR PKLR P30613 Pklr P53657
Pyruvate kinase PKM PKM P14618;P14618‐3 Pkm P52480
Glycogen phosphorylase, liver form PYGL P06737‐2;P06737 Pygl Q9ET01
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial SDHA P31040 Sdha Q8K2B3
Succinate dehydrogenase [ubiquinone] iron‐sulfur subunit, 
mitochondrial SDHB P21912 Sdhb Q9CQA3
Succinate dehydrogenase cytochrome b560 subunit, mitochondrial SDHC Q99643‐5;Q99643‐3;Q99643 Sdhc Q9CZB0
Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, 
mitochondrial SDHD O14521 Sdhd Q9CXV1
Succinyl‐CoA ligase [ADP‐forming] subunit beta, mitochondrial SUCLA2 Q9P2R7‐2;Q9P2R7 Sucla2 Q9Z2I9
Succinyl‐CoA ligase [ADP/GDP‐forming] subunit alpha, mitochondrial SUCLG1 P53597 Suclg1 Q9WUM5
Succinyl‐CoA ligase [GDP‐forming] subunit beta, mitochondrial SUCLG2 Q96I99;Q96I99‐2 Suclg2 Q9Z2I8;Q9Z2I8‐2
Transaldolase TALDO1 P37837 Taldo1 Q93092
Transketolase TKT P29401;P29401‐2 Tkt P40142
Transketolase‐like protein 1 TKTL1 P51854;P51854‐1 Tktl1 Q99MX0
Transketolase‐like protein 2 TKTL2 Q9H0I9 Tktl2 Q9D4D4
Triosephosphate isomerase TPI1 P60174‐1;P60174;P60174‐4 Tpi1 P17751
Appendix 3
Table. Patients list.
Sample Code Acquisition Date B/S Diagnosis (short) Diagnosis (full) Mutations detected Mutations confirmed Age Gender Proteome Metabolome Genome
1 2‐Nov‐09 B HBV, Fibrosis Chronic Hepatitis B, Fibrosis KIT 63 m ✓ ✓ ✓
2 18‐Feb‐09 B HBV Chronic Hepatitis B RB1 KDR TP53 TP53 RB1 57 f ✓ ✓ ✓
3 25‐Feb‐09 B HBV Chronic Hepatitis B TP53 44 m ✓ ✓ ✓
4 3‐Apr‐09 B HBV, Fibrosis Chronic Hepatitis B, mild Fibrosis TP53 45 f ✓ ✓ ✓
5 29‐Jul‐09 B HBV, Fibrosis Chronic Hepatitis B, Fibrosis TP53 KDR 45 m ✓ ✓ ✓
6 5‐Nov‐10 B HBV, Fibrosis Chronic Hepatitis B, Fibrosis TP53 34 f ✓ ✓ ✓
7 13‐Feb‐08 B Fatty Liver Fatty Liver (70%) TP53 PIK3CA KDR 47 f ✓ ✓
8 26‐Feb‐08 B Fatty Liver Fatty Liver TP53 MET 49 m ✓ ✓ ✓
9 3‐Dec‐08 B Fatty Liver Fatty Liver STK11 KDR STK11 59 f ✓ ✓ ✓
10 24‐Jun‐09 B Fatty Liver Fatty Liver PIK3CA KDR 49 f ✓ ✓ ✓
11 17‐Aug‐10 B Fatty Liver Fatty Liver 43 m ✓ ✓
12 17‐Nov‐10 B Fatty Liver Fatty Liver 40 m ✓ ✓ ✓
13 13‐Aug‐08 B Fibrosis+ Fibrosis, Primary sclerosing cholangitis TP53 51 f ✓ ✓ ✓
14 4‐Jan‐09 B Fibrosis+ Fibrosis or Autoimmune hepatitis‐sarkoidosis 34 m ✓ ✓
15 18‐May‐10 B Fibrosis+ Fibrosis, Primary Sclerosing Cholangitis PIK3CA KIT 30 f ✓ ✓ ✓
16 6‐Aug‐10 B Fibrosis+, Alcohol Alcoholic Fibrosis, NASH 31 m ✓ ✓
17 14‐Jan‐09 B Cirrhosis+, Alcohol Alcoholic Cirrhosis, NASH TP53 47 m ✓ ✓ ✓
18 19‐Apr‐11 B Fibrosis+, Alcohol, Obesity Fatty Liver, Alcoholic Cirrhosis, Obesity RET 51 m ✓ ✓ ✓
19 2‐Apr‐14 B HCC, HCV, Diab2 HCC, Chronic Hepatitis C, Cirrhosis, Diabetes Type 2 TP53 PIK3CA KIT KDR 58 m ✓ ✓ ✓
20 2‐Apr‐14 B HCC, Obesity HCC, Cirrhosis, NASH, Obesity TP53 KIT 70 m ✓ ✓ ✓
21 2‐Nov‐14 B HCC, Diab1 HCC, Diabetes Type 1 TP53 KDR 71 m ✓ ✓
22 25‐Feb‐14 B HCC HCC, Cirrhosis TP53 KDR 72 m ✓ ✓
23 3‐Nov‐14 B HCC, Diab2, Alcohol HCC, Alcoholic Cirrhosis, Diabetes Type 2 MET 63 m ✓ ✓ ✓
24 25‐Mar‐14 B HCC, HCV, Diab2, Obesity HCC, Cirrhosis, Chronic Hepatitis C, Diabetes Type 2, Obesity TP53 TP53 TP53 PIK3CA CTNNB1 
KDR
TP53 CTNNB1 69 m ✓ ✓
25 4‐Aug‐14 B HCC, HCV HCC, Chronic Hepatitis C KIT KDR 59 m ✓ ✓ ✓
26 24‐Jul‐14 B HCC, Alcohol HCC, Alcoholic Cirrhosis TP53 KDR 65 m ✓ ✓ ✓
27 29‐Jul‐14 B HCC, HAV, HBV HCC, Chronic Hepatitis B and A, Cirrhosis PTEN PTEN 35 f ✓ ✓
28 21‐Aug‐14 B HCC, Diab2 HCC, Cirrhosis, NASH, Diabetes Type 2 TP53 65 f ✓ ✓ ✓
29 26‐Aug‐14 B HCC HCC, Cirrhosis TP53 TP53 PIK3CA TP53 73 m ✓ ✓ ✓
30 26‐Aug‐14 B HCC, Alcohol HCC, Alcoholic Cirrhosis 77 m ✓ ✓ ✓
31 28‐Aug‐14 B HCC, HCV HCC, Chronic Hepatitis C TP53 KDR 73 f ✓ ✓ ✓
32 9‐Feb‐14 B HCC HCC 67 m ✓
33 9‐Apr‐14 B HCC HCC 80 f ✓ ✓
34 23‐Sep‐14 B HCC HCC TP53 78 m ✓ ✓ ✓
35 23‐Sep‐14 B HCC HCC TP53 PIK3CA CTNNB1 CDKN2A PIK3CA CTNNB1 CDKN2A 84 m ✓ ✓ ✓
36 27‐May‐09 B HCV, Fatty Liver Chronic Hepatitis C, <5% fatty liver 51 m ✓ ✓ ✓
37 23‐Jun‐09 B HCV, Fatty Liver Chronic Hepatitis C, 20% fatty liver TP53 KDR 47 m ✓ ✓ ✓
38 12‐Feb‐09 B HCV, Fatty Liver Chronic Hepatitis C, very mild fatty liver TP53 PIK3CA KDR TP53 38 m ✓ ✓ ✓
39 15‐Dec‐10 B HCV Chronic Hepatitis C KDR 60 m ✓ ✓
40 2‐Aug‐11 B HCV, Fatty Liver Chronic Hepatitis C, 5% fatty liver TP53 TP53 39 f ✓ ✓ ✓
41 16‐Feb‐11 B HCV Chronic Hepatitis C KDR 31 m ✓ ✓ ✓
42 24‐Nov‐10 B HCV, Fatty Liver Chronic Hepatitis C, 5% fatty liver TP53 KDR APC APC 53 f ✓ ✓ ✓
43 1‐Dec‐10 B HCV, Fatty Liver Chronic Hepatitis C, 10% fatty liver TP53 KDR SMARCB 40 f ✓ ✓
44 22‐Nov‐06 B HCV Chronic Hepatitis C TP53 KDR SMARCB MET 45 f ✓ ✓ ✓
45 29‐Mar‐11 B HCV, Fatty Liver Chronic Hepatitis C, 5% fatty liver TP53 38 f ✓ ✓ ✓
46 2‐Apr‐09 B Fatty Liver, Fibrosis, Obesity Fatty Liver (40%), mild fibrosis, Obesity TP53 46 m ✓ ✓
47 4‐Sep‐08 B Fatty Liver, Fibrosis Fatty Liver, mild fibrosis 30 m ✓
48 9‐Dec‐07 B Fatty Liver, Fibrosis Fatty Liver, mild fibrosis SMARCB KDR 48 m ✓ ✓ ✓
49 3‐Jul‐07 B Fatty Liver, Obesity Fatty Liver, Obesity TP53 51 m ✓ ✓ ✓
50 8‐Aug‐06 B Fatty Liver Fatty Liver TP53 PIK3CA KDR 31 m ✓ ✓
51 30‐May‐06 B Fatty Liver Fatty Liver (30%) 64 f ✓ ✓ ✓
52 11‐Sep‐10 B Fatty Liver, Fibrosis Fatty Liver, mild fibrosis TP53 KDR 58 f ✓ ✓ ✓
53 2‐Jun‐08 B Fatty Liver Fatty Liver (60%) TP53 APC APC 55 m ✓ ✓ ✓
54 18‐Jun‐08 B Fatty Liver, Fibrosis Fatty Liver (70%), mild fibrosis KDR MET 46 m ✓ ✓ ✓
55 6‐Apr‐08 B Fatty Liver Fatty Liver (40%), med‐tox TP53 KDR 36 m ✓ ✓ ✓
56 22‐Sep‐08 B HCV, Fibrosis+, Obesity Chronic Hepatitis C, Advanced Fibrosis/Cirrhosis, Obesity TP53 KDR 57 m ✓ ✓
57 23‐Jul‐08 B HCV, Fibrosis+ Chronic Hepatitis C, Advanced Fibrosis/Cirrhosis, 60% fatty liver 44 m ✓ ✓ ✓
58 15‐Jul‐08 B HCV, Fibrosis+ Chronic Hepatitis C, Advanced Fibrosis/Cirrhosis, 10% fatty liver TP53 TP53 47 m ✓ ✓ ✓
59 20‐Feb‐08 B HCV, Fibrosis+ Chronic Hepatitis C, Advanced Fibrosis/Cirrhosis KDR 64 f ✓ ✓ ✓
60 12‐Dec‐07 B HCV, Fibrosis+ Chronic Hepatitis C, Advanced Fibrosis/Cirrhosis TP53 MET 51 m ✓ ✓ ✓
61 19‐Jun‐07 B HCV, Fibrosis+ Chronic Hepatitis C, Advanced Fibrosis/Cirrhosis TP53 65 f ✓ ✓ ✓
62 16‐May‐07 B HCV, Fibrosis+ Chronic Hepatitis C, Advanced Fibrosis/Cirrhosis, 10% fatty liver TP53 MET 59 f ✓ ✓ ✓
63 28‐Mar‐07 B HCV, Fibrosis+ Chronic Hepatitis C, Advanced Fibrosis/Cirrhosis, 10% fatty liver 52 m ✓ ✓ ✓
64 4‐Nov‐07 B HCV, Fibrosis+, Alcohol Chronic Hepatitis C, Advanced Fibrosis/Cirrhosis, alcoholic fatty 
liver (30%) KDR NOTCH1 NOTCH1 47 m ✓ ✓
65 5‐Sep‐07 B HCV, Fibrosis+, Obesity Chronic Hepatitis C, Advanced Fibrosis/Cirrhosis, Obesity TP53 MET TP53 45 m ✓ ✓
66 4‐Jul‐12 S HCC, HCV HCC, Hepatitis‐C‐Cirrhosis KDR 67 m ✓ ✓ ✓
67 12‐Aug‐12 S HCC HCC, Child‐Pugh A Cirrhosis TP53 CTNNB1 KDR CTNNB1 56 m ✓ ✓ ✓
68 24‐Aug‐12 S HCC HCC KDR 73 m ✓ ✓ ✓
69 4‐Sep‐12 S HCC HCC, Fibrosis/Cirrhosis TP53 KDR 57 m ✓ ✓ ✓
70
21‐Aug‐12 S HCC  HCC  ATM TP53 SMARCB1 PIK3CA KDR ATM 86 m ✓ ✓ ✓
71 16‐Oct‐12 S HCC HCC, Child‐Pugh A Cirrhosis KDR TP53 TP53 76 m ✓ ✓ ✓
72 28‐Nov‐12 S HCC, HCV HCC, Hepatitis C, Steatosis hepatis (ca. 80 %) KDR 58 m ✓ ✓ ✓
73 19‐Dec‐12 S HCC, Nicotine HCC, Nicotine addiction KDR MET 79 m ✓ ✓ ✓
74 7‐Jan‐13 S HCC Recidive Recidive HCC, Cirrhosis 83 m ✓
75 5‐Feb‐13 S HCC, HBV HCC, Hepatitis B, Neoplastic vascular invasion, Fibrosis 40 f ✓ ✓ ✓
76 29‐Apr‐13 S HCC HCC, Cirrhosis CTNNB1 TP53 CTNNB1 TP53 59 m ✓ ✓ ✓
77 19‐Apr‐13 S HCC HCC TP53 KDR 61 f ✓ ✓ ✓
78 3‐Sep‐13 S HCC HCC 78 f ✓ ✓ ✓
79 7‐Oct‐13 S HCC HCC TP53 67 f ✓ ✓ ✓
80
17‐Oct‐13 S HCC, Alcohol, Nicotine
HCC, Neoplastic vascular invasion, Nicotine addiction, Alcohol 
addiction
TP53 KDR CDKN2A TP53 62 m ✓ ✓ ✓
81 20‐Dec‐13 S HCC, HBV HCC, Hepatitis B TP53 KDR TP53 60 m ✓ ✓ ✓
82 7‐Mar‐14 S HCC HCC, Cirrhosis SMARCB1 KIT KDR 73 m ✓ ✓ ✓
83 11‐Mar‐14 S HCC HCC ATM CTNNB1 KDR ATM CTNNB1 77 m ✓ ✓ ✓
84 12‐Mar‐14 S HCC, Recidive Recidive HCC TP53 74 m ✓ ✓ ✓
85 2‐Apr‐14 S HCC HCC KDR 72 m ✓ ✓ ✓
86 16‐Apr‐14 S HCC HCC PTEN TP53 KDR PTEN 62 f ✓ ✓ ✓
87 29‐Apr‐14 S HCC HCC, Child‐Pugh A Cirrhosis TP53 59 m ✓ ✓ ✓
88 6‐May‐14 S HCC, HAV HCC, Hepatitis A KDR 76 m ✓ ✓ ✓
89 9‐May‐14 S HCC HCC, Child‐Pugh A Cirrhosis KDR 68 m ✓ ✓ ✓
90 25‐Jul‐14 S HCC, HAV, HBV HCC,  Hepatitis B, Hepatitis A TP53 PIK3CA TP53 54 m ✓ ✓ ✓
91 28‐Oct‐14 S HCC HCC TP53 STK11 CTNNB1 KDR STK11 CTNNB1 53 m ✓ ✓ ✓
92 25‐Nov‐14 S HCC, HBV HCC, Hepatitis B TP53 SMARCB1 70 f ✓ ✓ ✓
93 1‐Dec‐14 S HCC, HBV, Alcohol HCC, Hepatitis B, Alcohol addiction PTEN TP53 KDR TP53 PTEN TP53 54 m ✓ ✓ ✓
94 9‐Mar‐15 S HCC HCC TP53 KDR 55 m ✓ ✓ ✓
95 31‐Mar‐15 S HCC HCC, Steatosis hepatis  CTNNB1 CTNNB1 61 ✓ ✓ ✓
Term Meaning
B Biopsy
S Surgery
HAV Hepatitis A virus
HBV Hepatitis B virus
HCV Hepatitis C virus
Fibrosis+ Advanced Fibrosis/Cirrhosis
NASH Non‐alcoholic steatohepatitis
Diab1 Diabetes Type 1
Diab2 Diabetes Type 2
Data not available
✓ Analysis performed
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